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ABSTRACT
DESIGN, SYNTHESIS AND BIOLOGICAL SCREENING OF NOVEL CUCSINSPIRED ESTRONE ANALOGUES TOWARDS TREATMENT OF
HEPATOCELLULAR CARCINOMA
MATER MAHNASHI
2017
Cucurbitacins (CUCS) are natural products with highly oxygenated tetracyclic
triterpenes produced mostly by Cucurbitaceae family plant. They are known for their
therapeutic efficiency with different biological activities, such as anti-inflammatory,
hepatoprotective and anti-cancer. Hepatocellular carcinoma (HCC) is the third leading
cause of death worldwide. Previous reports have shown the ability of CUCS to inhibit the
growth of hepatocellular carcinoma cell lines (HepG-2) significantly. Structural activity
relationship studies suggested the potential of the 23, 24 enone side chain of CUCS to bind
to the Epidermal Growth Factor Receptor (EGFR). Due to the limited quantities of CUCS
upon isolation and the challenges of total synthesis of CUCS, therefore estrone skeleton
were used as a starting scaffold to synthesize CUCS-inspire estrone analogues (CIEA)
targeting HCC. Molecular docking study of cucurbitacin-inspired estrone analogs was
conducted using 1M17 (EGFR receptor) co-crystallized with Erolitinib (known EGFR
HCC anti-cancer chemotherapeutic drug) and several analogs were identified from the
docking study and were processed for multiple steps organic synthesis. Novel CUCUSinspired estrone analogs with aliphatic enone side chain such as MMA102, MMA132 were
synthesized by installing the CUCS side chain at C17 of estrone scaffold. In addition,
various CUCUS-inspired estrone analogs with different aliphatic, aromatic and

xviii

heterocyclic pharmacophores at C-3, C-16 and C-25 were synthesized. The novel analogs
showed a comparable affinity to EGFR receptor based on the docking study and improved
binding through hydrophobic filling of the binding of EGFR pocket and hydrogen bonding
interactions. Cell proliferation inhibition assay results demonstrated the ability of
analogues MMA102 and MMA132 to inhibit HCC cell line (HepG2) proliferation with
IC50 3µM and 2µM, respectively in comparison to Erlotinib IC50 (of 25 µM). Western blot
experiments proved that compounds MMA132 has the ability to bind to the EGFR-TK and
inhibit its phosphorylation by 90%. Flow-cytometry/cell cycle arrest study showed that our
lead compound MMA132 induce a significant change in G1/S phases at different IC50
concentrations (1µM, 2µM and 3µM). The novel synthesized cucurbitacin-inspired estrone
analogs showed a significant 12 times more cytotoxicity than standard chemotherapy and
bind through hydrogen bonding to the same amino acids that Erlotinib binds to in the 1M17
EGFR pocket. Compound MMA311, which consist of 2-bromothiophene enone side chain
along with methoxy at C-3 and double bond at C-16 and C-17, showed a significant and
potent anti-proliferation activity with IC50 value of 0.7 µM. Due to the high hydrophobic
character of the first set of compounds and the expected metabolism of estrone by Odealkylation of methoxy group at C-3, which may trigger estrone side effects, C-3 methoxy
group were substituted with sulfamoyl moiety to improve the pharmacokinetic profile of
the synthesized analogues. Several CIEA analogs that contain sulfamoyl group at C-3 and
various aliphatic, aromatic and heterocyclic enone side chains at C-17 were synthesized
and biologically tested as EGFR inhibitors. Compounds that contain heterocyclic enone
side chains at C-17 along with sulfamoyl moiety or hydroxyl group at C-3 such as
MMA297, MMA314, MMA313 and MMA312 showed an outstanding cytotoxicity with

xix

IC50 1 µM, 1.5 µM, 9 µM and 8 µM; respectively, in comparison to the Erlotinib IC50 of
25 µM. The potential of our novel CIEA to overcome cancer resistance to current
chemotherapy was explored and identified their ability to decrease the drug resistance by
inhibiting MRP1 utilizing high-content based assay in presence of calcein-AM as MRP1
substrate. Compounds MMAmix, MMA242, MMA132, MMA335, MMA337 and
MMA320 showed potential inhibitory activity on MRP1 with inhibitory activity of 70%,
63%, 46.2%, 46%, 30% and 22%; respectively, in comparison to MK-571, which known
MRP1 inhibitor.
Our study demonstrated the design, synthesis of novel CIEA analogs of potent antiproliferation/anticancer activities toward hepatocellular carcinoma and potential
application to overcome cancer resistance to current chemotherapeutic agents.

1

Chapter One
General Introduction and Background
1.1

Drug Discovery:
Drug discovery is a convoluted procedure that consumes much time and money,

taking an average time of 10-15 years and cost of around $ 1 billion to get a new drug in
the market. This complex procedure needs a great number of steps, skills and technologies
such as chemoinformatics, molecular modeling, chemical synthesis, toxicity screening and
clinical studies [1]. Typically, the drug discovery pipeline starts from a disease description,
followed by molecular targets identification and validation, thus utilizing high throughput
screening (HTS) and/or Insilco–invitro screening to identify hit compounds. Finally, hit
compounds will be optimized to find the lead compound followed by animal studies to
identify the compounds pharmacokinetics, and finally the clinical trials to test the drug
before it reaches the pharmaceutical market (Fig.1.1) [1, 2]. All of these steps will be
completed sequentially so, if any one of these steps delayed, the whole process is slowed
[2]. A strategy known as High Throughput Screening (HTS) has adopted by pharmaceutical
industries to identify and develop a hit compounds which apply insilco molecular modeling
and computer assisted drug design (CADD) using scoring function and docking (Fig.1.1).
All of these processes used by pharmaceutical industries to speed the drug discovery
process.
HTS used by pharmaceutical companies to screen 1 to 5 million compounds in few
weeks which is a very coasty process. For example, an HTS of 1 million compounds might
cost an average of $ 500,000–1,000,000 [3]. However, the efficacy or toxicity problems
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associated with many compounds are the reason behind the fail test at the last stages of
clinical trials [4, 5].

Figure 1.1 Drug discovery processes (10-15 years/ 1 billion dollars).

In addition, the physic-chemical characteristics such as, absorption, distribution,
metabolism and elimination (ADME) could play an important role in the efficacy and
safety of a new drug [6-8]. Therefore, to eliminate some of these issues, scientists create a
virtual library of thousands of chemical compounds that can undergo virtual insilco
screening to obtain hit compounds prior to the bench work, which includes synthesis and
biological evaluation, to find potential drug candidates [8-10].
Virtual library generation in the drug discovery field is a time- and effort-saving
step, where different factors can be chosen during the design process of the library. The
process of designing the virtual library considers the possible synthetic approaches which
can be utilized on a chemical structure, including the capability of installing diverse
functional groups (pharmacophores) on the parent compound using viable chemical
reactions [9]. One of the common approaches used in the design stage is the concepts of
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bioisostrism, which is a planning technique used in medicinal chemistry field to manage
systematic molecular modifications aiming. The process of bioisostrism refers to
substituting chemical functional groups with others similar in their physical or chemical
properties, which generally result in similar or better biological activity. The bioisostrism
molecular modification process uses a lead compound (LC) in which its chemical structure,
mechanism of action, drug-protein interaction and important pharmacophores are known.
Additionally, the concept of bioisostrism is utilized to either improve biological activity or
to decrease the adverse side effects and toxicity of a compound [11].
At some point, the basic steps towards drug design should use either structurebased or ligand-based drug design concepts to create a chemical database in order to define
the desired scaffold or skeleton. The lead compounds (LC’s) will undergo additional
optimization to find the hit compounds, followed by the development of a route to
synthesize a high consensus score chemical scaffold with the designed functional groups,
which is then used for high throughput screening and biological activity evaluation.
In conclusion, drug discovery is a long-term process used to find the lead
compounds, which will go through different clinical tests and biological evaluation,s as
shown in Figure 1.2.

1.2 Natural Products and Drug Discovery:
Natural products, biologicals, total synthetic or vaccines are the main sources of
small organic molecule drugs [12]. Since ancient times, natural products have played an
important role as a resource for medicine; for example, herbs can be chewed to relieve pain
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or wrapped around wounds to heal them. Using natural products to treat diseases and
injuries is now known as folk medicine [13, 14]. Lately, significant advances in biological
screening techniques have allowed the study of the biological mechanisms and chemical
profiles of living systems, which has encouraged researchers to investigate the
pharmacological effects of natural compounds. Studies are done to clarify the natural
products' synergistic impacts and their clinical effects on the individual body, which could
help provide novel curative approaches to different diseases [15].

Figure 1.2 Process of drug design.
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Chain et al, 2006 clarified the criteria for evaluating natural products as three steps:
1) the rate of display of novel compounds of wide structure diversity to be used as model
and pharmacophore for systematic synthetic modification, total synthesis and semisynthetic; 2) different diseases healed or prevented by these compounds; and 3) their
number of use for treatment of diseases can be valued by pharmacoeconomic analysis
adjusting the number of prescriptions and the performance of the drugs. Currently, 56% of
the prescribed drugs in the United States are related to natural products [16].

A recent study ranked all drugs derived from natural products among the top 35
worldwide best ethical drugs sellers [17]. Additoinally, Newman et al, 2012 proved the
advantages and biological efficacy of the natural products approved by the Food and Drug
Administration (FDA) between 1981 and 2010 (Chart 1.1) [18]. Natural products have
been used as platform for drug discovery for many available drugs, such as anti-epileptics,
anti-angina, anti-obesity, anticancer, anti-viral, anti-migraine and bronchodilators.

Newman et al, 2012 additionally attracted attention to the significance of different
types of synthetic approaches utilizing natural products, such as total synthesis of a natural
product and semi-synthesis of compounds containing functional groups (parmacophore)
imitating natural products. This clarifies the role of nature in inspiring future organic
chemists to prepare novel organic compounds that can provide better or similar activity as
the natural compound but with fewer side effects [18].

6

Chart 1.1 All New Chemical Entities between 1981 -2012 which approved by FDA.

One of the better known examples of a natural product that has been used as a model
for a total or semi-synthetic drug is Taxol. Another example used as model for a partially
synthetic approach is cucurbitacins, a natural product which shows anti-cancer,
hepatoprotictive and anti-inflammatory activities.

1.3 Cucurbitacins:
Cucurbitacins are natural compounds extracted mostly from the plant of
cucurbitaceae family such as Ecballium Elaterium, Genystlus keithii, Cayaponia Tayuya,
Citrillus Colocynthic, Trichosanthes Kirilowii and Ecballium Elaterium. In addition, they
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can be found in other plant families, such as Scraphulaiaceae and Cruciferae [19]. The
Cucurbitaceae family was first used in folk medicine because of its biological significance
as an anti-inflammatory. According to various studies, the cucurbitacins plants were used
for the first time in Asia, the Middle East and other parts of the world as herbal remedies.
According to various studies, the cucurbitacins plants were used for the first time in Asia,
the Middle East and other parts of the world as herbal remedies. The Cucurbita plants were
used in ancient herbal medicine to treat chronic hepatitis, liver cirrhosis, jaundice,
dyspepsia and cancer [19-23].

The first isolation of cucurbitacins happened in 1831 usign Ecballium Elaterium,
but this did not show up in the market as a biologically active product until the 1960s.
There are twelve different types of cucurbitacins, as follows: A, B, C, D, and E, and so
forth to T. Additionally, hundreds of cucurbitacin derivatives have been synthesized and
identified [22].

Cucurbitacins can be isolated from different parts of the plant, including the seed,
roots, rhizomes and aerial parts of Cantaloupe, Watermelon, Pumpkin, Honeydew Melon,
Spaghetti Squash and Crenshaw Melon [23]. Various reports have proven the medicinal
activity of the cucurbitacins and their clinical effects. Some of the cucrbitacins are still
currently used as a treatment in some parts such as Asia, Africa and South America. Many
biological impacts have been connected with cucurbitacins and their glycosylic derivatives
[23-26]. Recently, cucurbitacins B,C, Q, and E showed antiproliferctive activity on
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different cancer cell lines, such as HepG2, MDA-MB-468, MCF-7 and A549. Animal
models and their apoptosis stimulating activity occurred through the inhibition of the Janus
kinase (JAK), signaling marker and activator transcription3 (STAT3) signaling [19, 2426].

Cucurbitacins R and 23, 24-dihydrocucurbitacin B have been isolated from the
roots of Cayaponia Tayuya by Recio et al [27]. These two cucurbitacins showed several
useful activities, such as anti-arthritic, anti-allergic and anti-inflammatory activity, both in
vitro and in vivo. This was due to their capabilities to block the expression of tumor
necrosis factor-Alpha (TFN-𝛼) in macrophages and in lymphocytes, as well as their
involvement with the action of the nuclear factors [22, 27]. The activity of cucurbitacins as
hepatoprotictive and anti-proliferative agents has been proved by Bartalis and Halaweish
on two different cell lines, HepG2 (hepatocellular carcinoma cell line) and HSC-T6
(Immortal hepatic stellate cell lines) [28].

Kintak et al. 2010 showed that cucurbitacin B has an inhibitory activity on
ERK/RAF/STAT3/MEK and RAS signaling pathway [29]. Subsequently, there is a huge
need to synthesize cucurbitacins because of their outstanding biological results, and also
their very low concentrations in natural sources. Several trials have been conducted trying
to synthesize cucurbitacins, but all of them failed to provide a final compound [30-32]. The
varieties of cucurbitacins functional groups or pharmacophores, as well as cucurbitacins'
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main structural complexity, are the main reasons that totally synthesizing cucurbitacins has
been difficult to achieve.

1.3.1

Physical Characteristics of Cucurbitacins:
Cucurbitacins are crystalline materials at room temperature which typically absorb

ultraviolet light at the range between 228 and 234 nm. Petroleum ether, benzene,
chloroform, ethel acetate, ethanol and methanol are the common solvents used to dissolve
cucurbitacins, since they are insoluble in ether and poorly soluble in water [33]. All of these
properties are reasonable because of the hydrophobic properties of the chemical structure
of cucurbitacins [26]. Mdavi et al. proved that both cucurbitacin B and I are soluble and
can be delivered in vitro and in vivo utilizing two different polymeric micelles, developed
[poly (ethyleneoxide)-block-poly (Ecaprolactone) (PEO-b-PCL). By using a polyemiric
micellar, the in vitro anti-cancer and STAT3 antagonist activity in the melanoma cell line
(B16.F10) demonstrated a similar performance to the free drug using the same cell line. A
mouse melanoma tumors study in vivo demonstrated similar anticancer activity against the
B16.F10 cancer cell line using intratumoral administration. This yielded an insignificant
drug level in the animal plasma while preserving high drug levels in the tumor. Some
research has indicated potential ways to deliver cucurbitacins, such as polymeric micelles
[34].
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1.3.2

Chemistry of Cucurbitacins:
Cucurbitacins are tetracyclic triterpenes characterized by highly oxygenated

functional groups. They possess 30 carbon atoms on their general structure, known as 19(10

9-β)-abeo-5 α-lanostane (9-β-methyl-19-nor-lanosta-5-ene). Cucurbitacins have

more than 100 different structures including glycosyl cucurbitacins and hexanol
cucurbitacins (Fig.1.3) [19, 22, 23, 35].
Cucurbitacins E and B are the most common in the cucubitacea plant family and
their biosynthetic pathways have been documented in several studies. Since cucurbitacins
are found in common plants, some of them are originated via enzymatic reactions during
the plant's natural processes such as growth. For example, cucurbitacins A,D, C, F, G and
H can be found via biotransformation of cucurbitanic B, whereas cucurbitacins I, K, J and
L can be formed via biotransformation of cucrbitacin E [22]. However, due to the
complexity of the stereochemistry of these natural analogues, organic synthesis has not yet
been established.

The cucurbitacins four-ring system resembles the structure of a steroid ring [36].
Two common features mark the difference between cucurbitacins and steroids structures,
with cucurbitacins having a gem-dimethyl group at C-4 and a C-10 methyl in C-9.
Cucurbitacins' main structures share common features, such as: 1) the double bond between
C-6 and C-5; 2) a high level of oxidation due to the substitutions of many carbons (C-16,
C-11, C-3, C-2) by oxygen atoms; 3) the presence of hydroxyl groups, α at C-16 and β at
C-20 and C-25; and 4) α-β-unsaturated ketone in the side chain located at C-22, C-23 and
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C-24. As shown in Figure 1.3, an aromatic ring is a common feature in some of the
cucurbitacin derivatives, such as Fevicordin A [37, 38]. Additionally, cucurbitacins can be
found as free glycone structures or glycosidic structures by a β-linkage to the hydroxyl
moiety from monoside at C-2, C-3 and C-25 or from bidesmosides at C-26 or C-27 [39].

Different studies have demonstrated that the biological effects of cucurbitacins are due to
the presence of a triterpenoid structure which resembles steroids. Additionally, multiple
studies on different cell lines have investigated the structure activity relationship (SAR) of
cucurbitacins. First, the presence of α-β-unsaturated ketone of the side chain at C-22 and
C-24 is very significant for cucurbitacin’s biological activities; cucurbitacin B showed
more activity than dihyedro-cucurbitacin B and cucurbitacin D showed more activity than
that of dihydero-cucurbitacin D in U-937 cell lines which are histiocytic lymphoma cell
lines in different intervals by about 1000 fold. Second, the toxicity of the glycosides of
cucurbitacin E and I is less than that of aglecones, while the cucurbitacin biological activity
increased by 1000 fold in the presence of 25-acetoxy moiety. For example, the IC50 of
cucurbitacin B is less than that of cucurbitacin D in U-937 histiocytic lymphoma cell lines
at different test intervals [39].
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1.4 Cucurbitacins as Potential Drug Candidates Targeting Different Molecular
Targets:
1.4.1

Cucurbitacins Activity as Anti-inflammatory Compounds:
Cucurbitacins have been proven to be anti-inflammatory compounds via targeting

many biological targets to decrease the inflammation. The anti-inflammatory activity of
cucurbitacins is due to the inhibition of cyclooxygenase (COX) enzymes, particularly
cyclooxygenase 2 (COX-2). In comparing the non-steroidal anti-inflammatory drugs
(NSAIDs) and cucurbitacins, the inhibitory rate for COX-2 by cucurbitacins is less than
the NSAIDs; for example, at 100mM concentrated cucurbitacins B, D, E and I showed
inhibitory rates of 32, 29, 35 and 27%, respectively, compared to the COX-2 of NSAIDs
such as Refeoxib, Ibuprofen and Naproxen. This study also proved the selectivity of
cucurbitacins towards COX-2, since they do not show any activity on the cyclooxygenase1 (COX-1) enzyme [27].

Additionally, other studies detected that 23, 24-dihydrocucurbitacin B particularly
have a significant inhibitory activity against COX-2 without reducing its expression. Also,
cucurbitacin R demonstrated noticeable inhibition in the proteins and mRNA for inducible
NO synthase (iNOS) by preventing the activation of nuclear factor-KB (NF-KB) [27].

Cucurbitacins isolated from the roots of C. tayuya such as cucurbitacin R and 23,
24-dihydrocucurbitacin B displayed anti-arthritic, anti-allergic and anti-inflammatory
activities in both in vivo and in vitro tests due to their efficacy to suppress tumor necrosis
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factor (TNF-α) expression in macrophages and lymphocytes. The in vivo studies
demonstrated the capability of both cucurbitacins to minimize the expression of nitricoxide cyclooxygenase-2 and synthease-2 (pro-inflammatory enzymes) [36].
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Figure 1.3 General structures of cucurbitacin with various functional groups and steroid.
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1.4.2

Cucurbitacins Effect on Filamentous-Actin:
Some studies demonstrated the activity of cucurbitacins E, I, and B on the

cytoskeleton, particularly on F-actin. Another study proved that some cucurbitacins
derivatives including cucurbitacin E, stimulate actin cytoskeleton disturbance [40]. This
disturbance connected with the effect of cucurbitacins on the actin-proliferative action in
prostate cancer cell lins. One of the astonishing attributes of cucurbitacin E is that it has a
selective inhibition on F-actin depolymerization, but not on monomeric globular G-actin,
by forming a covalent bond with CYS 257 amino acid residue [41].

Recent studies on cucurbitacins D, E, and I were conducted utilizing breast cancer
cell line (MCF-7) to detect their activities on actin-based structures and cell viability
suggested that cytotoxic characteristics of cucurbitacins might be largely separated from
their effects on cytoskeleton rearrangement [42]. In conclusion, cucurbitacins have
demonstrated strong effects on the cell cytoskeleton by essentially simulating actin through
the stimulation of depolymerization and aggregation.

1.4.3

Mitogen Activated Protein Kinase (MAPK) Pathway Activation by
Cucurbitacins:
One of the key parts in the cellular process is the MAPK pathway, which has

signaling transducing cascade including Ras/B-Raf/MEK/ERK (Fig.1.6). Very few
research studies have addressed the potential biological activities of cucurbitacins targeting
the MAPK pathway. Chean et al. stated that cucurbitacin B inhibits the STAT3 and
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RAS/B-Raf/MEK/ERK cell downstream signaling cascade using the K562 leukemia cell
line [29]. Utilizing computational semi-flexible molecular docking, MTT cell viability
assay and binding immune assay, Salama and Halaweish demonstrated the ability of
several types of cucrbitacins to target MAPK signaling pathway using mutant B-Raf cell
lines [43].

1.4.4

Cucurbitacins as Potential Modulator for Epidermal Growth Factor
Receptors (EGFR):
EGFR, in human cancer has been demonstrated to be involved in the mutation and

deletion of the cell upstream and downstream targets, which makes EGFR a promising
biological target for different types of human cancer [44]. Hollbro et al proved that ErbB
receptors, a member of the GFR family, are very important targets for the treatment of
different kinds of cancer [45]. Liovet et al. showed that activation of EGFR and its
downstream cascade has increased the survival rate of patients in the late stages of
hepatocellular carcinoma [46].

In conclusion, cucurbitacins have demonstrated wide and broad biological activities
toward various molecular targets, including anti-inflammatory agents, hepatoprotective,
anti-cancer agents and anti-virus agents. This makes cucurbitacins promising drug
candidates for various diseases and health problems. Additionally, cucurbitacins have been
proven to have effective inhibitory activity against various cancer cell lines, such as
hepatocellular carcinoma cell line (HepG2), colon cancer cell line (HCT-116), lung cancer
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cell lines (NCI-H460 and A-549), leukemia cell line (U-937), breast cancer cell line (MCF7) and melanoma cell line (B16/F10).

Understanding the genetic changes in HCC and its molecular targets is essential for
designing potential anti-cancer drugs.

1.5 Hepatocellular Carcinoma (HCC):
Hepatocellular carcinoma (HCC) is classified as one of the highest cause of
mortality and the third causing of death worldwide [47]. Asia and Africa have the highest
reports of HCC, with high incidence among men, while HCC is somewhat rare in the
United States compare to the other countries. HCC is a continuous and slowly progressing
disease that is generally associated with other factors, such as cirrhosis, hepatitis C virus
(HCV), hepatitis B virus (HBV) and toxin/ environmental disorders (obesity, diabetes and
alcoholic consumption) [48].

1.5.1

Etiology of HCC:
HCC influences all groups of people worldwide. However, regional differences and

ethnicity are also a significant influence on the prevalence and etiology of HCC incidence
[49, 50]. HCC is a continuous and slowly progressing disease that is generally associated
with other factors such as cirrhosis, hepatitis C virus (HCV), hepatitis B virus (HBV) and
toxin/ environmental disorders (obesity, diabetes and alcoholic consumption) [43, 49, 51].
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An additional factor that can lead to HCC is gender, with males having a higher prevalence
for HCC than females [49].

1.5.1.1 Hepatitis B Virus (HBV):
HBV is one of the Hepadnaviridae family, which consider as covered DNA virus.
It is a very common viral disease in that 2 billion people are HBV carriers and about
320,000 people die annually due to complications of HBV infection. Asia and Africa have
the highest reports of HBV incidence worldwide[52]. This disease is very contagious, so it
can infect other individuals in several ways— prenatally, percutaneouslly, and sexually
[52, 53]. Reverse transcriptase (RT) enzyme is responsible for the virus genome replication
[49, 53], but other proteins are also involved in the progression of HBV, such as capside
proteins, common as hepatitis B core antigen (HBcAg), and other enveloped proteins
connected with endoplasmic reticulum (ER) (HBV-1). Approximately one-third to onehalf of HBV-associated deaths are due to the progression of HCC [49, 53]. The influence
of the HBV infection on the progression of HCC is connected with the high incidence of
HCC in the infected individual, with a high level of HBV DNA in their biological serum
[54].

Various studies have proven the ability of HBV to transform into HCC. First, the
genome integration of HBV is related to the host DNA microdeletion, which has the ability
to target cancer-related proteins including platelet-derived growth factor receptor-B
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(PDGFR-B), telomerase reverse transcriptase (TERT), and mitogen activated protein
kinase-I (MAPK-I) [55, 56]. Second, an alteration in the expression of growth-control
proteins such as Ras, Raf, MEK, ERK, JNK and tyrosine kinases takes place through
activation of HBX transcription activity. Third, card inactivate and bind in invitro to the
tumor oppressor P53, which accelerates the cellular proliferation and survival [49, 57, 58].
Genetic validation of HBx as a hepatocarcinoginic has been proven in transgenic mice,
resulting in 90% transformation to HCC [59].

1.5.1.2 Hepatitis C Virus (HVC):
HCV is a member of Flaviviridee family that is a single-stranded RNA noncytoplasmic type virus. It is a contagious virus that can infect other individuals by direct
blood contact, perinatal from mother to fetus, and in rare cases, by sexual intercourse.
China, Egypt and Pakistan have the highest number of HCV cases worldwide [49, 60, 61].
Approximately 170 million individuals are HCV infected worldwide [61]. Six HCV
genotypes (1-6) have been isolated, with genotypes 1-3 being very common worldwide.
Genotype 4 is common in Egypt and the Middle East, genotype 5 is prevalent in South
Africa and genotype 6 is widespread in China [61, 62]. HCV has been shown to have
biological uniqueness compared to HBV, which is an associated hepatocarcinogenesis.
First, HCV has a better tendency (60-80%) to produce chronic infections compared to
HBV, which has only a 10% tendency. That tendency is connected to HCV's ability to
generate a fast rate of replication errors that can cause immune evasion [49, 63, 64].
Second, HCV has a 10-20 times higher tendency to initiate liver cirrhosis compared to
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HBV, with 10% of the patients infected by HCV incubating liver cirrhosis after 10 years
of contagion. The high connection of HCV with cirrhosis is a critical correlation in
developing HCC. Finally, since HCV is an RNA virus, it cannot combine into a host
genome [63].
1.5.1.3 Alcohol Consumption:
Alcohol consumption is one of the significant causal factors for HCC. Chronic
alcohol consumption causes pre-inflammatory cytokines by activating and disturbing the
monocyte which leads to an abnormal evaluation circulating endotoxin concentration. This
can cause the activation of Kupffer cells which emit various cytokines and chemokines,
such as prostaglandin E2, TNFα, 1L6 and interleukin-1B (IL1B). These bring about
hepatocyte damage [65]. In the case of chronic ethanol toxicity, the hepatocyte
demonstrates a high sensitivity to the TNFα cytotoxicity effect, which is a clear sign of
chronic hepatocyte disturbance, activation of stellate cell, liver cirrhosis, and eventually,
HCC [66].

In addition, alcohol can destroy the liver via a process called oxidative stress. An
increase in the isoprstane level is a sign of alcohol hepatitis, which indicates lipid
peroxidation [67]. Three explanations can be given for the connection between oxidative
stress and the liver damage that leads to HCC. First, oxidative stress elevates the
progression of cirrhosis and fibrosis, which are considered the main causes of HCC [68].
Second, oxidative stress resulting from ethanol toxicity shows a relevant effect on the
HCC-signaling cascade, such as a decrease in the tyrosine phosphorylation of the signaling
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transducer and the activator of transcription I (STATI) [69]. Third, oxidative stress might
increase the rate of telomere shortening which may interrupt the DNA replication process
and cause HCC [70].
1.5.1.4 liver Cirrhosis:
Liver cirrhosis consider as the main reason for HCC development, which mainly
caused by the most two common livers viral infection, HBV and HCV [71, 72]. Table 1.1
shows the annual percentage of individual who develop HCC from cirrhosis caused by
liver viruses or liver complications [71].
While these results show HCC development via liver cirrhosis caused by different
liver diseases, the development of HCC may also include additional factors [73]. The
development of cirrhosis usually comes when patients have chronic liver disease over a
period of years, which can be distinguished by a decrease in hepatocyte proliferation as a
sign of liver damage. This causes an increase in the fibrous tissue and a disturbance of liver
cells that leads to the development of liver cancer [71, 74]. Various studies have been
conducted to determine the exact mechanism associated with HCC development from liver
cirrhosis, but only a few possible mechanisms have been proposed, including micro- and
macro-environmental changes that induce cellular proliferation and telomese dysfunction
[75].
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Table 1.1 Annual percentage of HCC incidences caused by liver cirrhosis.

Disease

Annual percentage %

HBV

1-15

HCV

1-8

Liver disease due to alcohol
consumption
Liver disease due to non-alcoholic
reasons

1
2.6

1.5.1.5 Aflatoxin B1 and Environmental Factors:
Aflatoxin B1 (AFB1) is a mycotoxin found in Aspergillus fungus that infects
different foods, such as peanuts and corn. AFB1 has been proven as carcinogenic based on
several animal studies [75, 76]. When AFB1 is absorbed in the blood circulation, it is
activated by metabolism to AFB1-exo-8, 9-epoxide. The active metabolite binds to DNA
and damages it, so it can be distinguished by the activation of the P53 protein [77]. This
DNA damage has been distinguished in 30%- 60% of HCC patients in AFB1 epidemic
regions [78]. AFB1 as a risk factor for HCC development was supported by several studies
done between 1992-2007. These studies were conducted on an aflatoxin metabolite
developed from urine assays in order to find signs of aflatoxin-damaged DNA [75].
Environmental disorders such as obesity, diabetes mellitus and tobacco have also
been studied and proven as risk factors for HCC development [75]. A study on 900,000
people with obesity over a period of 16 years found that the incidence of hepatocarcinoma
death was five times higher than that of non-obese people [79]. Diabetes mellitus,
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specifically type-2, is another factor for HCC development via non-alcoholic fatty liver
disease (NAFLD) and non-alcoholic steatohepaties (NASH). The connection between
type-2 diabetes mellitus and HCC has been studied in several countries, with several
studies showing a significant connection between HCC and type-2 diabetes [75]. Another
significant factor involved in HCC development is cigarette smoking. Numerous studies
on HCC patients demonstrated positive and negative associations between tobacco and
HCC [80].
1.5.2

Diagnoses and Treatments of HCC:

1.5.2.1 Diagnosis of HCC:
HCC can be diagnosed by various tests, including imaging, histology and serological tests.
Imaging tests, such as ultrasound (US), computerized tomography (CT) and magnetic
resonance imaging (MRI) can be used to detect hepatic nodules. The molecular biomarker
test for the diagnosis of HCC is now becoming popular. With this test, the three types of
alfa-fetoprotein (AFP-1L1, AFP-L2 and AFP-L3) are the most popular molecular
biomarkers for the diagnosis of HCC [47, 81, 82]. The biomedical problems associated
with the AFP molecular biomarker are that it can be found in high levels in some nonmalignant cells such as with pregnancy and severe liver diseases. In addition, it can be
found in various levels in different types of HCC [81, 83]. Figure 1.4 demonstrates the
diagnostic strategy of the American Association for the Study of Liver Diseases (AASLD).
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1.5.2.2 Treatments of HCC:
Various treatment choices are available for HCC, with the type of treatment depending on
factors such as the condition of liver function, the HCC level, the type of local medical
resources available and the prevalence of other chronic diseases [47]. The treatment of
HCC can be divided into two types— curative and palliative. The curative options for HCC
treatment include ablation, surgical resection and liver transplantation; these usually
provide a high percentage of treatment response which increases the survival rate. On the
other hand, the palliative options of HCC treatment, such as chemotherapy and
radiotherapy, do not tend to provide a high rate of response compared to the curative
options, but they can improve the survival rate of HCC patients in general [84].

Figure 1.4 Diagnosis strategy of the American Association for the study of liver diseases
(AASLD) (reprinted from [81]).
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1.5.2.2.1

Surgical Resection:

HCC patients with a non-cirrhotic liver, an early stage of HCC and good liver function are
good candidates for the resection surgery. The process of liver resection consists of
removing the specific part of the liver that has the tumor mass, along with a small range of
liver tissues around the mass, leaving the healthy part of the liver to renew the whole organ.
Among all the HCC treatments choices, surgical resection for the early stage of HCC is
considered the best choice because it provides complete extirpation of the tumor mass and
allows for liver function regeneration [81]. However, surgical resection has some
limitations for curing HCC. First, some clinical tests should be made on the liver to ensure
that the remaining part of the liver has the ability to renew the liver function. For example,
HCC patients with liver cirrhosis are not suitable for surgical resection. Second, removing
the liver tumor mass will not remove the tumor completely, which will increase the chances
of generating a de novo primary tumor mass. The statistical studies indicate that 75-80%
of HCC patients who have had the tumor mass removed will survive [85]. Third, the chance
of treating HCC by surgical resection will be small if there are several tumor masses in the
liver. In addition, HCC diagnosed at the late stages with the association of liver cirrhosis
will make surgical resection an impractical option [86].

1.5.2.2.2

Liver Transplantation:

Liver transplantation is considered one of the best curative treatment options for
HCC patients, especially in the early stages, since it removes the whole liver including its
tumor masses. It thus provides a solution for the underlying cirrhosis [87]. The main
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problem with liver transplantation is the spread of the tumor to another organ. Mazzafero
et al, 1996 developed the Milan Criteria, which are criteria used to distinguish HCC
patients who are suitable for liver transplantation. These criteria include: a solitary tumor
< 5cm in diameter, total of 3 lesions <3cm in diameter, and no spread of the tumor to the
other organs or vessels. The Milan Criteria increased the survival rate to 80% and returning
survival rate to 83% after liver transplantation [81, 87]. The limited number of liver donors
is the major issue with this process [47].

1.5.2.2.3

Ablation Therapy:

Ablation therapy provides local management of the HCC cancer cells with only a
small influence on the neighboring cells and other hepatic tissues. Ablation therapy is a
convenient technique for HCC patients who are still in the early stage and do not have a
match for liver resection or liver transplantation. The three types of ablation therapy
include radiofrequency ablation (RFA), percutaneous ethanol injection (PEI) and
microwave ablation (MWA). RFA uses an electrical current with a high frequency to
deliver heat to the liver tissues and cause coagulative necrosis. PEI mainly causes liver cell
dehydration, which is responsible for the death of the exposed liver tissues, also produces
coagulative necrosis. Unlike RFA, MWA generates heat by applying an electromagnetic
source to the liver tissues that can cause the tumor masses to die [47, 81].
1.5.2.2.4

Chemotherapy:

The name chemotherapy refers to a treatment using drugs or medicines. Treatment
of HCC with chemotherapy agents has not been very promising to date, since they have
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not increased the survival rate. The major reason for this is multidrug resistance associated
with most of the drugs available [88]. Chemotherapy treatment is suitable for the patients
who are in advanced stages of HCC and do not fulfill the criteria for surgical resection or
liver transplantation [81]. Several goals are possible when using chemotherapy to treat
HCC patients, including curing the cancer, slowing cancer growth, and treating cancer
symptoms [89]. In general, four anti-cancer drugs types are available, including alkylating
agents, antineoplastic agents, intercalating agents and molecular target anti-cancer agents.
However, the Food and Drug Administration has approved only a few drugs for the
treatment of HCC (Sorefenib and Erlotinib), which are considered molecular target anticancer agents. [90].

1.5.2.2.5

Radiotherapy:

Radiotherapy is another option for the treatment of HCC. This therapy can achieve
necrosis by killing the tumor cells in a small liver tumor mass. However, radiotherapy has
some risks for the patients, such as causing abdominal injuries or extensive hepatitis. For
these reasons, the use of this technique for treating HCC is very limited [88].

1.5.2.3 Resistance of the Chemotherapeutic Agents:
The main available treatments for cancer are chemotherapeutic agents which can
either stop or slow the abnormal fast division of the cells. The major problem associated
with the available chemotherapeutic agents is drug resistance, which occurs with 30%-80%
of cancer patients. Cancer cells such as HCC cells produces drug resistance via three
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mechanisms: multidrug resistance (MDR), P-glycoprotein drug resistance (P-gp) and
multidrug resistance protein (MRP). All of them are activated and effective in the HCC
treatment process [94, 95]. Therefore, there is an urgent need to find a new agent to
overcome chemotherapeutic resistance.
1.5.3

Molecular Targets for Treatment of HCC:
HCC can be cured by either liver transplantation or surgical resection if discovered

in its early stages. However, most of the HCC cases are discovered in the late stages, which
decreases the general survival rate [91]. The HCC patients who are suitable for curative
treatments represent approximately 15% of those diagnosed [92]. The essential reason for
this disappointing survival rate is the lack of effective chemotherapeutic agents that can
cure HCC in its late stages. A large number of studies have demonstrated that only 10%20% of HCC patients respond to the chemotherapy treatments, with toxicity and cellular
resistance to available chemotherapeutic agents being the main obstacle to successful
treatment [93]. In conclusion, searching for new active molecular target anti-cancer agents
for HCC has become a popular area for research due to the urgent need to overcome the
toxicity and cellular resistance problems. In addition, identifying molecular targets is
essential for the discovery of a therapeutic treatment that overcomes the resistance and
decreases the side effects.

1.5.3.1 Epidermal Growth Factor:
Epidermal growth factor receptor (EGFR) tyrosine kinase (TK) is one of the
tyrosine kinases that has been studied as a promising target for the treatment of different
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carcinomas, including HCC [96]. EGFR, which is also known as ErbB1, is a member of a
family of growth factor receptors that also includes ErbB2, ErbB3 and ErbB4 (Fig. 1.5).
Paracrine or juxtacrine extracellular ligand binding, such as epidermal growth factor
(EGF), and transforming growth factor (TGF)-α stimulate the EGFR which leads to hetroor homo-dimerization and conformational change that activates the tyrosine kinase and
allows autophosphorylation. When the phosphorylation occurs, a number of signaling
pathways activate, leading to cancer cell invasions, proliferation, metastasis, inhibitory of
apoptosis and angiogenesis (Fig. 1.5).

Figure 1.5 Potential molecular targets for treatment of HCC.
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Therefore, inhibition of the EGFR-TK signaling cascades provides a potential
approach for the treatment of hepatocellular carcinoma (HCC). In the signaling cascade,
either upstream or downstream targets of EGFR can be used for the treatment of any cancer
in general and HCC specifically [97-100]. Different organic compounds, such erlotinib and
lapatinib (Fig. 1.6), have shown potent inhibitory activity against EGFR by inhibiting its
phosphorylation; these are known chemotherapeutic agents for the treatment of HCC (Fig
1.6). Erlotinib (Tarceva) is a very active and selective inhibitor of the EGRF-TK protein.
It has an advantage over most of the anti-cancer agents in that it can be taken orally, inhibits
cellular proliferation and causes cell cycle arrest at the G1 phase. In addition, it has been
approved as an active drug for pancreatic and lung cancer by the FDA but is still in Phase
II clinical trials as an anti-cancer drug for HCC [101].

1.5.3.2 Vascular Endothelial Growth Factor (VEGF):
HCC is considered a hypervascular cancer, which has a large amount of tumor
vascularity. VEGF is connected to the angiogenesis of various cancer types and is a
significant part of HCC angiogenesis [102], enhancing the progression of HCC and its
resistance [97]. HCC and all other tumor masses need blood vessels to survive and enlarge,
so these blood vessels are considered abnormal since they are responsible for the high fluid
pressure inside the tumor mass. Therefore, VEGF targeting agents may cause a decrease in
the tumor vessels' supplies and their sinuosity, which leads to a decrease in the internal
pressure of the tumor mass. All of these processes will lead to normal blood vessels [103].
Gerber et al, 2005 proved the ability of anti-VEGF drugs, in combination with other anti-
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cancer agents, to cause a fast decrease in the internal vessel pressure of the tumor mass,
which resulted into faster targeting of the agents to the tumor mass, a reduction in the tumor
size and an increase in the survival rate [104]. Different agents have been designed to treat
HCC by targeting VEGF or VEGFR. Some of them have been proven effective, such as
Sorafenib (Fig. 1.6), and some are still in clinical trials to verify their pharmacokinetic
profiles. Sorafenib is the first molecular target drug approved by the Food and Drug
Administration (FDA) for the treatment of HCC. It is considered a multi-kinase agent that
stops tumor cell proliferation by inhibiting different molecular targets, including VEGFR
and PDGFR tyrosin kinases, which produces an anti-angiogenic effect. In addition, it
targets the downstream cascades such as the Raf/MEK/ERK signaling pathway (Fig. 1.6)
[91, 97, 105].
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1.5.3.3 Mitogen Activated Protein Kinase (MAPK) Pathway:
MAPK includes, in its downstream, four main kinases— Ras, Raf, MEK and ERK
(Fig. 1.5)— which communicate with each other by phosphorylation. They are responsible
for cell division, growth and regulation. These downstream proteins are connected to the
upstream receptors such as PDEFR, EGFR, and VEGFR (Fig. 1.5) [105, 106]. So the
MAPK pathway is an essential player in the growth and survival of HCC cells, which
makes it a promising target for the treatment of HCC [107, 108]. ABT-100 is one of the
anti-cancer agents in phase II clinical trials that inhibits the farnsylation process of the
protein Ras by inhibiting the enzyme farnesyl transferase, which leads to a decrease in
tumor cell growth [105, 109]. The family of the protein Raf includes three members: ARaf, B-Raf, C-Raf. Hyperactivation of C-Raf (wild type) in various cancer types, including
HCC, was the only reported one, which makes it a valuable target for treating HCC [110].
Sorefineb is an approved HCC chemotherapeutic agent that inhibits B-Raf, C-Raf, FGFR,
PDGFR and VEGFR [111]. The family of the protein MEK includes two subunits, MEK1
and MEK2. Huynh et al reported that overexpression of MEK1 and MEK2 lead to an
activation of ERK1 and ERK2; in the case of HCC, this occurs in different percentages.
Additionally, it has been proven in in vitro studies that the addition of a MEK1 or MEK2
inhibitor to HepG2 or Hep3B HCC cell lines will inhibit the autophosphorylation and cause
cell apoptosis. MEK inhibitors, including include Selunetinib, RDEA119 and ASCO2010,
are still in phase II clinical trials, [112].
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1.5.3.4 PI3K/Akt/mTOR Pathway:
PI3K/Akt/mTOR pathway is a downstream signaling cascade that connected to the
upstream receptors of the cell (Fig. 1.5). Cellular activation of the protein PI3K will
automatically activate the Akt protein kinase and result in number of phosphorylation,
which leads to cellular proliferation and apoptosis. In the case of HCC, this pathway will
be superexpressed, making it a good target for the treatment. mTOR is a protein that is
responsible for the regulation of the cellular translation process. This process includes
various numbers of initiation factors, such as 40s ribosomal, protein S6 kinase and 4Ebinding protein-1, which are involved in the mRNA translation process during cell
proliferation and angiogenesis. All of these features make mTOR an interesting target for
the treatment of HCC [113]. The immunosuppressive and antibiotic agent Rapamycin is
known as an mTOR inhibitor and has demonstrated inhibition activity against HCC cell
lines [105, 114].

In general, to find new agents that have the ability to selectively target the biological
molecular targets, understanding the nature and behaviors of these molecular targets with
the designed compounds is essential. One of the known techniques to assist with the design
and to predict the simulation of the designed compounds inside the molecular targets is
molecular modeling.
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Figure 1.7 Approved and clinical trials agents for treatment of HCC. (Copied from
[106]).

1.6

Molecular Modeling:

1.6.1

Introduction:
Research and development to discover a new drug in the pharmaceutical industries

requires much time and a high cost, so new approaches are always needed to reduce the
time and cost. Molecular modeling is one means to provide a fast prediction of the proposed
compounds' behavior in the molecular biological target with a low cost [115]. Molecular
modeling is used to calculate the action and characteristics of each atom and molecule of
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the structure with a logical conclusion of the synthetic strategies and verification of the
mechanistic approaches by predicting the patterns of transition states (TS). In addition, the
molecular docking technique can be utilized to calculate the binding affinity between the
compounds and the molecular biological targets, such as proteins, receptors and enzymes,
in order to determine the potential drug candidates and hit compounds [115, 116].
Molecular modeling has a number of programs and applications that can predict the
physical and chemical properties of a compound, such as absorption, distribution,
metabolism and excretion (ADME) [117].

The drug discovery process has improved since the use of computational
approaches began in the 1980s [116, 118]. Several computational methods have been
involved in the process of drug discovery, such as structure-based drug design (SBDD) and
ligand-based drug design (LBDD) [118]. SBDD utilizes the 3D structure and biological
data of the protein of interest to determine the best compounds (usually small organic
molecules) that bind to the selected protein. The compounds that show a high binding
affinity to the targeted protein are called a "hit" which will be screened in a fast biological
screening system, called high throughput screening (HTS), to find the lead compound (LC).
On the other hand, LBDD uses known active compounds (known drugs) and then identifies
their pharmacophores as the origin for the lead compound determination [119]. LBDD is
considered a significant approach in the drug discovery process; however, it needs a large
group of known ligands for which biological tests are handy. Thus, SBDD considered
easier to utilize for the process of drug discovery [118].
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Molecular docking is a process where small organic compounds are docked against
a specific molecular active site of a protein (target). This is considered a very helpful
process in the computational methodology of drug discovery. The main goal of the
molecular docking process is to find the appropriate conformational structure that binds to
the active site of the protein and score a high binding affinity. Therefore, the docking
process is a powerful technique because it can provide a pattern of set compounds with
specific pharmacophores based on their interaction with the targeted protein. This may lead
to the discovery of promising novel candidates. The process of docking begins with the
building of a database of molecules and a structure of targeted proteins in order to detect
the compound with a high binding affinity to the protein. The main obstacle involved in
this process is comparing the resulting binding affinity of the proposed molecules toward
a specific protein with the binding affinity of known standards; this is called relative
binding affinity. In general, molecular docking may take a long time to determine the hit
molecules which can be optimized to a lead compound (LC). However, docking is a safe
financial technique that protects the research in case of a failure to discover the lead
compound; the research can then return to the database to find another hit molecule [120].

1.6.2

Molecular Docking Approaches:
Two main approaches have been developed to conduct molecular docking: 1) the

simulation approach, which is based on a computer simulation to calculate the energy
differences during the compound-protein docking process; 2) the shape complementarity
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approach, which uses a specific application to estimate the compound-protein surface
complementarity [121, 122].

1.6.3

Molecular Docking Types:
Molecular docking consists of three different types based on the docked molecules

and the protein of interest. First, flexible molecular docking includes different conformers
of the ligands, as well as the targeted proteins, to find the best ligand-protein conformers
complex. This type relies on the induced-fit model [121, 123, 124]. The second type is
semi-flexible molecular docking, in which different conformers of the compounds will be
generated and docked on a rigid protein to find the best ligand conformer to create a stable
complex with the protein. This type of molecular docking is the most popular type among
all molecular docking types [121]. Third, in rigid molecular docking, both the compounds
and the targeted proteins are rigid, so the concept of key and lock will be applied [121].

1.6.4

Limitation of Molecular Docking:
Some noticeable points in the molecular docking process, from both site ligand and

protein, may cause limitations for the molecular docking process. These include
conformational changes in both the ligands and targeted proteins that occur during the
binding, the accuracy of the X-ray crystallography of the protein structure crystalized with
the known ligand, entropic and enthalpic influence, the reality that the whole biological
system can be represented by a single protein and the effect of metals and water molecules
in the interaction between the ligand and protein [115, 119]. Multi-step approaches have
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been used in the docking process to overcome all of these limitations. The steps begin with
putting a small organic molecule (ligand) into the active site of a protein that mimics a
favorable interaction with the protein. Then by evaluating the interaction between the
ligand and the protein, their source of binding affinity can be determined; this is called
scoring.

1.6.5

Overview of Docking Scoring:

The interaction between the protein and the ligand is the main output of the process and
takes into consideration multiple molecular factors, such as H-bonds, hydrophobic
interactions, overlay with the co-crystalized ligand, and types of amino acids involved in
the interaction. During the docking, the protein can be represented at three different levels:
atomic, surface and grid [125, 126]. In regard to the ranking steps of molecular docking,
the atomic representation and potential energy function are relatively easy to determine due
to the intricacy of computer calculations at the atomic interaction level. Protein-protein
molecule docking can utilize surface-dependent molecular docking for their receptor
representation. Various docking programs using potential energy grid functions are
available to perform the energy calculation. Van der waals and electrostatic potential can
be saved as grid points using grid-based docking [127, 128]. Ligand and protein flexibilities
can be measured by utilizing algorithm search procedures. Three methods have been
developed for measuring the ligand flexibility simulation— systemic and random methods.
Molecular dynamics simulation is the cornerstone for simulation ligand flexibility search
methods [129]. However, simulation search methods have a disadvantage, in that they
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cannot pass high energy barriers during the measurement of flexibility in a short time. The
ligand flexibility systemic search mainly discovers all possible classes of reedom in a
ligand. However, an alternative method for a systemic ligand flexibility search starts by
generating a library of compounds and creating different conformers for each one of the
compounds. By utilizing this approach, the library of different ligand conformers will be
docked against the biological target at one time, which reduces the time and efforts of this
step. Lastly, the random ligand flexibility search method allows the ligand to change to
different conformers and mimic the degrees of ligand freedom. Genetic algorithm and
Mento Carlo are the most popular random ligand flexibility search methods [129].

The ligand flexibility search method is considered more advanced than the protein
flexibility search method [125]. In general, search methods measure the flexibility in a
particular part of the protein, usually the side chain, which is accomplished by various
methods such as rotomer libraries, molecular dynamic, protein ensemble grids and Monte
Carlo [126, 130, 131].

1.6.6

Types of Docking Scoring Functions:
The main goal of docking scoring is to calculate the energy difference (∆G) of the

binding of a ligand-protein complex. Generally, various attempts have been made to
accomplish the ∆G calculation in a short time, since it is considered a time- and moneyconsuming process. The three types of docking scoring functions are called empiricalbased, force-field based and knowledge-based [125]. Empirical-based scoring functions
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rely on the binding energy of the ligand-protein complex that can be measured by the
addition of single unrelated terms; the coefficients of the terms are measured from a
regression examination utilizing experimental measurements of binding energy and known
data from an X-ray crystallography (3D structure). In the force-field scoring function, the
sum of the internal-ligand energy and protein-ligand energy is the main consideration. The
majority of force-field scoring functions do not count the various conformer structures of
one protein, which make the internal protein energy measurement useless for most
purposes [125, 128]. The force-field scoring functions are dependent on various groups of
force-field parameters, including AMBER, Tripos force field, OPLS-AA and MMFF94.
Electrostatic and Van der Waals energy interactions are the parameters that describe the
protein-ligand interactions. The electrostatic expression is described by Coulomb equations
that explain the force interaction between two differently charged particles, while the Van
der Waals interaction expression is explained by Lennrd-Jones potential functions, where
scoring functions are responsible for different results [125, 128]. Knowledge-based
docking scoring functions were invented to ignore binding energy and instead lean on
experimental X-ray crystallography (3D structure) [125]. The complex interaction of a
ligand-protein is designed utilizing an uncomplicated atomic interaction system.
The computational effort is the distinguishing characteristic of these scoring
functions, which facilitate the process of scoring huge libraries in a short time. However,
their use relies on known information from small numbers of ligand-protein complex
structures. The numerous interactions that rule ligand-protein interaction formation cannot
be managed by a single scoring function. Therefore, consensus scoring functions are very
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common, since they acquire information from various scores, which minimizes the errors
of a single score and enhances the chance of finding the hits [125, 132]. However, if the
terms in the various scoring functions are safely matched, it may destroy the balance and
increase the errors.

In conclusion, molecular modeling is a helpful technique to find potential
candidates to be synthesized and structurally optimized. These candidates can then be
followed by biological evaluation to provide the clinical form of the synthesized
compounds.

1.7

Biological Evaluation of Synthesized Compounds:
All new compounds should be biologically screened on various biological assays.

Biological evaluation can be conducted in animals, isolated organs, lower organisms, or
ex-vivo and in-vivo screening assays. Some of these assays, such as whole animal
evaluations, are very expensive to use, especially in the early stages of biological screening,
compared to less expensive biological assays such as cultured cell lines known as in-vitro
assays [133].

The most commonly used in-vitro biological assay is cytotoxicity. This assay
measures the lowest concentration of a particular compound that can inhibit the growth of
50% of a particular cell line (IC50). The cell growth inhibition can be tested by one of the
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following tests: cellular biomass assay, membrane integrity assays, day binding assays and
metabolic impairment assays.

To measure the dissolution of enzyme activity or the concentration metabolites, a
metabolic impairment assay can be used by adding a toxin. The MTT assay mainly checks
the capability of live cells to convert by reduction the yellow 3-(4, 5-dimethylthiazol-2-yl)2, 5-diphenyltrazollium bromide salts, known as MTT salt, to its purple formazan state
utilizing a mitochondrial oxidoreductase enzyme [134].

The ligand-binding biological assay is a very common assay in the drug discovery
process. This assay can be conducted utilizing Enzyme Linked Immunoassays (ELISA)
which simply confirm the binding between the protein and the ligand [135, 136]. In order
to pinpoint a particular protein in the cell, the target specific assay in a cell-based ELISA
kit can be utilized to identify this particular protein. This is considered a very powerful
assay compared to other assays, such as the western blot.

In conclusion, biological evaluation is one of the cornerstones of the drug discovery
process because it confirms the hypothesis using molecular modeling studies. In addition,
it helps to identify the significant pharmacophores for further chemical optimization in the
synthetic scheme. All of these connected steps are very helpful in order to develop active
promising candidates for future drugs.

42

1.8

Project Objectives:
This project concentrated on using cucurbitacins as a natural product that has

inhibitory activity toward the epidermal growth factor receptor (EGFR) to develop drug
candidates for the treatment of hepatocellular carcinoma (HCC). Few studies have defined
the activity of cucurbitacins toward EGFR in HCC cell lines, such as the HepG2 cell line.
In addition, no cucurbitacin-like compounds have been synthesized and biologically
evaluated targeting HCC. The main objectives of this project are:
A- Design of novel CUCS-inspired estrone analogues targeting epidermal growth factors
receptor (EGFR) using molecular modeling studies.
B- Synthesis of novel CUCS-inspired estrone analogues targeting epidermal growth factors
receptor (EGFR).
C- Biological screening of the synthesized novel CUCS-inspired estrone analogues targeting
epidermal growth factors receptor (EGFR).
D- Inhibitory activity screening of CUCUS-inspired estrone on MRP1 in order to overcome
the cancer resistance for current chemotherapeutic drugs.
E- Structure activity relationships (SAR) studies on the synthesized novel CUCS-inspired
estrone analogues.
Docking studies were performed on cucurbitacins structure to identify the
significant pharmacophores in order to design novel CUCS-inspired estrone analogues
targeting epidermal growth factors receptor (EGFR). The synthetic route was designed and
outlined by using hybrid structural design methods in which the cucurbitacin side chain
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was installed in the steroidal skeleton structure, then structural modifications were
conducted on the C-17 and C-17, C-3 and B/C juncture of the steroidal skeleton structure.
In addition, a series of various aldehydes were installed on the side chain as part of the
chemical design using Aldol condensation reactions. The biological screening tests were
used to analyze the synthesized compounds to be evaluated for further optimizations
targeting EGFR.

1.9
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Chapter Two
Design of CUCUS-Inspired Estrone Analogs (CIEA) Targeting Epidermal Growth
Factor Receptor (EGFR)
2.1

Introduction:
Natural products are known as one of the major source for drug design and

treatment of cancer. Cucurbitacins is a group of steroidal-triterpene tetracyclic natural
products, which reported for their anti-cancer activities [1, 2]. Although cucurbitacins have
reported for their potent activities, synthesis of these compounds is challenging due to the
complexity of the carbon skeleton and functionalities of these compounds. Current studies
in Halaweish’s group to study cucurbitacins targeting epidermal growth factor receptor
(EGFR) in unclear and limited [3].

Molecular modeling and docking methods were utilized to find potential affinity
between cucurbitacins and EGFR along with downstream proteins cascade including Ras,
Raf, MEK and ERK (Fig. 1.5). In addition, additional studies including cytotoxicity,
western blot and ELISA were used to confirm the molecular docking studies results.
Cucurbitacins proved to have activities against different cancer cell lines; however, their
activities don’t show specificity or selectivity toward their biological targets [4].
Gastrointestinal toxicity is one of the side effects involved with cucurbitacins subjections
due to their cellular activations [5]. Potent cytotoxicity of cucurbitacins in in-vivo model
toward renal carcinoma demonstrated narrow safety and have been withdrawn from
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preclinical studies due to their fatal activity [6]. The broad biological activities of
cucurbitacins, non-selectivity and toxicities are due to their complex chemical structures.
Model the bioisosters of these compounds to mimic the structure functionalities on
steroidal skeleton. Cucurbitacins inspired estrone compounds was accomplished in
Halaweish’s group targeting melanoma [15]. The success in Halaweish’s group of utilizing
the molecular docking inspired us to model novel analogues to target hepatocellular
carcinoma (HCC).
Due to the similarity in chemical structure, particularly the cyclopentane and the
four-ring system, redesigning and mimicking cucurbitacins utilizing steroids may improve
their biological activities and selectivities. Cucurbitacins side chain, which contain α-βunsaturated ketone, is significant pharmacophore for their biological activities. Also, the
presence of C-16 hydroxyl group increased the chance of forming H-bond with C-24
ketone which may enhance the electrophilisity of the α-β-unsaturated ketone [7,8].
Studying and testing cucurbitacins as promising EGFR inhibitors is not favorable
sometimes due to availability limitation, has encouraged us to identify the most significant
pharmacophores of cucurbitacins in order to synthetically modify their main skeleton to
increase the selectivity toward EGFR and minimized their undesirable side effects [14].
Few researches and studies on the structure modifications of cucurbitacins have been
conducted including quantitative structure activity relationship (QSAR) studies of semi
synthetic of cucurbitacins by Bartalis and Halaweish [8], partial synthesis of cucurbitacin
B and D by Jung [9], hexanorcucurbitacin compounds by Ryu [10] and synthesis of
dihydrocucurbitacin B by Lang [11]. However, some of these synthetic studies are
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impracticable for certain wanted cucurbitacins pharmacophores to be modified for certain
biological activities.
In order to understand and test the potential interactions between the designed
ligands and their biological targets, molecular modeling considered a precious technique
for this study. Precise ligand conformation is highly recommended during drug design to
perform an accurate structure-based drug design and virtual screening in order to have full
understand of ligand-target complex interactions through reading the energy parameter [12,
13].
The biological activity of any molecule should rely on one conformation that
possesses the lowest energy conformation which can be distinguished among all other lowenergy conformers by using Cambridge crystallographic database (Fig. 2.1). All of these
signs promoted us to build an assumption that utilizing steroidal skeleton to install
cucurbitacins pharmacophores to inhibit EGFR could be a potential assumption as shown
in figure 2.2.

Figure 2.1 X-ray crystallography of cucurbitacin D showing the potential functional
groups for the binding with biological targets.
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Figure2.2 General structures of Cucurbitacins and steroid.

Assigning the significant pharmacophores of the steroids is complicated mission.
The B and C rings of the steroids have trans configuration but it is cis configuration at
cucrbitacins B and C rings which should be taken in the consideration during the designing
process [14, 15].
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Bartalis et. al 2011 showed that possessing α-β-unsaturated ketone moiety of the
cucurbitacins is essential for the biological activity [8]. In addition, Matsuda et al. 2010
demonstrated the significant of α-β-unsaturated ketone moiety of the cucurbitacins
scaffolds at C-22 and C-24 for their biological activities when he found that some
cucurbitacins-like structures that has no α-β-unsaturated ketone such as hexanor
compounds lost their biological activities [7, 15]. Furthermore, Rodrigues et al, 2016
showed that one sixth of all known natural compounds contain α-β-unsaturated carbonyls
[16]. Which prove the biological significant of α-β-unsaturated ketone at the cucurbitacins
side chain.
Estrogens including estriol, estradiol and estrone are group of popular steroids that
naturally present in women and men and they involved in different biological processes
[17]. In addition, estrogens are involved in the human body with hormonal activities and
development of estrogen-dependent breast cancer [17, 18]. The ability of estrogens and
their derivatives to influence various biological activities and their few adverse effects
make them very interested analogues to be modified for other biological interests. For these
reasons, estrone was chosen as starting material for installing the cucurbitacins α-βunsaturated ketone side chain with different functional groups to see their effects on the
binding affinity toward the biological targets particularly EGFR.
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Modifications of steroids skeleton have got the interest of organic chemist due to
number of reasons 1) steroidal skeleton provides important and significant chemical
challenges; 2) modification in their main structure may provide an interested biological
changes as these compounds may act as pharmacophore carrier; 3) their total synthesis is
very interested for chemist which may need to find new synthetic approaches for further
structural modifications [19]. Serious of estrone modified compounds have been developed
based on the fact that small structure modifications on estrone skeleton scaffold may lead
to large variations in the biological activities [20]. Estrone structural modifications can be
categorized into two types 1) structural modifications by adding new chemical moieties to
the estrone scaffold; 2) structural modifications on the steroids complicated ring system by
either addition of heteroatoms to one of the steroids carbons, or by chemical modifications
in one of the ring system (Figure 2.3) [20, 21]. The most popular type is the first one since
it provides an overall synthetic tasks that is needed to combine various heteroatoms with
the steroids skeleton structure.
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Various pharmacophores of natural compounds such as cambretastatin A4, gallic
acid and chelcones were installed into the estrone skeleton structure, which is known to
possess estrogenic activity and anti-cancer activities targeting different biological targets
[22, 23]. However, this hybrid structure modification is not always providing the desired
biological activity. Another examples are derivatives of 2-methoxyestradiol such as alkoxy
and benzyloxy methylestradiol which proved as anti-breast cancer agents through
stabilizing the microtubule without having estrogenic activity as side effect [24]. Because
of the low bioavailability of methoxyestradiol, number of modified estradiol in different
positions such as C-17, C-16, C-3, and C-2 have been conducted to improve their
bioavailability as well as their biological activities [24-27].
Small modifications at C-2 of estrone main structure by installing sulfamate moiety
change the biological properties of the estrone dramatically by blocking the estrogenic
activity and performing anti-peroflorative activity in breast cancer cells [28]. Bodnar et al,
2016 proved that triazol substitution at C-3 position of estrone enhanced the biological
activity as anti-cancer with IC50=0.3-0.9µM [27]. Ahmed et al. 2014 demonstrated that
substitution on C-17 of the estrone skeleton structure showed a potent inhibitory activity
of MAPK pathway toward treatment of melanoma [15]. Therefore, by utilizing molecular
modeling, series of modified estrone at C-25, C-17, C-16, C-11 and C-3 positions were
designed and developed to target Epidermal Growth Factor Receptor (EGFR) toward
treatment of Hepatocellular Carcinoma (HCC).
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Estron

Cucurbitacin D

MMA-132

Figure 2.4 3-D structure demonstrated the conformations of Estrone, Cucurbitacin D and
MMA-132 analog.

2.1.1

Molecular Modeling and Rational of Inhibitor Design:

2.1.1.1 Protein Kinase:
Protein kinases are the most common family among human enzymes representing
1.7% of the total proteins, which involve in the regulation of several of biological functions
in the cell via autophosphorylation including angiogenesis, cell growth and differentiation,
which make them an interested target for treatment of cancer [30].
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Protein kinase transfer the ATP phosphate group to the amino acids residues of the
protein such as theronin, tyrosin and serin. It consists of two main domains, cyctain-rich
(CR) domain and ligand domain (LD). In order to design a protein kinase inhibitor, deep
understanding of signaling pathway mechanism of interactions should be known, which
categorized the protein kinases inhibitors into three categories. 1) Inhibitors that directly
bind to the ATP binding pocket of the protein kinase, which usually consist of H-bond
donors and acceptors to form at least single H-bond such as erlotinib, fasudil and gefitinib
[32]. 2) Inhibitors that bind with inactive protein kinase ATP binding pocket which consist
of extra hydrophobic site which increase the selectivity to this site compare the first type
such as sorefinib, nilotinib and lapatinib. 3) Allosteric protein kinase inhibitors and they
don’t compete with ATP to bind to its binding site.
Briefly, most of the protein kinase inhibitors that approved as anti-cancer are ATP
competitive inhibitors and form at least one H-bond with protein amino acid residues [2933].
2.1.1.2 PI3K/Akt/mTOR and RAS/Raf/MEK/ERK Proteins Cascades:
PI3K/Akt/mTOR is significant downstream proteins cascade which can be
activated by various cellular activators that lead to number of cellular processes including
cell-growth, cell-survival, translation, angiogenesis and transcription. Different types of
cancer lead to disturbance in PI3K/Akt/mTOR pathway which make them promising
targets for designing promising inhibitors as ant-cancer agents.
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Known Raf inhibitor proved to be one of the ATP competitive inhibitors
performing various kind of interactions with hydrophobic binding site such as PLX-4720
which has been advanced by Plexxikon to possess high selectivity to B-Raf and high oral
bioavailability. Other B-Raf inhibitors includes PLX-4032 (Vemurfenib) and Sorefinib.
Various MEK inhibitors have been discovered such as Selumetinib, U0126, PD184352 and
PD0325901. MEK inhibitors bind allosterically to the non-ATP binding site of MEK
protein which increase their specificity and selectivity. MEK1/2 crystal structures
demonstrated that they have outstanding hydrophobic binding pocket beside the ATPbinding pocket [34, 35]. Some other compounds such as resorcyclic inhibitors which
demonstrated MEK inhibitory activity and other kinases as well. The presence of enonebased pharmacophore in these inhibitors as Micheal acceptor is the base of their broad
biological activities [36]. Our hypothesis of development of esterone to possess anti-cancer
activities is by installing the cucurbitacins enone side chain which consist of α-βunsaturated ketone at C-22 and C-24 of the estrone main scaffold.

2.1.1.3 Compounds with α-β-unsaturated Carbonyl (Micheal Acceptor):
Michael acceptor or α-β-unsaturated carbonyl pharmacophores considered as one
of the most reactive functional groups in natural compounds. Recent review in nature
chemistry showed that 1/6 of the all known natural compounds contain α-β-unsaturated
carbonyl groups. It is a question mark about weather adding Michael acceptor
pharmacophores to design a potential candidates targeting specific biological target is
valuable or not since these groups are very reactive electrophiles and have broad biological
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activities because they can react with various number of nucleophiles in the body such as
DNA, RNA and proteins which lead to unwanted side effects. However, Michael acceptor
functional groups demonstrated various beneficial activities such as anti-oxidants by
trapping thiol and radical scavenger [16, 37].
Therefore, a virtual library of estrone modified structures at different positions
including C-3, C-11, C-16, C-17, C-24 and C-25 were generated containing cucurbitacins
enone side chain , known EGFR inhibitors and cucurbitacins to be investigated as antihepatocellular carcinoma agents utilizing OpenEye® Scientific software including Omega,
FRED and VIDA. The designing strategies were divided into two different series using
molecular modeling. First series is to assemble cucurbitacins enone side chain at C-17 of
estrone with different aliphatic and aromatic moieties at C-25, double bond at C-16 and C17 and methoxy moiety at C-3. The last functional groups is to block the estrogenic activity
of the estrone. Second series is to install cucurbitacins enone side chain at C-17 of estrone
with different aliphatic and aromatic moieties at C-25 and sulfamyl or hydroxyl groups at
C-3.
2.2

Methods of Molecular Modeling:

All computer works were conducted on Gateway Computer with Windows XP. OpenEye®
software, semi flexible molecular docking program, were utilized to conduct the docking
process. It consist of different applications such as OMEGA, FRED and VIDA and each
one of them is directly related to the other functionally as they will be described in detail
in next paragraphs.
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Figure 2.5 Proposed modified estrone structures.
2.2.1

2-D and 3-D Structures Molecular Modeling:
A virtual library of 200 CUCUS-inspired estrone analogues, which contain

cuucurbitacins enone side chain assembled in C-17 of estrone skeleton, other related
derivatives, known EGFR inhibitors and different cucurbitacins as standards were
generated utilizing Chem office 2012, and using MMFF94 calculation for energy
minimization in order to acquire similar structural confirmation mimic to natural 3-D
structure for each compound.

2.2.2

Utilizing OMEGA to Generate Conformers:
The energy minimized compounds were converted into *.pdb forms and then all of

the *.pdb files collected as one *.pdb file to be utilized as an input parameter for Omega
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calculations. Omega created different conformers of each single compound in the virtual
library using MMFF94 calculation parameters so as to perform ligand-protein flexible
docking. Some of Omega settings were modified from the default settings such as highest
number of output conformers 400 (GP-NUM-OUT-CONFS), rejecting conformers that has
energy differences compare to standards minimum ˃ 0.5 Kal/mol (GP-ENERGY-WINDO)
and choosing the conformers with lowest energy from the final calculations (GP-SELECTRANDOM false). Furthermore, increase the number of free rotatable bonds in each ligand
to be 30 (GP-MAX-ROTORS) so as to create different conformers for all molecules in our
library [38].

2.2.3

Preparation of the Receptor Utilizing FRED:
PDB format of the receptors were downloaded from the protein data bank (PDB)

database (EGFR PDB ID # 1M17, RAS PDB ID # 4DTS, RAF PDB ID # 3OMV, MEK
PDB # 4AN2, ERK PDB ID # 2OJJ) (Fig.2.6). These proteins were prepared utilizing
FRED (Receptor preperation program of OpenEye® software). For the preparation of the
proteins, graphical interface was used as part of FRED make receptor application. There
are three main components of FRED make receptor application including mode selection,
mode control and 3D viewing window [39].
The process of receptor preparation started by opening the receptor of interest into
the FRED make receptor application which convert the .pdb file into 3-D view of the
receptor chains including its binding ligands and co-factors. Then the next step is pointing
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to the binding pocket and the co-crystalized ligand binds to it. Then mode selection window
of the application will allow the generation of the grid box which should be in specific size
not exceeding 60,000 Ao. However, if a large grid box is required to accommodate (larger
than 60.000 Ao) then the box can be divided to two sites, otherwise the docking process
will not be conducted smoothly. Final step is the mode selection window which is the one
responsible for specifying the pocket shape so the docking program can recognize the inner
and outer contour [39]. After conducting all of the previous steps, the protein should be
prepared for executive molecular docking.
Newman et al, 2012 additionally attract attention to the significant of possessing
different types synthetic approaches utilizing the natural products such as, total synthesis
of natural product and semi-synthesis of compounds contain functional groups
(parmacophore) mimic from natural products, which clarify the role of the nature to inspire
future organic chemist to prepare novel organic compounds, that can give better or the
same activity as the natural compound with less side effects [18].
Consensus score of the docking study can be calculated by various scoring
functions at the final stage such as shapegauss, chemgauss3, oechemscore, screenscore and
PLP. All the functional commands for OpenEye® FRED can be found in this link
www.eyesopen.com/products. 3D structure of the docked ligands with protein can be
visualized utilizing OpenEye® VIDA application where 3D picture of the ligand-protein
complex can be taken [40].
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PDB ID: 1M17
Epidermal Growth Factor
Receptor
tyrosine
kinase
domain
with
4anilinoquinazoline
inhibitor
erlotinib.

PDB ID: 4DST
Small-molecule ligands bind to a
distinct pocket in Ras and inhibit
SOS-mediated nucleotide exchange
activity.

PDB ID: 4AN2
PDB ID: 3OMV
Crystal structure of c-Raf
(Raf-1).

Crystal structures of human MEK1 with
carboxamide-based
allosteric
inhibitor
XL518 (GDC-0973), or related analogs.

PDB ID: 2OJJ
Crystal structure of ERK2 in complex with (S)-N-(1-(3chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(4-(3chlorophenyl)-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide.

Figure 2.6 3-D structure of all proteins and their standards inhibitors (downloaded from
PDB).
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2.3

Results and Discussions:
The prepared virtual library, which include estrone modified structures,

cucurbitacins and known receptors inhibitors, were docked on five different proteins
starting from the upstream cellular receptor EGFR and going down to the cellular
downstream proteins pathway including Ras, Raf, MEK and ERK. Novel visual
compounds of the CUCUS-inspired estrone analogues were designed in systemic way by
assembling the cucurbitacins pharmacophores I n the estrone scaffold. Specifically, five
main positions of the estrone skeleton were modified. First, installing cucurbitacins enon
side chain at C-17 with different functional groups at C-25. Second, substituting C-3
hydroxyl group with methoxy or sulfamoyl moieties. Third, modification at ∆9,11 position
of the estrone core structure. Finally, installing various functional groups at C-25 of the
enone side chain (Fig. 2.5).
An average of 40-55 modified estrone showed lower consensus scores (better
binding affinity) toward the targeted receptors than the known inhibitors such as erlotinib,
cobimetinib and sorefinib.
All of the designed virtual compounds were divided into two main groups: 1)
modified estrone compounds with cucurbitacins enone side chain at C-17 of the estrone
scaffold, double bond at C-16 and C-17 position, methoxy group at C-3 and different
aliphatic and aromatic functional groups at C-25 (Fig.2.7); 2) modified estrone analogues
with cucurbitacins side chain at C-17 of the estrone skeleton structure, sulfamoyl or
hydroxyl groups at C-3 and various aliphatic and aromatic functional groups at C-25
(Fig.2.8 and Fig.2.9).
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The rational of building these different groups of estrone derivatives is to compare
between different enon side chain by adding various functional groups at C-25 and their
effect on the biological activities (to be discussed in Ch.3 and Ch.4).
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Figure 2.7 First set of synthesized MMA analogues that contain methoxy at C-3, double
bond at C-16 and C-17 and various aliphatic and aromatic functional groups at C-25.
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Figure 2.8 Second set of synthesized MMA analogues that contain sulfamoyl at C-3 and
various aliphatic and aromatic functional groups at C-25.
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Figure 2.9 Third set of synthesized MMA analogues that contain hydroxyl at C-3 and
various aliphatic and aromatic functional groups at C-25.
2.3.1

Results of the Molecular Modeling of CIEA on EGFR:
The results of molecular docking on the crystal structure of EGFR showed an

outstanding binding affinity with the CUCUS-inspired estrone analogues containing
various functional groups compare to the known EGFR inhibitor, Erlotinib. Modified
estrone at C-17 with isopropanol enon side chain, methoxy group at C-3 and double bond
at C-16 and C-17 position such as MMA102, MMA128, MMA129 and MMA132
demonstrated various binding mods with EGFR binding pocket. MMA102 and MMA132
are diastereomers to each other and showed varieties in the binding mode with the receptor.
MMA132, which possess the stereochemistry of cucurbitacin D side chain, showed an
outstanding binding mode with EGFR by forming H-bond with MET:769:A, which is same
amino acids residues that erlotinib binds to in EGFR to induce anti-cancer activity by Hbonding with the same amino acid MET:769-A; also MMA132 perform hydrophobic
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interactions with the amino acids residues inside the binding pocket. While MMA102
which has the opposite stereochemistry of cucurbitacin D demonstrated less binding
affinity toward the EGFR binding site only with a hydrophobic interaction mode with the
EGFR binding pocket. This result proved the significant of assembling the enone side chain
with the stereochemistry of cucurbitacin D (Fig.2.10).

A

Figure
2.10
Visual
representation of A) MMA102 (orange) B) MMA-132
(blue) in the EGFR ATPbinding site along with
Erlotinib (purple).

B
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In addition, the presence of C-16 and C-17 double bond plays a significant role for
the binding affinity which corresponds to our group publication before [14]. On the other
hand, CUCUS-inspired estrone analogues with aromatic enone side chain such as
MMA265, MMA270, MMA271, MMA287, MMA288, MMA289, MMA290,
MMA292, MMA305 and MMA311 showed good binding affinity with H-bonds and
hydrophobic interactions with the crystal structure of EGFR. Compounds with strong
electron withdrawing groups at C-25 of the enone side chain such as MMA290, MMA292
and MMA311 showed both H-bonds and hydrophobic mode of interactions (Fig.2.11);
while compounds with electron donating groups at C-25 of the enone side chain such as
MMA-265 showed only hydrophobic-hydrophobic interaction with amino acid residues of
the EGFR (Fig2.12).

Figure 2.11 Visual representation of MMA-292 (Red) in the crystal structure of EGFR.
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Figure 2.12 Visual representation of MMA-265 (Green) in the crystal structure of EGFR.

Second group of modified estrone that contain enone side chain at C-17, sufamoyl
or hydroxyl groups at C-3 and different aliphatic and aromatic functional groups at C-25,
such as MMA-240, MMA-241, MMA-294, MMA-295, MMA-297, MMA-300, MMA301, MMA-306, MMA-307, MMA-308, MMA-309, MMA-310, MMA-312, MMA-313
and MMA-314, docking calculations showed strong binding affinities with the EGFR
binding site with H-bonds and hydrophobic interactions with the amino acid residues at the
binding site. Compounds with different enone side chains at C-17, sulfamoyl moiety at C3 and different functional groups at C-25 demonstrated outstanding binding affinity with
the EGFR binding pocket by forming both H-bonds and hydrophobic interactions, while
analogues with same functionalities at C-17 but with hydroxyl group at C-3 showed less
binding affinity and lost their ability of forming H-bonds and only demonstrated
hydrophobic interactions. These results revealed the significant of the presence of
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sulfamoyl moiety at C-3 for the binding affinity toward the binding pocket of the 3D
structure of EGFR (Fig.2.13).

In conclusion, CUCUS-inspired estrone analogues with cucurbitacin D enone side
chain at C-17, double bond at C-16 and C-17 and methoxy group at C-3 such as MMA132 are showing the highest binding affinity toward the crystal structure of the EGFR
binding pocket with H-bonds and hydrophobic interactions. On the other side, estrone
derivatives with cucurbitacins enone side chain at C-17 and sulfamoyl group at C-3
demonstrating significant binding mode comparet to the known EGFR inhibitor
(Erlotinib).
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A

Figure 2.13 Visual
representation of A)
MMA-240 (Red) B)
MMA-301 (purple)
in the EGFR ATPbinding site.

B

2.3.2

Results of Molecular Docking of CIEA on Ras:
CUCUS-inspired estrone analogues with various functional groups demonstrated

special binding affinity with the 3D structure binding pocket of Ras protein. In particular,
estrone cmodified compounds with cucurbitacins enone side chain at C-17, double bond at
C-16 and C-17, methoxy group at C-3 and various aliphatic and aromativ functional groups

83

at C-25 such as MMA102, MMA128, MMA129, MMA132, MMA265, MMA270,
MMA271, MMA287, MMA288, MMA289, MMA290, MMA292, MMA305 and
MMA311 showed strong binding affinities toward the targeted pocket in Ras protein. The
presence of Cucurbitacin D enone side chain stereochemistry or the opposite
stereochemistry in some derivatives such as MMA102 and MMA132 did not play role in
affecting the binding affinity since both compounds demonstrated very good binding mode
with Ras along with H-bons and hydrophobic interactions as shown in figure 2.14.

A

Figure 2.14 Visual representation
of A) MMA-102 (blue) B) MMA132 (purple) in the Ras binding
site.

B
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Estrone derivatives with aromatic functional groups at C-25 of enone side chain,
methoxy at C-3 and double bond at C-16 and C-17 positions such as MMA265, MMA270,
MMA271, MMA271, MMA287, MMA288, MMA289, MMA290, MMA292, MMA305
and MMA311 showed slight decrease in the binding affinity toward the Ras crystal
structure in comparison to the aliphatic enone side chain such as MMA-102, MMA-128,
MMA129 and MMA132 which has higher binding affinity (Fig.2.15).

A

Figure 2.15 Visual
representation of A) MMA132 (purple) B) MMA-311
(purple) in the Ras binding
site.
B

On the other hand, CUCUS-inspired estrone analogues with cucurbitacins enone
side chain at C-17 of the estrone skeleton structure, sulfamoyl or hydroxyl groups at C-3
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and various aliphatic and aromatic moieties at C-25 such as MMA240, MMA241,
MMA294, MMA295, MMA297, MMA300, MMA301, MMA306, MMA307,
MMA308, MMA309, MMA310, MMA312, MMA313 and MMA314 demonstrated
lower binding affinity toward the 3D structure of Ras compare to that of first group
discussed before. Even though most of these analogues don’t show high binding affinity
but they show both H-bonds and hydrophobic interactions with the binding pocket of Ras
(Fig.2.16), which may demonstrate significant biological activities as Ras inhibitors.

Figure 2.16 Visual representation of MMA-240 (Blue) at the binding pocket of Ras.

2.3.3

Results of Molecular Modeling of CIEA on Raf:
Molecular docking calculations of CUCUS-inspired estrone analogues with Raf

protein showed varieties of binding modes. Cucurbitacins enone side chain at C-17 of
estrone analogues scaffold, methoxy at C-3, double bond at C-16 and C-17 and various
aliphatic and aromatic moieties at C-25 showed different binding modes such as MMA132,
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which possess the stereochemistry of cucurbitacin D side chain, has hydrophobic
interaction with Raf binding pocket, while MMA102, which has the opposite
stereochemistry of cucurbitacin D, which show H-bonding with the same targeted protein
(Fig.2.17).

A

Figure
2.17
Visual
representation of A) MMA-102
(purple) B) MMA-132 (yellow)
in the Raf binding pocket.

B

In addition, compounds with aromatic functional groups at C-25 of the enone side
chain such as MMA265, MMA270, MMA271, MMA271, MMA287, MMA288,
MMA289, MMA290, MMA292, MMA305 and MMA311 demonstrated various binding
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affinities toward the targeted protein, Raf. For example, MMA292, which contain Ptrifluromethyl benzene at C-25 of the enone side chain, showed significant binding affinity
toward the crystal structure of Raf compare to MMA-311, which has bromothiophene at
C-25 of the enone side chain (Fig.2.18).

A

Figure
2.18
Visual
representation of A) MMA-292
(blue) B) MMA-311 (green) in
the Raf binding pocket.

B

For the second group of CUCUS-inspired estrone analogues that contain
cucurbitacins enone side chain at C-17 of the estrone skeleton structure, sulfamoyl or
hydroxyl groups at C-3 and different aliphatic or aromatic groups at C-25 of the enone side

88

chain such as MMA240, MMA241, MMA294, MMA295, MMA297, MMA300,
MMA301, MMA306, MMA307, MMA308, MMA309, MMA310, MMA312, MMA313
and MMA314, the molecular docking study revealed that they demonstrated different
levels of binding mods toward the targeted Raf protein. For example, compounds that
possess strong electronwithdrawing aromatic functional groups at C-25 of the estrone
enone side chain such as P-trifluromethyl benzene in MMA300, showed lower level
binding affinity compare to the other compounds that have electron donating groups at the
same position such as MMA267 which has P-methoxy benzene at C-25 (Fig.2.19).

A

Figure 2.19 Visual
representation of A) MMA-267
(yellow) B) MMA-300 (orange)
in the Raf binding pocket.

B
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2.3.4

Results of Molecular Docking of CIEA on MEK:
The first set of CUCUS-inspired estrone analogues that consist cucurbitacins enone

side chain at C-17 of the estrone scaffold, methoxy at C-3, double bond at C-16 and C-17
and different functional groups at C-25 including MMA102, MMA128, MMA129,
MMA132, MMA265, MMA270, MMA271, MMA287, MMA288, MMA289,
MMA290, MMA292, MMA305 and MMA311 showed strong binding affinities toward
MEK protein. Stereochemistry of the enone side chain play an important role in the binding
affinity; for example, analogue MMA132, which contains the stereochemistry of
cucurbitacin D side chain, showed less binding affinity toward MEK with hydrophobic
interaction compare to analogue MMA102, which has the reversed stereochemistry of
cucurbitacin D side chain, that demonstrated an outstanding binding affinity with H-bonds
and hydrophobic interactions with MEK amino acid residues at the binding pocket
(Fig.2.20).
On the other hand, the estrone analogues with C-17 enone side chain, sulfamoyl or
hydroxyl groups at C-3 and number of aliphatic and aromatic functional groups at C-25
showed structural specificity correlation with binding affinity; for example, derivatives
with aliphatic enone side chain showed higher binding affinities with H-bonds and
hydrophobic interactions such as MMA240 in comparison to the other derivatives that
have aromatic enone side chain such as MMA314 (Fig.2.21).
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A

Figure
2.20
Visual
representation of A) MMA102 (blue) B) MMA-132
(red) in the MEK binding
pocket.

B
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A

Figure
2.21
Visual
representation of A) MMA240 (green) B) MMA-314
(purple) in the MEK binding
pocket.

B

In addition, the presence of sulfamoyl moiety at C-3 of the esterone scaffold along
with the enone side chain at C-17 of MMA300 showed a significant increase for the
binding affinity by forming H-bonds and hydrophobic interactions with the crystal
structure of MEK binding pocket compare to the derivatives that have hydroxyl group at
C-3 along with the enone side chain such as MMA308 (Fig.2.22).
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A

Figure
2.22
Visual
representation of A) MMA300 (brown) B) MMA-308
(red) in the MEK binding
pocket.

B

2.3.5

Results of Molecular Docking with ERK:
The molecular docking study of CUCUS-inspired estrone analogues that contain

cucurbitacins enone side chain at C-17 of the estrone scaffold, methoxy at C-3, different
aliphatic and aromatic moieties at C-25 and double bond at C-16 and C-17 such as
MMA102, MMA128, MMA129, MMA132, MMA265, MMA270, MMA271,
MMA287, MMA288, MMA289, MMA290, MMA292, MMA305 and MMA311
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showed strong binding affinities toward ERK 3D structure which is consistent to their
structure; for example, compound MMA132, which possess the stereochemistry of
cucurbitacin D side chain, showed very high binding affinity toward the ERK binding site
compare to analogue MMA102, which has the opposite stereochemistry of the side chain
which proved the important of the stereochemistry choice for the structure design
(Fig.2.23).

A

Figure
2.23
Visual
representation of A) MMA102 (green) B) MMA-132
(purple) in the ERK binding
pocket.

B
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Very distinguishable results of the molecular docking calculations that all of the
derivatives with aromatic enone side chain substituents at C-25 form H-bonds with the
same amino acid (MET:106:A) at the ERK binding site; while all aliphatic enone side
chain derivatives at C-25 don’t bind to that particular amino acid (MET:106:A), which
may play role for their biological activities (Fig.2.24).

Figure 2.24 Visual representation of Various Modified estrone with aromatic functional
groups at C-25.

CUCUS-inspired estrone analogues along with cucurbitacins enone side chain at
C-17 of the estrone scaffold, different aliphatic and aromatic substituents at C-25 and
sulfamoyl or hydroxyl groups at C-3 such as MMA240, MMA241, MMA294, MMA295,
MMA297, MMA300, MMA301, MMA306, MMA307, MMA308, MMA309,
MMA310, MMA312, MMA313 and MMA314 proved by molecular docking studies to
have some distinguishable results. For example, compound MMA240, which contain in its
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structure cucurbitacin D enone side chain at C-17 of the estrone scaffold along with
sulfamoyl group at C-3 showed high binding affinity toward the ERK binding pocket
compare to MMA301, which has hydroxyl group at C-3 instead of sulfamoyl, by forming
H-bonds with MET:106:A and ARG:65:A along with hydrophobic interaction with other
amino acid residues inside the binding pocket (Fig.2.25), which prove the importance of
sulfamoyl for the binding mods.

A

Figure
2.25
Visual
representation of A) MMA240 (red) B) MMA-301
(yellow) in the ERK binding
pocket.

B
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2.4

Conclusion:
Molecular modeling for the drug design process is very powerful technique for drug

discovery since it can calculate how the small organic compounds will behave in the
biological system before spending millions of dollars without knowing their behaviors. In
our molecular docking study, we considered the pharmacophores of cucurbitacins
structures to be assembled on the estrone main skeleton targeting several EGFR proteins
biological targets aiming to discover drug candidates for the treatment of HCC.

The molecular docking study demonstrated the significance of CUCUS-inspired
esterone analogues with cucurbitacins enone side chain at C-17 of the estrone main
structure to bind to the EGFR. So, analogues with cucurbitacin D enone side chain at C-17
(with the right stereochemistry) such as MMA132 showed significant binding affinity
toward EGFR binding pocket compare to the opposite stereochemistry as in MMA102. In
addition, CUCUS-inspired esterone analogues with cucurbitacins enone side chain at C-17
and sulfamoyl moiety at C-3 of the estrone such as MMA240 proved by molecular docking
to demonstrate significant binding modes with the 3D crystal structure of EGFR.

All of the EGFR downstream pathway proteins such as Ras, Raf, MEK and ERK
were presented in this molecular docking study, which showed the importance of the
presence of cucurbitacins enone side chain at C-17 for the binding affinity with the targeted
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proteins. Also, it revealed the significant of other functional groups such as double bond at
C-16 and C-17, sulfamoyl group at C-3 and hydroxyl group at C-3.
Therefore, the results of molecular docking calculations proved the possibility of
designing drug candidates for the inhibition of EGFR and all downstream proteins (Ras,
Raf, MEK and ERK) by assembling specific functional groups such as cucurbitacins enone
side chain at C-17, methoxy, sulfamoyl, hydroxyl at C-3 and various aliphatic and aromatic
functional groups at C-25.
These results guided our tension to build our synthetic schemes for assembling the
cucrbitacins enone side chain at C-17 of the estrone main skeleton, installing different
functional groups at C-3 and assembling various aliphatic and aromatic groups at C-25.
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Chapter Three

Design, Synthesis, and Biological Screening of Novel CUCS-Inspired Estrone
Analogues (CIEA) towards Treatment of Hepatocellular Carcinoma

3.1

Introduction:
Natural products, biological compounds, total synthesis or vaccines are the

main sources of small organic molecules used as drugs [1]. Since the ancient times, natural
products play an important role as resource of medicines. For example, some herbes used
to be chew to decrease the pain and some of them used to be wrapped around wounds to
heal it. Using natural products to treat diseases and injuries known as folk medicine [2].
Lately, the large improve in developing materials to study the biological mechanism of all
new chemical entities, encouraged researchers to investigate more in the pharmacological
effects of natural compounds in order to clarify their synergistic impact and their clinical
effects on the individual body. Natural compounds could be provide novel curative
approaches toward a variety of diseases [3].

Cucurbitacins (CUCS) (Fig. 3.1) are natural products extracted from plant of
Cucurbitacea family such as Gonystylus keithii, Cayaponia tayu, and Citrillus colcynte.
Cucurbitacins plant family first used in folk medicine due its biological significant as antiinflammatory agents. There are different types of cucurbitacins range as following A, B,
C, D, and E, to T. Additionally, hundreds of cucurbitacins derivatives have been
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synthesized and identified some of them listed in Fig. 3.1 [4]. They have been used for
treatment of different diseases such as chronic hepatitis, liver cirrhosis, jaundice,
dyspepsia, inflamation and cancer [5]. Recent studies have shown a significant activities
of CUCS as potential candidates for treatment of hepatocellular carcinoma (HCC) [6].
Current knowledge of molecular targets and singling pathways of different types of cancers
provide a clear understanding of tumor cell regulation, which in turn paved the way to
design promising potential drug candidates.

Hepatocellular carcinoma (HCC) classified as one of the highest cause of
mortality and the third causing of death worldwide [7]. Asia and Africa have the highest
report of HCC with high incidence between men. HCC was somewhat rare in the United
States compare to the other countries; however, in the last recent decades it became one of
the main cause of death in the United States. HCC is a continuous and slowly progressing
disease that is generally associated with other factors such as cirrhosis, hepatitis C virus
(HCV), hepatitis B virus (HBV) and toxin/ environmental disorders (obesity, diabetes and
alcoholic consumption) [8]. There are different therapeutical options for HCC such as local
ablation therapy, surgical resection and liver transplantation. However, these options are
not applicable for late diagnostic patients. Chemotherapeutic drugs such as Erlotinib,
Soreftinib are common treatments for HCC. However, drugs resistance and undesirable
side effects are the most common problems associated with these drugs [9]. Therefore,
there is an urgent need to find a new drug candidate to overcome these problems.
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Two main complex mechanisms for HCC molecular pathogenesis; 1)
mutation, which happen in some tumor suppress genes or oncogenes; 2) some diseases or
metabolic disorder such as hepatitis infection, metabolic effects (such as obesity, insulin
resistance, type-2 diabetes), toxin (such as alcohol) that cause tissue damage which lead to
cirrhosis [10, 11]. Both of these mechanism have been connected with irregularity in
different cell signaling pathways that continue the process of carcinogenic results. From a
therapeutic view, all of these signaling pathways are very significant in order to treat HCC.
Thus, growth factors-mediated, angiogenic signaling, epidermal growth factor (EGFR),
vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF), insulinlike growth factor (IGF), platelet-derived growth factor (PDGF), and the mitogen activated
protein kinase (MAPK) pathways are the most distinguished targets for treating HCC due
to their noticeable overexpression during the disease [10].

Epidermal growth factor receptor (EGFR) tyrosine kinase (TK) (Fig. 1.5) is
one of the tyrosine kinase that have been studied as a promising target for the treatment of
different carcinoma including HCC [12]. EGFR, which also known as ErbB1, is a member
of family of growth factor receptors including ErbB2, ErbB3 and ErbB4. Paracrine or
juxtacrine extracellular ligand binding such as epidermal growth factor (EGF) and
transforming growth factor (TGF)-α stimulate the EGFR, which lead to hetro- or homo
dimerization and conformational charge that activate the tyrosine kinase and allow
autophosphorylation [13-15]. When the phosphorylation occurs, number of signaling
pathways activated leading to cancer cell invasions, proliferation, metastasis, inhibitory of
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apoptosis and angiogenesis [14-16]. Therefore, inhibition of EGFR-TK signaling cascades
provides an approach for the treatment of hepatocellular carcinoma (HCC).
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Figure 3.1 Structures of different types of Cucurbitacins and Starting Material Estrone.

CUCS demonstrated a wide range of biological activities due to their
cytotoxicity on cancer cells and their potency on different biological pathways [17]. These
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biological activities nominate CUCS as a potential drug that targeting multiple types of
cancer. In order to avoid the undesirable adverse effects of the natural products and increase
their selectivity, structural modifications to their structure may improve their efficiency
[18]. Therefore, the identification of the most significant pharmacophore of the natural
products is essential in order to conduct structural modifications.

Based on twenty-four different CUCS, Van Dang et. al. build some structural
relationships of CUCS structures and determined the most significant pharmacophores
[19]. They found that the presence of α-β-unsaturated ketone of the side chain, the free
16α-OH, and the different functionalities on C-3 of the ring A are critical for the biological
activity [19, 20]. Therefore, maintaining the CUCS’s side chain during the modifications
is essential for the biological activity. In addition, installing different functional groups in
various positions of the tetracyclic core structure of Estrone will enhance the biological
activity of the synthesized compounds.

CUCS has tetracyclic moiety, they are very similar to that of steroids (Fig. 3.1).
However, they are different from each other in the fact that C-10 methyl is located at C-9,
possess a gem-dimethyl group at C-4 and the configuration of ring B and ring C [21]. Due
to the similarity between the core structures of CUCS and steroids, the concept of hybrid
drug design were used to install the essential pharmacophore of the CUCS into the steroid
structure as promising alternative for the complicated functionalized structure of the CUCS
[22, 23]. Specifically, using the estrone skeleton as a starting material to install different
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functional moieties including the CUCS side chain and other functionalities has been done
by Ahmed et. al [22]. Furthermore, adding various moieties to the estrone skeleton
structure at C-3, such as methoxy and hydroxyl groups, beside the CUCS side chain at C17 in the presence of double bond at C16-C17 (Fig. 3.2) proved to enhance the biological
activity of these series of compounds. The presence of the double bond at C16-C17
changed the conformation of estrone CUCS-like compounds which improve its binding
affinity towards the EGFR-TK [24]. Supporting to this hypothesis comes from the
capability of estrone derivatives involved in other biological process a voiding its side
effects as estrogen treatment [25-27].

To find hit compounds and to develop candidates targeting the EGFR-TK
pathways, the concept of bioisosterism was utilized to systematically design and install
CUCS functionality on the steroidal core structure and to build a virtual library of 900
compounds, then molecular docking was conducted for these virtual analogues against
EGFR-TK [5]. The four structural positions of estrone skeleton investigated were; 1)
combination of multiple substituted enone side chain at C-17; 2) Modification of C-16, C17; 3) Functionalization on C-3 of the phenol ring and 4) Installation of aliphatic, aromatic
and heterocyclic functional groups at C-25 of the enone side chain (Fig. 3.2). OpenEye®
Scientific software were used for the molecular modeling studies including fast exhaustive
docking (FRED), Omega, and VIDA.
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Figure 3.2 Proposed modified estrone structure.
3.2

Results and Discussions:

3.2.1

Results of Molecular Docking of CIEA on EGFR:

Molecular docking data for the estrone CUCS-inspired analogues containing olefin at
C-16, C-17, cucurbitacins enone side chain with α,β-unsaturated ketones functional group
and methoxy group at C-3 showed an outstanding binding affinity towards the crystal
structure of EGFR, when compared with the standard EGFR inhibitors such as Erlotinib,
which has H-bond with MET:796:A and this H-bond is responsible for its biological
activity along with hydrophobic interaction as anti-cancer agent (Fig. 3.3). CUCS side
chain at C-17 of the estrone scaffold, substitutions at C-3 and double bond at C-16 and C17 of the CUCS-inspired analogues such as MMA102 and MMA132 demonstrated a very
promising binding affinity by making a hydrophobic interaction as in MMA102, which
has the opposite stereochemistry of cucurbitacin D side chain (Fig. 3.3) with amino acids
residues of the crystal structure of EGFR binding pocket; while analogue MMA132,
which possess the exact stereochemistry of the side chain of cucurbitacin D, demonstrated
an outstanding binding affinity through hydrophobic interaction with amino acids residues
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of the EGFR along H-bond with MET:796:A, which is the same amino acid that Erlotinib
make H-bond with and responsible for its anti-cancer activity (Fig. 3.3). These results
showed the significant of possessing the cucurbitacin D stereochemistry for the enone side
chain at C-17 of the estrone scoffold, which make analogue MMA132 a very promising
candidate to be synthesized and biologically tested to confirm its biological activity as an
anti-cancer candidate.

On the other hand, CUCUS-inspired estrone analogues with aromatic and
heterocyclic enone side chain that possess the stereochemistry of cucurbitacin D side chain
such as MMA265, MMA270, MMA287, MMA288, MMA289, MMA290, MMA292,
MMA305 and MMA311 (Fig. 3.2) showed promising binding affinity with H-bonds and
hydrophobic interactions with the binding site of the crystal structure of EGFR.
Compounds with strong electron withdrawing groups at C-25 of the enone side chain such
as MMA290, MMA292 and MMA311 showed both H-bonds and hydrophobic modes of
interactions (Fig. 3.4); while molecules with electron donating groups at C-25 of the enone
side chain such as MMA265 showed only hydrophobic-hydrophobic interaction with
amino acid residues of the EGFR crystal structure (Fig. 3.5). CIEA possess cucurbitacin
aromatic enon side chain with the opposite stereochemistry of cucurbitacin D such as
MMA316, MMA317, MMA318, MMA319, MMA320, MMA321, MMA330 and
MMA334 (Fig. 3.2) demonstrated similar binding affinities to the estrone derivatives that
have similar aromatic functional groups at the enone side chain but with stereochemistry
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of the cucurbitacin D. All of the top consensus score compounds will be chemically
synthesized in order to be evaluated biologically as anti-cancer candidates.

A

B

Figure 3.3 Visual representation of A) MMA-102 (orange) B) MMA-132
(blue) in the EGFR ATP-binding site along with Erlotinib (purple).
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Figure 3.4 Visual representation of MMA-292 (Red) in the crystal structure of EGFR.

Figure 3.5 Visual representation of MMA-265 (Green) in the crystal structure of EGFR.
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3.2.2

Synthesis of MMA Analogues:
To explore these novel CUCS-inspired estrone analogues (CIEA), installation

of cucurbitacins α,β-unsaturated ketone side chain with the double bond in C-16, C-17
position into the estrone skeleton structure were synthesized at C-17 (Fig. 3.1). Number of
synthetic approaches were investigated in order to accomplish this task. First approach was
started with installing p-toluenesulfonyl hydrazide in C-17 of the estrone structure followed
by Shipiro reaction (scheme 3.1) and adding two equivalents of strong base such as nbutyllithium to form nucleophilic center followed by the addition of various electrophiles
such as paraformaldhehyde, dimethyl formamide, N-methoxy-N-methylacetamide and 2,3butanedione [28, 29] as shown in scheme 3.2. This approach was used to save steps from
the original route, which will be discussed in the next paragraph, but unfortunately, several
electrophiles gave a very small yield which make this approach not convenient to start with
and built the whole scheme in (scheme 3.1).
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Then synthesis of MMA analogues started again with protection of ketone at C-17
of commercially available estrone (Fig. 3.1) with ketal group in order to methylate
hydroxyl group at C-3 using methyl iodide in presence of potassium hydroxide to provide
compound 2 [30, 31], followed by deprotection of the ketal group under acidic condition
to produce methoxy estrone 3 [31]. This followed by addition of TMSCN in presence of
ZnI2 was added to 3 to form cyanohydrin intermediate 4, followed by elimination reaction
using POCl3 and DBU as a base to obtain double bond in C-16, C-17 position 5 [32].
Nucleophilic substitutions reaction of nitrile group using methyl lithium was used to
provide methyl ketone 6 [33]. Adding catalytic zinc iodide followed by TMSCN to ketone
6 to form (1:1) diasteriomers mixture of cyanohydrin 7 [22]. It was very challenging to
separate the diasteriomers mixture of 7 using silica gel chromatography which have the
same RF on the TLC plate. Then by treatment of diasteriomers mixture of cyanohydrin 7
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with methyl lithium resulted in formation of required diasteriomers mixture (1:1) of
hydroxyl methyl ketone 8 (MMA225) and 8` [22]. Column chromatography was used to
separate the diasteriomers mixture 8 and 8` to obtain pure seperated 8 and 8` (Scheme 3.3).
The configuration of 8 (MMA225) were confirmed using X-ray crystallography (Fig. 3.5).
At this stage of the synthesis, Aldol condensation reaction used to install aliphatic and
aromatic aldehydes into hydroxyl ketone 8 and 8`, with in situ elimination in order to
provide the required enone. In attempting to install CUCS-side chain, a three synthetic
reactions steps were used to prepare aldehyde 14 which started by the protection hydroxyl
group of methyl 2-hydroxyisobutyrate 11 using tert-butyldimtylsillyl chloride (TBSCl).
The synthesized ester 12 was treated by reducing agent diisobutylaluminum hydride
(DIBAL-H) to form alcohol 13. Control oxidizing agent tetrapropyl ammonium
perrutherate (TPAP) and N-methylmorphline N-oxide (NMO) were utilized to prepare the
desired aldehyde 14 [5] (Scheme 3.4) . Aldol optimized reaction condition of aldehyde 14
and hydroxyl ketone 8 and 8` separately in presence of lithium diisopropylamine (LDA) at
-78oC to room temperature to give enone 9 and 9`. Final compounds MMA102 and
MMA132 were obtained by the addition of tetrabutyl ammonium fluoride (TBAF) in THF
(schemes 3.5 and 3.6) [5].
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Figure 3.6 X-ray crystal of compound 8 which confirm the right stereochemistry to
install Cucurbitacin D enone side chain.

Further derivativesation into hydroxyl ketone 8 started with the assembly of ∆9,11
olefin at the B/C ring ligament to gain the pseudo-cis configuration by adding 2,3-dichloro5,6-dicyano-1,4-benzoquinone (DDQ) in methanol resulted in ∆9,11 hydroxyl ketone 15
and 15`. The produced intermediate ∆9,11 hydroxyl ketone 15 and 15` processed through
the same Aldol condensation reaction with aldehyde 14 to produce in ∆9,11 enone 16
followed by the deprotection of TBSCl using TBAF to obtain ∆9,11 enone MMA128
(scheme 3.7) [5].

Different aromatic and heterocyclic aldehydes have been reacted with hydroxyl
ketone 8 and 8 to produce different aromatic enone side chains that have two different
stereochemistry of each analogue such as para-methoxybenzene (MMA265 and
MMA333), para-flurobenzene (MMA279 and MMA334), para-chlorobenzene (MMA287
and

MMA316),

para-bromobenzene

(MMA288

and

MMA319),

para-
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dimethylaminobenzene (MMA289 and MMA317), 5-bromofuran (MMA290 and
MMA318), para-trifluromethylbenzene (MMA292 and MMA320), para-nitrobenzene
(MMA305 and MMA321) and 5-bromothiophene (MMA311 and MMA330) (scheme
3.8). All aromatic α,β-unsaturated enone side chain increased the hydrophobicity of the
CUCS-inspired analogues so, it can be compared biologically with more polar first
synthesized set of compounds MMA102, MMA128, and MMA132.
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3.2.3

Biological Evaluations of the CIEA for the Treatment of HCC :
In vitro biological evaluation of CIEA was conducted to study their ability to target

and inhibit EGFR-TK as anti-cancer candidates. First, MTT cell viability assay was used
to measure the cytotoxicity and anti-proliferative activity of the synthesized compounds.
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Analogues that contain aromatic enone side chains such as MMA265, MMA270,
MMA287, MMA288, MMA292, MMA305, MMA316, MMA319, MMA320,
MMA321, MMA333 and MMA334 showed strong cytotoxicity with IC50 values 16 𝜇𝑀,
7 𝜇𝑀, 25 𝜇𝑀, 32𝜇𝑀, 2 𝜇𝑀, 29𝜇𝑀, 𝑁𝐴, NA, 3 𝜇𝑀, 20𝜇𝑀, 2 𝜇𝑀 and 8 𝜇𝑀 ; respectively
toward hepatocellular carcinoma cell line (HepG2) in comparison to the known EGFR
inhibitor, Erlotinib, which has IC50 value of 25 𝜇𝑀 (Table 3.1). While CIEA that contain
heterocyclic enone side chains such as MMA290, MMA311, MMA318 and MMA330
showed variety of cytotoxicity on HepG2 cell line based on their stereoisomer; for
example, compound MMA290 and MMA311, which possess cucurbitacin D side chain
stereoisomer, showed potent cytotoxicity with IC50 values 6 𝜇𝑀 and 0.7 𝜇𝑀, respectively.
On the hand, the same compounds but with the opposite stereoisomer such as MMA318
and MMA330 showed significant change in their cytotoxicity since analogue MMA318
lost its cytotoxicity completely and compound MMA330 showed IC50 of 11𝜇𝑀 compare
to 0.7 𝜇𝑀 in MMA311. These results demonstrated the importance of possessing the exact
stereochemistry of cucurbitacin D enone side chain for antiproliferation activity of these
isomers. Meanwhile, compounds MMA102, and MMA1320, which contain isopropanol
enone side chains of cucurbitacin D, demonstrated outstanding cytotoxicity with IC50
values 3𝜇𝑀, and 2𝜇𝑀, respectively (Table 3.1). All of the previous IC50 results were
compared to Erlotinib (current chemotherapeutic drug for treatment of HCC), which has
an IC50 value of 25 𝜇𝑀 (Table 3.1). Second, for more and deep understanding of the antiproliferation mechanism of the potent analogues, MMA102 and MMA132, western blot
analysis was conducted (Fig. 3.8). The western blot data indicate the potential of compound
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MMA132 to bind to the upstream signaling pathway through the inhibition of EGFR-TK
and inhibit its phosphorylation at 2 𝜇𝑀 after 48 hours incubation compare to the loading
control (Actin) and Erlotinib as positive control as shown in Figure 3.8. Third, cell cycle
arrest experiment using flowcytometry was conducted on MMA132 at various
concentration (1/2 IC50, IC50, 2 IC50), which showed its ability to induce G1/S phases cell
cycle arrest as shown in Figure 3.9. The promising data of compound MMA132
demonstrated the importance of the presence of the CUCS-side chain at C-17, double
bound in C-16, C-17 and C-3 methoxy group. Docking results showed that compound
MMA132 has H-bond with MET:796:A (Fig. 3.3), the same as the standard Erlotinib.
This observation in addition to biological results demonstrated the importance of
possessing the CUCS-side chain configuration to gain a promising binding affinity inside
the pocket and inhibit the targeted receptor, EGFR. On the other hands, compounds that
contain aromatic and heterocyclic enone side chains showed a wide range of cytotoxicity
toward HepG2 cell line. The wide range of cytotoxicity can be attributed to several factors
including stereochemistry of the enone side chain, types of the pharmacophores at enone
side chain and the electron withdrawing or donating functional groups of the enone side
chain that effect the electrophilicity of Michael acceptor at enone side chain.
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Table 3.1 MTT cell viability results in HepG2 cell line.
Compound

IC50 (𝝁𝑴)

Compound

IC50 (𝝁𝑴)

Erlotinib

25 𝜇𝑀

MMA305

29 𝜇𝑀

MMA102

3 𝜇𝑀

MMA311

0.7 𝜇𝑀

MMA132

2 𝜇𝑀

MMA316

NA

MMA225

25 𝜇𝑀

MMA318

NA

MMA265

16 𝜇𝑀

MMA319

NA

MMA270

7 𝜇𝑀

MMA320

3 𝜇𝑀

MMA287

25 𝜇𝑀

MMA321

20 𝜇𝑀

MMA288

32 𝜇𝑀

MMA330

11 𝜇𝑀

MMA290

6 𝜇𝑀

MMA333

2 𝜇𝑀

MMA292

2 𝜇𝑀

MMA334

8 𝜇𝑀

30
25
20
15

IC 50

10
5

MMA334

MMA333

MMA321
MMA330

MMA320

MMA319

MMA318

MMA316

MMA311

MMA305

MMA292

MMA290

MMA287
MMA288

MMA270

MMA265

MMA225

MMA132

MMA102

Erlotinib

0

Figure 3.7 Chart represent the ability of CIEA to inhibit the growth of HepG2 cell line.
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(Hepatocellular Carcinoma cell line).

Figure 3.8 Analogue MMA132 manage to inhibit p-EGFR after 48h incubation at IC50 3
μM.

Figure 3.9. Cell cycle arrest analysis for analogue MMA132 showed induction activity
for G1/S phases.

3.3 Conclusion:
In conclusion, CUCS-inspired analogues were designed using molecular
modeling to mimic cucurbitacins structure more specifically its side chain, which is the
most important pharmacophore for its biological activities and installed it into the estrone
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skeleton structure at C-17 in the presence of double bond at C-16, C-17 position and
methoxy group at C-3 which significantly improved their activity and the selectivity.
Assortment of enone side chain were installed at the estrone skeleton structure such as
isopropanol,

para-flourobenzene,

para-chlorobenzene,

para-bromobenzene,

para-

methoxybenzene, para-trifluromethyl benzene, para-nitrobenzene, 5-bromofuran and 5bromothiophene along with methoxy at C-3 and alkene at C16, C17. The cytotoxicity
results showed that MMA102 and MM132 are the most potent analogues among the
compunds that contain aliphatic enone side chains with IC50 3 𝜇𝑀 and 2 𝜇𝑀 respectively.
On the other hand compound MMA311 which contain thiophene enone side chain at C-25
along with methoxy group at C-3 showed an outstanding IC50 value of 0.7𝜇𝑀. Further
biological experiments including western blot showed that compounds MMA102 and
MMA132 have the ability to bind to the EGFR-TK and inhibit its phosphorylation by 90%.
Additionally, cell cycle arrest has been conducted on the same analogues and demonstrated
that they have the ability to arrest the cell cycle at G1/S phases.

3.4

Experimental section:

3.4.1

General:
All chemicals and solvents (ACS grades) were provided from Fisher Scientific or

Sigma Aldrich and used without any additional purification. All glassware were cleaned,
washed and dried in oven for overnight before conducting chemical reactions requires
anhydrous environment and nitrogen gas applied at the reaction time. Pre-coated silica gel
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PE plates were used to analyze the reaction condition and UV-light were also used at 254
or 365 to visualize the chemical reactions spots. All synthetic intermediate and final
compounds were purified using column chromatography with 230ˣ400 mesh silica gel. 1H
and

13

C NMR spectra were using Bruker AVANCE-400 MHZ and 600 MHZ NMR

spectrometer, in CDCl3 and D-acetone. NMR chemical shifts were presented in 𝛿(PPM)
using residual solvent peaks as standards (CDCl3, 7.26 (H), 77.16 (C)). High resolution
mass (HRMS) was gained using thermofinnigan MAT 95XL mass spectrometer at Buffalo
mass spectroscopy facility. X-ray crystallography were conducted in University of South
Dakota on compound 8 using Bruker APEXᴵᴵ diffractometer.

3.4.2

Protected Estrone:
O

O
Ethlyne glycol/ PTSA

H

Toluene

H

H

H

97%
HO

HO
Estrone

O

H
H

1

To a stirred solution of estrone (5g, 18.49mmole) in 308 ml of toluene, ethylene
glycol (4.52ml, 81.35mmole) was poured in one portion. Then para-toluene sulfonic acid
(0.21g, 1.10 mM) was added. The reaction mixture was allowed tom be stirred and reflux
for 8 hours utilizing Dean-Stark apparatus to prevent water from going back to the reaction
mixture. Then the reaction was cooled to the room temperature followed by the addition of
NaHCO3. Ethyl acetate (3 ˣ 50) was used to extract the aqueous level, then the organic layer
dried over sodium sulfate anhydrous and evaporated by vacuo to provide white solid of the
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protected estrone 1 (5.65g, 97%). The crude material was used in the next step without
purification. 1H NMR proved >95% purity.

1H

NMR (400 MHz, CDCl3) δ 7.20 (d, J = 8.6 Hz, 1H, -CH(1)), 6.72 (dd, J = 8.6,

2.8 Hz, 1H, -CH (2)), 6.62 (d, J = 2.7 Hz, 1H, -CH (4)), 3.93 (m, 4H, 2X -CH2 (20, 21)),
2.88 (m, 2H), 2.29 (m, 2H, CH2 (11)), 2.03 (m, 1H), 1.84 (m, 4H), 1.49 (m, 6H), 0.92 (s,
3H).
13C

NMR (100 MHz, CDCl3) δ 157.5 (C-3), 138.1 (C-5), 132.9 (C-10), 126.3 (C-

1), 118.9 (C-17), 113.8 (C-4), 111.5 (C-2), 65.4 (C-20), 64.7 (C-21), 49.46 (C-13), 46.16
(C-14), 43.92 (C-9), 38.56 (C-8), 34.33 (C-16), 30.72 (C-6), 29.68 (C-11), 26.67 (C-7),
26.05 (C-12), 22.48 (C-15), 14.4(C-18).

3.4.3

Methoxy Protected Estrone 2:

O
H
H
HO

O
O

KOH/MeI
DMSO

H

93%

O

H
H
O

H

2

1

Protected estrone 1 (5.65g, 17.97 mmole) was dissolved in DMSO (90 ml),
followed by the addition of crushed granulate potassium hydroxide (4.032g, 71.88 mmole),
then methyl iodide (2.24g, 35.94 mmole) was added to the reaction mixture. The reaction
was stirred at room teprature for 2 hours and quenched by the addition of water (400 ml)
to be stirred for 15 minutes. Methylene dichloride (3 ˣ100 ml) was used to extract the
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aqueous layer. The organic layer was dried over sodium sulfate anhydrous and
concentrated in Vacuo to obtained the methoxy protected estrone 2 (5.5g, 93%) as a white
powder. The crude material was used in the next step without purification.

1H

NMR (400 MHz, CDCl3) δ 7.20 (d, J = 8.6 Hz, 1H, -CH(1)), 6.72 (dd, J = 8.6,

2.8 Hz, 1H, -CH(2)), 6.62 (d, J = 2.7 Hz, 1H, -CH(4)), 3.93 (m, 4H, 2 X -CH2 (20, 21)),
3.77 (s, 3H, -OCH3 (3)), 2.88 (m, 2H), 2.29 (m, 2H), 2.03 (m, 1H), 1.84 (m, 4H), 1.49 (m,
6H), 0.92 (s, 3H).

13C

NMR (100 MHz, CDCl3) δ 157.5 (C-3), 138.0 (C-5), 132.5 (C-10), 126.3 (C-

1), 118.9 (C-17), 113.9 (C-4), 111.6 (C-2), 65.4 (C-20), 64.7(C-21), 55.8 (-OCH3), 49.46
(C-13), 46.16 (C-14), 43.92 (C-9), 38.56 (C-8), 34.33 (C-16), 30.72 (C-6), 29.68 (C-11),
26.67 (C-7), 26.05 (C-12) , 22.48 (C-15), 14.43 (C-18).

3.4.4

Methoxy Estrone 3:
O
H
H
O

2

H

O
O

10%HCl/
Aceton

H
H

95%
O

H

3

To stirred solution of methoxy protected estrone 2 (5.5g, 16.745mmole) in acetone
(140ml), 10% HCl (140ml) was added. The reaction mixture allowed to stirred at room
temperature for overnight. The reaction was quenched by dropwise addition of NaHCO3 to
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balance the acidity of the mixture. Ethyl acetate (3 ˣ 50) was used to extract the aqueous
level, and then the organic layer dried over sodium sulfate anhydrous and evaporated by
vacuo. The crude product was purified using silica gel column chromatography (20% ethyl
acetate in hexane) to provide methoxy estrone 3 (4.52g, 95%) as white solid.

1H

NMR (400 MHz, CDCl3) δ 7.20 (d, J = 8.6 Hz, 1H, -CH (1)), 6.72 (dd, J = 8.6,

2.8 Hz, 1H, -CH (2)), 6.62 (d, J = 2.7 Hz, 1H, -CH (4)), 3.77 (s, 3H, -OCH3 (3)), 2.88 (m,
2H), 2.29 (m, 2H), 2.03 (m, 1H), 1.84 (m, 4H), 1.49 (m, 6H), 0.92 (s, 3H).

13C

NMR (100 MHz, CDCl3) δ 220.8 (C-17), 157.5 (C-3), 138.0 (C-5), 132.5 (C-

10), 126.3 (C-1), 113.9 (C-4), 111.6 (C-2), 55.8 (-OCH3), 49.46 (C-13), 46.16 (C-14),
43.92 (C-9), 38.56 (C-8), 34.33 (C-16), 30.72 (C-6), 29.68 (C-11), 26.67 (C-7), 26.05 (C12), 22.48 (C-15), 14.43 (C-18).

4.4.5 Cyanohydrin:

Si
O

O
H
H
O

3

H

TMSCN/ZnI2
H

DCM
91%

H
O

N

H

4

To a stirred solution of 3 (6g, 21.09mmole) in a dry dichloromethane (DCM) (42.2
ml), zinc iodide (0.6g, 1.87mmole) were added followed by the addition of trimethylsillyl

129

cyanide (TMSCN) (11.8ml, 94.94mmole). The reaction were allowed to be stirred for 3h
at the room temperature then concentrated in vacuo. A mixture of water/ethyl acetate (1:1)
ration were added to the concentrated slurry, then the aqueous layer was extracted using
ethyl acetate (3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4) and concentrated
under vacuo. The crude product was purified using silica gel column chromatography (20%
ethyl acetate in hexane) to give (7.2g, 89%) of compound 4 as a white solid.

1H

NMR (400 MHz, Chloroform-d) δ 7.04 (dd, J = 8.6, 1.0 Hz, 1H), 6.56 (dd, J =

8.6, 2.8 Hz, 1H), 6.47 (d, J = 2.8 Hz, 1H), 3.61 (s, 3H), 2.70 (m, 2H), 2.36 – 2.18 (m, 2H),
2.10 (td, J = 10.9, 10.4, 4.2 Hz, 1H), 1.91 – 1.58 (m, 5H), 1.48 (m, 1H), 1.39 – 1.27 (m,
3H), 1.27 – 1.13 (m, 1H), 0.72 (d, J = 8.8 Hz, 1H), 0.68 (s, 2H), 0.11 (s, 9H).

13C

NMR (101 MHz, Chloroform-d) δ 156.26, 136.44, 130.77, 125.08, 121.07,

112.52, 110.26, 80.39, 53.86, 47.04, 46.95, 42.04, 38.04, 36.75, 32.00, 28.44, 25.90, 25.00,
21.76, 10.97.
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3.4.6

Alkene 5:

Si
O
H
H
O

H

4

N

N
POCl3/ DBU
Pyridine
69%

H
H
O

H

5

To a stirred solution of 4 (5g, 13.047mmole) in dry pyridine (125ml), phosphorus
oxychloride (POCl3) (8.65ml, 92.83mmole) and 1, 8-Diazabicyclo[20]undec-7-ene (DBU) (8.8ml,
58.7115mmole). The mixture were heated to the reflux temperature and stirred for 28h, then cooled
to the room temperature. The black mixture was spilled into cooled mixture of (1:1) 5%
hydrochloric acid (75ml) and ethyl acetate (75ml). The aqueous phase was extracted with ethyl
acetate (3ˣ50ml), dried with sodium sulfate anhydrous (Na2SO4), and concentrated under vacuo.
The crude material was purified using silica gel chromatography (10% ethyl acetate in hexane) to
yield (2.4g, 64.05%) as a white solid.

1H

NMR (400 MHz, Chloroform-d) δ 7.24 (dd, 1H), 6.78 – 6.59 (m, 3H), 3.74 (s,

3H), 2.97 (m, 2H), 2.40 (m, 2H), 2.31 – 2.11 (m, 2H), 2.04 (m, 1H), 1.89 (m, 1H), 1.72 –
1.50 (m, 3H), 1.51 – 1.35 (m, 1H), 1.34 – 1.23 (m, 1H), 0.92 (s, 3H).

13C

NMR (101 MHz, Chloroform-d) δ 157.68, 147.36, 137.59, 132.07, 127.56,

126.07, 115.90, 113.96, 111.56, 55.24, 55.22, 48.51, 44.15, 37.24, 34.13, 32.73, 29.59,
27.74, 26.28, 16.47.
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3.4.7

Methyl ketone 6:

H
H
O

5

O

N
MeLi/MTBE
TFA
H

H
H

83%
O

H

6

In a 2-nacked flask, methyl lithium (MeLi) (12.8ml, 20.4654mmole) were added in a
dropwise matter to a stirred solution of alkene 5 (3g, 10.2327mmole) in methyl tert-butyl ether
(MTBE) (55ml) at 0oC. the reaction stirred at 0oC for 1h, then the reaction cooled down to -78 oC
to quench it with trifluroacetic acid (2.554ml, 33.38mmole) in one portion followed by the addition
of 10%H3PO4 (26ml). The mixture was allowed to stir for 30 min. the mixture was poured into
50ml ethyl acetate and 25ml 10% H3PO4. The aqueous layer was washed with ethyl acetate
(3ˣ50ml). The organic extract was washed with 250ml water, 15ml 1M Na2CO3, then 250ml water,
and 100ml water. The organic extract was dried over sodium sulfate anhydrous (Na2SO4), filtrated,
concentrated under vacuo. The resulted product purified by silica gel column chromatography (10%
ethyl acetate in hexane) to give (2.97g, 93.6%) of methyl ketone 6 as a white solid.

H NMR (400 MHz, Chloroform-d) δ 7.24 (m, 1H), 6.77 – 6.66 (m, 3H), 3.76 (s, 3H), 2.98

1

(m, 2H), 2.56 (m, 2H), 2.44 – 2.30 (m, 2H), 2.27 (s, 3H), 2.19 – 2.04 (m, 1H), 1.96 – 1.85 (m, 1H),
1.72 – 1.60 (m, 3H), 1.56 (m, 1H), 1.45 (m, 1H), 1.26 (m, 1H), 0.91 (s, 3H).

13

C NMR (101 MHz, Chloroform-d) δ 196.78, 157.48, 155.52, 144.38, 137.73, 132.75,

126.13, 113.87, 111.41, 55.61, 55.20, 46.52, 44.26, 37.04, 34.84, 32.03, 29.67, 27.81, 27.19, 26.50,
15.97.
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3.4.8

Cyanohydrin 7:

Si O

O
H
H
O

6

H

TMSCN/ZnI2

H

H

DCM

76%

N

O

H

7

To a stirred solution of methyl ketone 6 (3g, 9.67mmole) in a dry dichloromethane
(DCM) (20ml), zinc iodide (0.1g, 0.3mmole) were added followed by the addition of
trimethylsillyl cyanide (TMSCN) (1.6ml, 12.6mmole). The reaction were allowed to be
stirred for 3h at the room temperature then concentrated in vacuo. A mixture of water/ethyl
acetate (1:1) ration were added to the concentrated slurry, then the aqueous layer was
extracted using ethyl acetate (3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4) and
concentrated under vacuo. The crude product was purified using silica gel column
chromatography (10% ethyl acetate in hexane) to give a mixture (1:1) diasteriomers of
Cyanohydrin 7 (3.1g, 78.3%).

1H

NMR (400 MHz, Chloroform-d) δ 7.33 (m, 1H), 6.86 – 6.68 (m, 2H), 6.04 (m,

1H), 3.92 (s, 3H), 3.00 (m, 2H), 2.52 – 2.26 (m, 2H), 2.18 – 1.88 (m, 7H), 1.88 – 1.62 (m,
2H), 1.60 – 1.39 (m, 2H), 1.33 – 1.08 (m, 3H), 1.08 – 0.93 (m, 1H), 0.42 (s, J = 2.9 Hz,
9H).
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13C

NMR (101 MHz, Chloroform-d) δ 156.07, 152.88, 136.22, 131.08, 126.35,

124.52, 120.07, 112.40, 109.95, 68.03, 67.21, 56.16, 53.58, 46.13, 45.60, 42.50, 35.70,
34.16, 33.55, 33.28, 30.23, 29.35, 29.02, 28.21, 26.16, 24.98, 23.90, 21.29, 15.90, 12.80.

3.4.9

Hydroxyl methyl ketone 8 and 8`:

Si O

O

7

HO

MeLi/ Et2O/ 0Co

H
H

O

N

H

H
H

Glacial acetic acid

79%

O

H

8 and 8

To a stirred solution of diasteriomers 7 (2.5g, 6.108mmole) in a dry ether (18ml),
methyl lithium (MeLi) (11.5ml, 18.324mmole) was added in dropwise at 00C. The reaction
mixture was allowed to stir for 2h at 00C, then the reaction quenched by adding glacial
acetic acid (2.3ml) in one portion at 00C and allowed to stir for 30 min. at 00C. Sodium
bicarbonate solution was added to neutralize the acidic mixture. Dichloromethane (DCM)
was used to extract the aqueous layer (3ˣ50ml), dried under sodium sulfate anhydrous
(Na2SO4), then concentrated under vacuo. The resulted diasteriomers were purified by
silica gel column chromatography (100% hexane, 5% ethyl acetate in hexane and 10%
ethyl acetate in hexane) to give the two separated diasteriomers hydroxyl methyl ketone 8
and 8`.
Compound 8 1H NMR (400 MHz, Chloroform-d) δ 7.15 (m, 1H), 6.70 (m, 1H),
6.62 (m, 1H), 5.90 (m, 1H), 4.25 (s, 1H), 3.76 (s, 3H), 2.87 (m, 2H), 2.31 – 2.14 (m, 3H),
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2.10 – 1.99 (m, 2H), 1.91 (m, 2H), 1.66 – 1.53 (m, 3H), 1.53 (s, 3H), 1.48 – 1.33 (m, 1H),
1.31 – 1.12 (m, 2H), 1.01 (s, 3H), 0.98 – 0.79 (m, 1H).
13

C NMR (101 MHz, Chloroform-d) δ 211.7, 157.45, 155.56, 137.86, 132.73, 128.85,

126.04, 113.86, 111.39, 79.55, 57.49, 55.20, 47.79, 44.07, 37.09, 34.48, 31.05, 29.70, 27.64, 26.27,
25.31, 23.33, 17.24.

Compound 8` 1H NMR (400 MHz, Chloroform-d) δ 7.28 (m, 1H), 6.69 (m, 1H),
6.62 (m, 1H), 5.89 (m, 1H), 4.08 (s, 1H), 3.76 (s, 3H), 2.96 – 2.85 (m, 2H), 2.85 – 2.78 (m,
2H), 2.37 – 2.15 (m, 3H), 2.08 – 1.76 (m, 3H), 1.76 – 1.47 (m, 3H), 1.47 – 1.34 (m, 2H),
1.30 – 1.08 (m, 3H), 1.06 – 0.85 (m, 3H), 0.85 – 0.80 (m, 1H).

13C

NMR (101 MHz,

Chloroform-d) δ 210.93, 157.40, 155.48, 137.78, 132.75, 128.71, 126.01, 113.81, 111.32,
80.04, 56.61, 55.16, 48.09, 43.82, 37.16, 36.13, 31.01, 29.62, 27.59, 26.49, 24.88, 23.69,
16.93.

3.4.10 ∆9,11 hydroxyl methyl ketone 15 and 15`:
O

O

HO

HO
H
H

H

DCM
H

O
8 and 8

DDQ/MeOH
72%

H
O

15 and 15

To a stirred solution of hydroxyl methyl ketone 8 and 8` (1g, 2.823mmole) in a dry
dichloromethane (DCM) (14.1ml), a solution

of

2,3-Dichloro-5,6-dicyano-1,4-
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benzoquinone (DDQ) (0.83ml, 3.6699mmole) dissolved in methanol (31ml) was added at
00C under nitrogen. The reaction was raised to the room temperature and allowed to be
stirred for 1h. The resulted crude material was concentrated under vacuo, then silica gel
column chromatography were used to purify the crude material (10% ethyl acetate in
hexane) to provide ∆9,11 hydroxyl methyl ketone 15 and 15`(0.82g, 82.4%) as a white
material.
Compound 15 1H NMR (400 MHz, Chloroform-d) δ 7.49 (m, 1H), 6.69 – 6.49
(m, 2H), 6.25 (m, 1H), 5.73 (m, 1H), 4.42 (s, 1H), 3.70 (s, 3H), 2.80 – 2.68 (m, 2H), 2.23
– 2.17 (m, 3H), 2.14 (m, 1H), 2.12 – 1.99 (m, 1H), 1.99 – 1.85 (m, 1H), 1.55 (m, 3H), 1.43
(m, 1H), 1.35 – 1.24 (m, 1H), 1.18 (m, 2H), 1.03 (s, 3H), 0.79 (m, 1H).
13C

NMR (101 MHz, Chloroform-d) δ 211.13, 158.33, 153.91, 138.72,135.69,

128.77, 127.45,125.16, 117.25, 113.30, 112.61, 79.73, 55.22, 54.01, 46.13, 37.14, 36.62,
31.89, 29.96, 28.40, 25.59, 23.19, 17.15.

3.4.11 Ester 12:
O
O

TBSCl/
Imidazol
OH

11

O
O

O

DMF

TBS

12

To a stirred solution of commercially available methyl2-hydroxy isobutyrate 11
(5g, 42.3mmole) in dimethyl formmide (DMF) (12.5ml), tert-butylsilyl chloride (TBSCl)
(7.65g, 50.75mmole) were added followed by the addition of imidazole (7.45g,
110mmole). The reaction was stirred for 24h, then solution of sodium bicarbonate (25ml)

136

was added. The aqueous layer was extracted using ethyl acetate (3ˣ50ml), dried over
sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under vacuo. The crude
product was purified using silica gel column chromatography (10% ethyl acetate in hexane)
to give ester 12 (7.2g, 73.2%) as a yellow oil.
1H

NMR (400 MHz, CDCl3): d=3.60(s, 3H), 1.34 (s, 6H), 0.80 (s, 9 H), 0.08 ppm

(s, 6H);
13C

NMR (100 MHz, CDCl3): d=175.8, 74.5, 51.4, 28.4, 25.5, 17.9, 3.2 ppm.

3.4.12 Alcohol 13:
O
DiBAL-H

O

O
12

HO
TBS

O

Hexane/ -78oC

TBS

13

To a stirred solution of ester 12 (7.2g, 30.98mmole) in hexane (98ml),
Diisobutylaluminium hydride (DiBAL-H) (56.8ml, 68.16mmole) was added at -78oC in a
dropwise matter. The reaction stirred for 30 min. at 00C, then for 20 min. at the room
temperature. The reaction then cooled back to -78oC, followed by the addition of solution
of potassium tartrate (45ml). The reaction was allowed to stir for overnight. The aqueous
phase was extracted using ethyl acetate (3ˣ50ml), dried over sodium sulfate anhydrous
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was
used to purify the crude material (20% ethyl acetate in hexane) to give alcohol 13 (5.75g,
90.8%) as colorless liquid.
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1H

NMR (400 MHz, CDCl3): d=3.19 (s, 2H), 2.31 (s, 1 H), 1.11 (s, 6 H), 0.76 (s,

9 H), 0.08 ppm (s, 6H);
13C

NMR (100 MHz, CDCl3): d=76.3, 74.4, 28.5, 28.0, 20.3, 0.3 ppm.

3.4.13 Aldehyde 14:
O
TPAP/NMO

HO

O
13

TBS

DCM/ 5oMS

H

O
14

TBS

To a stirred solution of alcohol 13 (2g, 9.7858mmole) in a dry dichloromethane
(DCM) (98ml), active molecular sieves (4oA, 2.3g) was added, then the reaction mixture
was allowed to stir for 5 min. followed by the addition on N-Methylmorpholine N-oxide
(NMO) (2.3g, 19.57mmole), then Tetrapropylammonium perruthenate (TPAP) (0.34g,
0.98mmole) was added at 00C. The reaction stirred at 00C for 2h, then at room temperature
for 24h. Pad of silica gel were used to filtrate the reaction mixture using diethyl ether as
eluting solvent. The filtrated material concentrated under vacuo to provide aldehyde 14
(1.45g, 73.3%) as colorless oil.
1H

NMR (400 MHz, CDCl3): d=9.44 (s, 1H), 1.17 (s, 6 H), 0.79 (s, 9H), 0.08 ppm

(s, 6H).
13C

NMR (100 MHz, CDCl3): d=206.4, 80.3, 28.0, 27.2, 20.4, 0.3 ppm.
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3.4.14 Protected enone 9 and 9`:
O
HO

LDA/ -78 C
THF

H
H
O

O
HO

o

O
H

8 and 8

H

/THF,-78oC
OTBS
53%

O TBS

H
H
O

H

9 and 9

To a stirred solution of hydroxyl ketone 8 and 8 (0.5g, 1.4115mmole) in a dry
tetrahydrofuran (THF) (3ml), lithiumdiisopropyl amine (LDA) (2.5ml, 5.08mmole) was added in
a dropwise at -78oC the reaction mixture was allowed to stir at -78oC for 1 h, then the solution of
aldehyde 14 (0.6g, 2.823mmole) in THF (18.8ml) was added to the reaction mixture at -78oC. The
reaction was allowed to stir and warm to the room temperature for 24h. The quench of the reaction
was completed by the addition of ammonium chloride (NH4Cl) (25ml). The aqueous layer was
extracted using ethyl acetate (3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and
concentrated under vacuo. Silica gel column chromatography was used to purify the crude material
(10% ethyl acetate in hexane) to provide protected enone 9 and 9` (0.44g, 57.9%).
Compound 9 1H NMR (400 MHz, Chloroform-d) δ 7.13 – 6.92 (m, 2H), 6.70 – 6.54 (m,
2H), 6.52 (s, 1H), 5.82 (m, 1H), 4.32 (s, 1H), 3.65 (d, J = 4.2 Hz, 3H), 2.76 (m, 2H), 2.20 – 2.05
(m, 1H), 1.97 (m, 1H), 1.86 – 1.76 (m, 1H), 1.81 – 1.68 (m, 1H), 1.54 – 1.39 (m, 2H), 1.37 (d, J =
9.8 Hz, 3H), 1.33 – 1.19 (m, 6H), 1.23 – 1.03 (m, 4H), 0.93 (s, 2H), 0.91 – 0.81 (m, 1H), 0.86 –
0.73 (m, 12H), 0.78 – 0.70 (m, 1H), 0.11 (s, 3H).

13

C NMR (101 MHz, Chloroform-d) δ 203.82, 159.48, 158.50, 157.15, 139.80, 134.70,

131.27, 128.01, 120.90, 115.87, 113.42, 80.52, 76.84, 59.54, 57.12, 49.55, 46.26, 39.10, 36.14,
33.07, 31.88, 31.72, 29.70, 28.37, 28.26, 27.88, 27.79, 27.75, 27.24, 20.22, 20.05, 19.98, -1.47.
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Compound 9

1

H NMR (400 MHz, Chloroform-d) δ 7.19-7.07 (m, 2H), 6.94-6.92 (m,

2H), 6.65 (s, 1H), 5.90 – 5.77 (m, 1H), 4.26 (s, 1H), 3.67 (d, J = 4.2 Hz, 3H), 2.87 – 2.71 (m, 2H),
2.22 (m, 1H), 2.19 (m, 1H), 2.15 (m, 1H), 1.62 (m, 1H), 1.55 – 1.42 (m, 2H), 1.41 (d, J = 9.8 Hz,
3H), 1.31 – 1.21 (m, 6H), 1.21 – 1.12 (m, 4H), 0.93 (m, 2H), 0.91 – 0.81 (m, 1H), 0.88 – 0.75 (m,
12H), 0.80 – 0.74 (m, 1H), 0.12 (s, 3H).

C NMR (101 MHz, Chloroform-d) δ 203.55, 159.45, 157.93, 157.44, 139.86, 134.92,

13

131.22, 128.12, 121.43, 115.91, 113.41, 81.27, 75.61, 58.83, 57.20, 50.10, 45.99, 39.28, 38.38,
33.08, 31.92, 31.76, 29.74, 28.61, 28.41, 28.07, 27.90, 27.82, 27.12, 20.28, 20.12, 19.24, -1.43.

3.4.15 MMA102 and MMA 132:

HO
H
H
O

H
9 and 9

O

HO

O
OH

OTBS
TBAF
THF

H
H

H

O
MMA102 and MMA132

To a stirred solution of protected enone 9 and 9` (0.4g, 0.742mmole) in
tetrahydrofuran (THF) (11.5ml), tetrabutyl ammonium fluoride

(TBAF) (2.3ml,

2.3mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was added
to quench the reaction. Ethyl acetate (3ˣ50ml), dried over sodium sulfate anhydrous
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was
used to purify the crude material (10% ethyl acetate in hexane) to provide MMA102 and
MMA132 (0.28g, 88.88%).
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Compound MMA102 1H NMR (400 MHz, Chloroform-d) δ 7.14 – 6.98 (m, 2H),
6.65 – 6.45 (m, 2H), 5.83 (m, 2H), 4.02 (s, 1H), 3.67 (s, 3H), 2.77 (m, 2H), 2.26 – 2.06 (m,
2H), 1.97 – 1.70 (m, 3H), 1.61 (m, 1H), 1.45 (s, 3H), 1.42 (m, 6H), 1.24 – 1.07 (m, 4H),
0.85 – 0.74 (m, 2H), 0.65 (s, 3H).
13C

NMR (101 MHz, Chloroform-d) δ 201.30, 157.39, 155.23, 154.75, 137.86,

132.85, 129.19, 126.07, 119.36, 113.83, 111.36, 79.17, 71.18, 56.77, 55.21, 48.08, 43.87,
37.21, 36.20, 31.08, 29.67, 29.45, 29.31, 27.61, 26.51, 24.90, 17.36. HR-FT-MS calcd for
C27H36O4Na1 447.2506 found 447.24952.
Compound MMA132 1H NMR (400 MHz, Chloroform-d) δ 7.13 – 7.01 (m, 2H),
6.65 – 6.50 (m, 2H), 5.84 (m, 2H), 4.02 (s, 1H), 3.67 (s, 3H), 2.77 (m, 2H), 2.22 – 1.88 (m,
2H), 1.78 (m, 3H), 1.64 (m, 1H), 1.57 (s, 3H), 1.36 (m, 6H), 1.28- 1.15 (m, 4H), 1.08 (m,
2H), 0.98 (s, 3H).
13C

NMR (101 MHz, Chloroform-d) δ 201.55, 157.38, 155.40, 154.86, 137.88,

132.75, 129.45, 126.01, 118.76, 113.81, 111.39, 78.61, 71.18, 57.40, 55.19, 47.71, 44.07,
37.06, 34.29, 31.10, 29.70, 29.47, 29.42, 27.59, 26.23, 25.18, 17.27. HR-FT-MS calcd for
C27H36O4Na1 447.2506 found 447.24952.
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3.4.16 ∆9,11 protected enone 16:
O
HO

O
HO

LDA/ -78oC
THF

H

O
H

O
H

H

O
15

OTBS

/THF,-78oC

51%

TBS

H
O

16

To a sirred solution of ∆9,11 hydroxyl ketone 15 (1g, 2.84mmole) in a dry
tetrahydrofuran (THF)

(5.7ml), lithiumdiisopropyl amine (LDA) (5.112mlml,

10.224mmole) was added in a dropwise at -78oC the reaction mixture was allowed to stir
at -78oC for 1 h, then the solution of aldehyde 14 (1.15, 5.68mmole) in THF (37.8ml) was
added to the reaction mixture at -78oC. The reaction was allowed to stir and warm to the
room temperature for 24h. The quench of the reaction was completed by the addition of
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate
3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl
acetate in hexane) to provide ∆9,11 protected enone 16.

1H

NMR (600 MHz, Chloroform-d) δ 7.43 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 15.2

Hz, 1H), 6.72 – 6.63 (m, 1H), 6.66 – 6.61 (m, 1H), 6.54 (dd, J = 14.5, 3.2 Hz, 1H), 5.94
(dt, J = 5.2, 2.3 Hz, 1H), 5.85 (dd, J = 3.3, 1.6 Hz, 1H), 4.37 (s, 1H), 3.71 (s, 3H), 2.91 –
2.71 (m, 2H), 2.26 (ddt, J = 13.9, 7.1, 3.6 Hz, 1H), 2.23 – 2.15 (m, 1H), 2.09 – 1.92 (m,
2H), 1.91 (dt, J = 17.4, 3.2 Hz, 1H), 1.58 – 1.48 (m, 1H), 1.46 – 1.33 (m, 2H), 1.34 – 1.20
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(m, 4H), 1.23 – 1.12 (m, 3H), 1.15 – 1.04 (m, 2H), 0.95 (s, 3H), 0.93 – 0.77 (m, 9H), 0.80
– 0.71 (m, 6H).
13C

NMR (151 MHz, Chloroform-d) δ 203.89, 160.41, 158.95, 155.34 (d, J = 26.4

Hz), 139.50, 137.55, 131.35, 129.65, 127.20, 120.62, 119.70, 115.42, 114.71, 80.74, 75.69,
57.33, 56.15, 47.97, 38.91, 38.66, 33.96, 32.03, 31.96, 31.90, 30.48, 27.98 – 27.82 (m),
27.56, 20.25 (d, J = 5.7 Hz), 19.23, -0.04 (t, J = 7.5 Hz).

3.4.17 MMA 128 (∆9,11 OH enone):
O

O

HO

HO
O

H

H

TBAF
H

O

OH

TBS

16

THF
85%

H
O

MMA128

To a stirred solution of ∆9,11 protected enone 16 and 16 (0.25g, 0.466mmole) in
tetrahydrofuran (THF) (7.2ml), tetrabutyl ammonium fluoride

(TBAF) (1.44ml,

1.44mmole) was added and stirred for 6h. ammonium chloride (NH4Cl) solution was added
to quench the reaction. Ethyl acetate (3ˣ50ml), dried over sodium sulfate anhydrous
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was
used to purify the crude material (10% ethyl acetate in hexane) to provide MMA128
(0.162g, 82.35%).
1H

NMR (400 MHz, Chloroform-d) δ 7.11 – 7.02 (m, 2H), 6.63 – 6.47 (m, 2H),

5.82 (m, 2H), 5.72 (m, 1H), 4.01 (s, 1H), 3.64 (s, 3H), 2.73 (m, 1H), 2.20 – 1.86 (m, 2H),
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1.78 (m, 2H), 1.64 (m, 1H), 1.57 (s, 3H), 1.36 (m, 6H), 1.28- 1.15 (m, 3H), 1.08 (m, 2H),
0.98 (s, 3H).
13C

NMR (101 MHz, Chloroform-d) δ 201.53, 157.37, 155.38, 154.83, 137.87,

132.74, 129.43, 125.92, 118.74, 113.80, 111.37, 78.59, 71.16, 57.39, 55.17, 47.72, 44.05,
37.04, 34.27, 31.07, 29.68, 29.45, 29.40, 27.57, 26.21, 25.15, 17.24. HR-FT-MS calcd for
C27H34O4Na1 447.25181 found 447.24621.

3.4.18 Para-methoxyphenyl enone MMA265 and MMA333:
O

HO

HO
LDA/ -78oC
THF

H
H

H

O
8 and 8

P-PhOMeCO
49%

O

H
H
O

O
H

MMA265 AND MMA333

To a sirred solution of hydroxyl ketone 8 and 8` (0.3g, 0.847mmole) in a dry
tetrahydrofuran (THF) (1.7ml), lithiumdiisopropyl amine (LDA) (1.5ml, 3.05mmole) was
added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC for 1 h, then
the solution of Para-anisaldehyde (0.206ml, 1.7mmole) in THF (11.33ml) was added to
the reaction mixture at -78oC. The reaction was allowed to stir and warm to the room
temperature for 24h. The quench of the reaction was completed by the addition of
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate
(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl
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acetate in hexane) to provide Para-methoxy benzene enone MMA265 and MMA333
(0.26g, 65%).
Compound 265 1H NMR (400 MHz, Chloroform-d) δ 7.75 – 7.59 (m, 1H), 7.49 –
7.37 (m, 2H), 7.15 – 7.01 (m, 1H), 6.86 – 6.74 (m, 3H), 6.57 (dd, J = 8.6, 2.8 Hz, 1H), 6.56
– 6.47 (m, 1H), 5.86 (m, 1H), 4.30 (s, 1H), 3.72 (s, 3H), 3.64 (s, 3H), 2.84 – 2.66 (m, 2H),
2.23 – 2.08 (m, 4H), 2.00 – 1.72 (m, 3H), 1.64 – 1.55 (m, 3H), 1.48 (s, 3H), 1.35 – 1.25
(m, 1H), 1.24 – 1.08 (m, 3H).
13C

NMR (101 MHz, Chloroform-d) δ 200.61, 161.99, 157.43, 155.97, 144.24,

137.83, 132.89, 130.47, 128.74, 127.08, 126.07, 117.20, 114.47, 113.85, 111.35, 79.03,
60.42, 55.43, 55.17, 48.13, 43.90, 37.24, 36.26, 31.97, 29.76, 29.71, 29.69, 27.67, 26.56,
25.26, 21.06. HR-FT-MS calcd for C31H36O4Na1 495.2506 found 495.24909.

Compound MMA333 1H NMR (400 MHz, Chloroform-d) δ 7.74 – 7.57 (m, 1H),
7.47 – 7.35 (m, 2H), 7.13 – 6.99 (m, 1H), 6.84 – 6.72 (m, 3H), 6.55 (dd, J = 8.6, 2.8 Hz,
1H), 6.54 – 6.45 (m, 1H), 5.84 (m, 1H), 4.28 (s, 1H), 3.70 (s, 3H), 3.62 (s, 3H), 2.82 – 2.64
(m, 2H), 2.21 – 2.06 (m, 4H), 1.98 – 1.70 (m, 3H), 1.62 – 1.53 (m, 3H), 1.46 (s, 3H), 1.32
– 1.23 (m, 1H), 1.22 – 1.06 (m, 3H).
13C

NMR (101 MHz, Chloroform-d) δ 200.59, 161.97, 157.41, 155.95, 144.22,

137.81, 132.87, 130.45, 128.72, 127.06, 126.05, 117.18, 114.45, 113.83, 111.33, 79.01,
60.40, 55.41, 55.15, 48.11, 43.88, 37.22, 36.24, 31.95, 29.74, 29.69, 29.67, 27.65, 26.54,
25.24, 21.04. HR-FT-MS calcd for C31H36O4Na1 495.2506 found 495.24883.
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3.4.19 Para-flurophenyl enone MMA270 and MMA334:
O

HO

HO
LDA/ -78oC
THF

H
H

H

O
8 and 8

P-PhFCO
51%

O

H
H
O

F
H

MMA270 and MMA334

To a stirred solution of hydroxyl ketone 8 and 8` (0.4g, 1.13mmole) in a dry
tetrahydrofuran (THF) (2.3ml), lithiumdiisopropyl amine (LDA) (2.034ml, 4.068mmole)
was added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC for 1
h, then the solution of Para-flurobenzaldehyde (0.242ml, 2.26mmole) in THF (15ml) was
added to the reaction mixture at -78oC. The reaction was allowed to stir and warm to the
room temperature for 24h. The quench of the reaction was completed by the addition of
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate
(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl
acetate in hexane) to provide Para-flurobenzene enone MMA270 and MMA334 (0.32g,
61.5%).
Compound MMA270 1H NMR (400 MHz, Chloroform-d) δ 7.70 (m, 1H), 7.54 –
7.35 (m, 2H), 7.10 (m, 1H), 7.05 – 6.96 (m, 2H), 6.87 (m, 1H), 6.69 – 6.51 (m, 2H), 5.91
(m, 1H), 4.22 (s, 1H), 3.68 (s, 3H), 2.79 (m, 2H), 2.29 (s, 1H), 2.25 – 2.01 (m, 3H), 1.93 –
1.76 (m, 3H), 1.76 – 1.37 (m, 3H), 1.37 – 1.36 (m, 1H), 1.36 – 1.22 (m, 2H), 1 1.04 – 0.75
(m, 1H), 0.67 (s, 3H).
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13C

NMR (101 MHz, Chloroform-d) δ 200.56, 157.43, 155.69, 143.10, 137.99,

137.84, 132.84, 130.64, 130.60, 130.55, 129.05, 126.07, 119.29, 116.32, 116.10, 113.85,
111.37, 79.20, 55.21, 53.48, 48.13, 43.88, 37.23, 36.23, 31.14, 29.67, 27.64, 26.54, 25.10,
17.49. HR-FT-MS calcd for C30H33O3F1Na1 483.2306 found 483.22909.

Compound MMA334 1H NMR (400 MHz, Chloroform-d) δ 7.68 (m, 1H), 7.52 –
7.33 (m, 2H), 7.08 (m, 1H), 7.03 – 6.94 (m, 2H), 6.85 (m, 1H), 6.67 – 6.49 (m, 2H), 5.89
(m, 1H), 4.20 (s, 1H), 3.66 (s, 3H), 2.77 (m, 2H), 2.27 (s, 1H), 2.23 – 1.99 (m, 3H), 1.91 –
1.74 (m, 3H), 1.74 – 1.35 (m, 3H), 1.35 – 1.34 (m, 1H), 1.34 – 1.20 (m, 2H), 1.02 – 0.73
(m, 1H), 0.65 (s, 3H).
13C

NMR (101 MHz, Chloroform-d) δ 200.54, 157.41, 155.67, 143.08, 137.97,

137.82, 132.82, 130.62, 130.58, 130.53, 129.03, 126.05, 119.25, 116.30, 116.08, 113.83,
111.35, 79.18, 55.19, 53.46, 48.11, 43.86, 37.21, 36.21, 31.12, 29.65, 27.62, 26.52, 25.08,
17.47. HR-FT-MS calcd for C30H33O3F1Na1 483.2306 found 483.22909.

3.4.20 Para-chlorophenyl enone MMA287 and MMA316:
O

HO

HO
LDA/ -78oC
THF

H
H

H

O
8 and 8

P-PhClCO
59. 5%

O

H
H
O

Cl
H

MMA287 and MMA316
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To a stirred solution of hydroxyl ketone 8 and 8` (0.3g, 0.847mmole) in a dry
tetrahydrofuran (THF) (1.7ml), lithiumdiisopropyl amine (LDA) (1.5ml, 3.05mmole) was
added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC for 1 h, then
the solution of Para-anisaldehyde (0.206ml, 1.7mmole) in THF (11.33ml) was added to
the reaction mixture at -78oC. The reaction was allowed to stir and warm to the room
temperature for 24h. The quench of the reaction was completed by the addition of
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate
(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl
acetate in hexane) to obtained P-chlorobenzene enone MMA287 and MMA316 (0.25g,
62%).
Compound 287 1H NMR (600 MHz, Chloroform-d) δ 7.80 (m, 1H), 7.56 – 7.51
(m, 2H), 7.44 – 7.38 (m, 2H), 7.21 (m, 1H), 7.03 (m, 1H), 6.73 (m, 1H), 6.66 (m, 1H), 6.03
(m, 1H), 4.29 (s, 1H), 3.80 (s, 3H), 2.97 – 2.84 (m, 2H), 2.36 – 2.25 (m, 2H), 2.10 – 2.00
(m, 1H), 1.97 – 1.87 (m, 1H), 1.77 (m, 1H), 1.64 (s, 3H), 1.55 – 1.41 (m, 2H), 1.37 – 1.25
(m, 2H), 0.94 (m, 2H), 0.79 (s, 3H).
13C

NMR (151 MHz, Chloroform-d) δ 200.54, 157.45, 155.66, 142.92, 137.84,

136.86, 132.83, 129.77, 129.30, 129.12, 126.07, 120.00, 113.86, 111.38, 79.24, 56.83,
55.21, 48.14, 43.88, 37.24, 36.23, 31.96, 31.15, 29.74, 29.67, 29.40, 27.64, 26.54, 25.07,
17.51. HR-FT-MS calcd for C30H33O3Cl1Na1 499.2010 found 499.19958.
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Compound 316 1H NMR (600 MHz, Chloroform-d) δ 7.78 (d, m, 1H), 7.54 – 7.49
(m, 2H), 7.42 – 7.36 (m, 2H), 7.19 (m, 1H), 7.01 (m, 1H), 6.71 (m, 1H), 6.64 (m, 1H), 6.01
(m, 1H), 4.27 (s, 1H), 3.78 (s, 3H), 2.95 – 2.82 (m, 2H), 2.34 – 2.23 (m, 2H), 2.08 – 1.98
(m, 1H), 1.95 – 1.85 (m, 1H), 1.75 (m, 1H), 1.62 (s, 3H), 1.53 – 1.39 (m, 2H), 1.35 – 1.23
(m, 2H), 0.92 (m, 2H), 0.77 (s, 3H).
13C

NMR (151 MHz, Chloroform-d) δ 200.52, 157.43, 155.64, 142.90, 137.82,

136.84, 132.81, 129.75, 129.28, 129.10, 126.05, 119.98, 113.84, 111.36, 79.22, 56.81,
55.19, 48.12, 43.86, 37.22, 36.21, 31.94, 31.13, 29.72, 29.65, 29.38, 27.62, 26.52, 25.05,
17.49. HR-FT-MS calcd for C30H33O3Cl1Na1 499.2010 found 499.19943.

3.4.21 Para-bromophenyle enone MMA288 and MMA319:
O

HO

HO
LDA/ -78oC
THF

H
H

H

O
8 and 8

P-PhBrCO
59%

O

H
H
O

Br
H

MMA288 and MMA319

To a stirred solution of hydroxyl ketone 8 and 8` (0.4g, 1.13mmole) in a dry
tetrahydrofuran (THF) (2.3ml), lithiumdiisopropyl amine (LDA) (2.034ml, 4.068mmole)
was added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC for 1
h, then the solution of Para-flurobenzaldehyde (0.242ml, 2.26mmole) in THF (15ml) was
added to the reaction mixture at -78oC. The reaction was allowed to stir and warm to the
room temperature for 24h. The quench of the reaction was completed by the addition of
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate
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(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl
acetate in hexane) to provide para-bromobenzene enone MMA288 and MMA319 (0.35g,
59%).
Compound MMA288 1H NMR (600 MHz, Chloroform-d) δ 7.70 – 7.61 (m, 1H),
7.53 – 7.42 (m, 2H), 7.41 – 7.32 (m, 2H), 7.15 – 7.08 (m, 1H), 6.93 (m, 1H), 6.63 (m, 1H),
6.55 (d, 1H), 5.91 (m, 1H), 4.16 (s, 1H), 3.74 (s, 3H), 2.86 – 2.74 (m, 2H), 2.27 – 2.15 (m,
2H), 2.03 (s, 1H), 1.98 – 1.89 (m, 1H), 1.86 – 1.76 (m, 1H), 1.65 (s, 3H), 1.51 (d, 2H), 1.47
– 1.31 (m, 2H), 0.93 – 0.75 (m, 2H), 0.67 (s, 3H).
13C

NMR (151 MHz, Chloroform-d) δ 200.6, 157.5, 155.6, 142.9, 133.3, 132.9,

132.4, 129.8, 129.3, 129.1, 126.1, 125.3, 120.1, 113.9, 111.4, 79.3, 55.2, 53.4, 48.2, 43.9,
37.3, 36.3, 31.2, 29.8, 29.6, 27.8, 26.6, 25.2, 25.01, 17.6. HR-FT-MS calcd for
C30H33O3Br1Na1 543.1505 found 543.15269.
Compound MMA319 1H NMR (600 MHz, Chloroform-d) δ 7.68 – 7.59 (m, 1H),
7.51 – 7.40 (m, 2H), 7.39 – 7.30 (m, 2H), 7.13 – 7.06 (m, 1H), 6.91 (m, 1H), 6.61 (m, 1H),
6.53 (d, 1H), 5.89 (m, 1H), 4.14 (s, 1H), 3.72 (s, 3H), 2.84 – 2.72 (m, 2H), 2.25 – 2.13 (m,
2H), 2.01 (s, 1H), 1.96 – 1.87 (m, 1H), 1.84 – 1.74 (m, 1H), 1.63 (s, 3H), 1.49 (d, 2H), 1.45
– 1.29 (m, 2H), 0.91 – 0.73 (m, 2H), 0.65 (s, 3H).
13C

NMR (151 MHz, Chloroform-d) δ 200.4, 157.3, 155.4, 142.7, 133.1, 132.7,

132.2, 129.6, 129.1, 128.99, 127.99, 125.1, 119.99, 113.7, 111.2, 79.1, 54.99, 53.2, 48.02,
43.7, 37.1, 36.1, 31.01, 29.6, 29.4, 27.6, 26.4, 25.03, 24.99, 17.4. HR-FT-MS calcd for
C30H33O3Br1Na1 543.1505 found 543.14872.
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3.4.22 2-bromofuran enone MMA290 and MMA318:
O

HO

HO
LDA/ -78oC
THF

H
H

H

O
8 and 8

5-Br-2-furanaldehyde
53.7%

O
O

Br

H
H
O

H

MMA290 and MMA318

To a stirred solution of hydroxyl ketone 8 and 8` (0.4g, 1.13mmole) in a dry
tetrahydrofuran (THF) (2.3ml), lithiumdiisopropyl amine (LDA) (2.034ml, 4.068mmole)
was added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC for 1
h, then the solution of Para-flurobenzaldehyde (0.242ml, 2.26mmole) in THF (15ml) was
added to the reaction mixture at -78oC. The reaction was allowed to stir and warm to the
room temperature for 24h. The quench of the reaction was completed by the addition of
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate
(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl
acetate in hexane) to provide para-bromobenzene enone MMA290 and MMA318 (0.31g,
53.7%).
Compound MMA290 1H NMR (600 MHz, Chloroform-d) δ 7.47 (m, 1H), 7.21
(m, 1H), 6.88 (m, 1H), 6.73 (m, 1H), 6.67 (m, 2H), 6.48 (m, 1H), 6.04 – 6.00 (m, 1H), 4.33
(s, 1H), 3.83 (s, 3H), 2.97 – 2.84 (m, 2H), 2.31 (m, 2H), 2.11 – 1.98 (m, 1H), 1.99 – 1.88
(m, 1H), 1.76 (m, 1H), 1.64 – 1.55 (m, 3H), 1.53 – 1.41 (m, 2H), 1.36 – 1.26 (m, 2H), 0.98
– 0.83 (m, 2H), 0.78 (m , 3H).
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13C

NMR (151 MHz, Chloroform-d) δ 200.53, 157.43, 155.42, 153.03, 137.88,

132.90, 129.22, 128.92, 126.35, 126.07, 119.01, 117.47, 114.76, 113.85, 111.37, 79.17,
56.78, 55.21, 48.13, 43.89, 37.24, 36.29, 31.16, 29.69, 27.65, 26.56, 25.06, 17.48. HR-FTMS calcd for C28H31O4Br1Na1 533.1298 found 533.12803.

Compound MMA318 1H NMR (600 MHz, Chloroform-d) δ 7.45 (m, 1H), 7.19
(m, 1H), 6.86 (m, 1H), 6.71 (m, 1H), 6.65 (m, 2H), 6.46 (m, 1H), 6.02 – 5.98 (m, 1H), 4.31
(s, 1H), 3.81 (s, 3H), 2.95 – 2.82 (m, 2H), 2.29 (m, 2H), 2.09 – 1.96 (m, 1H), 1.97 – 1.86
(m, 1H), 1.74 (m, 1H), 1.62 – 1.53 (m, 3H), 1.51 – 1.39 (m, 2H), 1.34 – 1.24 (m, 2H), 0.96
– 0.81 (m, 2H), 0.76 (m , 3H).
13C

NMR (151 MHz, Chloroform-d) δ 200.51, 157.41, 155.40, 153.01, 137.86,

132.88, 129.20, 128.90, 126.33, 126.05, 118.99, 117.45, 114.74, 113.83, 111.35, 79.15,
56.76, 55.19, 48.11, 43.87, 37.22, 36.27, 31.14, 29.67, 27.63, 26.54, 25.04, 17.46. HR-FTMS calcd for C28H31O4Br1Na1 533.1298 found 533.12807.

3.4.23 Para-trifluromethyl phenyl enone MMA292 and MMA320:
HO

H

HO
LDA/ -78oC
THF

H
O

O

H

8 and 8

P-PhCF3CO
61.7%

O

H
H
O

CF3
H

MMA292 and MMA320
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To a stirred solution of hydroxyl ketone 8 and 8` (0.3g, 0.847mmole) in a dry
tetrahydrofuran (THF) (1.7ml), lithiumdiisopropyl amine (LDA) (1.5ml, 3.05mmole) was
added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC for 1 h, then
the solution of Para-anisaldehyde (0.206ml, 1.7mmole) in THF (11.33ml) was added to
the reaction mixture at -78oC. The reaction was allowed to stir and warm to the room
temperature for 24h. The quench of the reaction was completed by the addition of
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate
(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl
acetate in hexane) to obtained para-trifluromethyl benzene enone MMA292 and MMA320
(0.21g, 61.7%).
Compound MMA292 1H NMR (600 MHz, Chloroform-d) δ 7.77 (m, 1H), 7.62 –
7.53 (m, 4H), 7.05 – 6.98 (m, 2H), 6.59 (m, 1H), 6.53 (m, 1H), 5.97 – 5.93 (m, 1H), 4.32
(s, 1H), 3.67 (m, 3H), 2.88 – 2.71 (m, 2H), 2.21-2.12 (m, 2H), 2.02 (m, 1H), 1.81 (m, 1H),
1.53 (m, 1H), 1.49 – 1.37 (m, 3H), 1.30 (m, 1H), 1.11 (m, 1H), 0.97 (s, 3H), 0.90 – 0.71
(m, 4H).
13C

NMR (151 MHz, Chloroform-d) δ 200.66, 157.42, 155.15, 142.93, 137.83,

137.67, 132.74, 129.72, 128.80, 126.00, 125.98, 125.95, 125.93, 121.08, 113.82, 111.36,
78.80, 57.47, 55.17, 47.85, 43.93, 37.09, 34.48, 31.96, 31.23, 29.74, 29.69, 27.59, 26.27,
25.26, 17.21. HR-FT-MS calcd for C31H33O3F3Na1 533.2274 found 533.22689.
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Compound MMA320 1H NMR (600 MHz, Chloroform-d) δ 7.75 (m, 1H), 7.60
– 7.51 (m, 4H), 7.03 – 6.96 (m, 2H), 6.57 (m, 1H), 6.51 (m, 1H), 5.95 – 5.91 (m, 1H), 4.30
(s, 1H), 3.65 (m, 3H), 2.86 – 2.76 (m, 2H), 2.19-2.10 (m, 2H), 2.01 (m, 1H), 1.79 (m, 1H),
1.51 (m, 1H), 1.47 – 1.35 (m, 3H), 1.28 (m, 1H), 1.09 (m, 1H), 0.95 (s, 3H), 0.88 – 0.69
(m, 4H). HR-FT-MS calcd for C31H33O3F3Na1 533.2274 found 533.22544.

13C

NMR (151 MHz, Chloroform-d) δ 200.64, 157.40, 155.13, 142.91, 137.81,

137.65, 132.72, 129.70, 128.78, 125.98, 125.96, 125.93, 125.91, 121.06, 113.80, 111.34,
78.878, 57.45, 55.15, 47.83, 43.91, 37.07, 34.46, 31.94, 31.21, 29.72, 29.67, 27.57, 26.25,
25.24, 17.19. HR-FT-MS calcd for C31H33O3F3Na1 533.2274 found 533.22544.

3.4.24 Para-nitrophenyl enone MMA305 and MMA321:
O

HO

HO
LDA/ -78oC
THF

H
H

H

O
8 and 8

P-PhNO2CO
52.7%

O

H
H
O

NO2
H

MMA305 and MMA321

To a stirred solution of hydroxyl ketone 8 and 8` (0.4g, 1.13mmole) in a dry
tetrahydrofuran (THF) (2.3ml), lithiumdiisopropyl amine (LDA) (2.034ml, 4.068mmole)
was added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC for 1
h, then the solution of Para-flurobenzaldehyde (0.242ml, 2.26mmole) in THF (15ml) was
added to the reaction mixture at -78oC. The reaction was allowed to stir and warm to the
room temperature for 24h. The quench of the reaction was completed by the addition of

154

ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate
(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl
acetate in hexane) to provide para-nitrobenzene enone MMA305 and MMA321 (0.29g,
52.7%).

Compound MMA305 1H NMR (400 MHz, Chloroform-d) δ 8.16 (m, 2H), 7.77
(m, 1H), 7.63 (m, 2H), 7.14 (s, 1H), 7.10 – 6.98 (m, 2H), 6.61 – 6.54 (m, 1H), 6.51 (d, 1H),
5.97 (d, 1H), 4.26 (s, 1H), 3.66 (s, 3H), 2.81- 2.75 (m, 2H), 2.22-2.12 (m, 2H), 2.01 (m,
1H), 1.81 (d, 1H), 1.50 – 1.37 (m, 1H), 1.34 – 1.15 (m, 3H), 1.10 (m, 1H), 0.96 (s, 3H),
0.87- 0.78 (m, 4H).
13C

NMR (101 MHz, Chloroform-d) δ 200.47, 157.42, 154.97, 148.75, 141.76,

140.37, 137.81, 132.64, 129.99, 129.26, 125.98, 124.22, 122.60, 113.80, 111.37, 78.91,
57.50, 55.16, 47.85, 43.93, 37.07, 34.69, 34.56, 31.62, 31.26, 29.67, 27.59, 26.27, 25.31,
25.20, 22.69, 17.21, 14.18. HR-FT-MS calcd for C30H33O5N1Na1 510.2251 found
510.22450.

Compound MMA321 1H NMR (400 MHz, Chloroform-d) δ 8.14 (m, 2H), 7.75
(m, 1H), 7.61 (m, 2H), 7.12 (s, 1H), 7.08 – 6.96 (m, 2H), 6.59 – 6.52 (m, 1H), 6.49 (d, 1H),
5.95 (d, 1H), 4.24 (s, 1H), 3.64 (s, 3H), 2.79- 2.73 (m, 2H), 2.20-2.10 (m, 2H), 2.01 (m,
1H), 1.79 (d, 1H), 1.48 – 1.35 (m, 1H), 1.32 – 1.13 (m, 3H), 1.08 (m, 1H), 0.94 (s, 3H),
0.85- 0.76 (m, 4H).
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13C

NMR (101 MHz, Chloroform-d) δ 200.45, 157.40, 154.95, 148.73, 141.74,

140.35, 137.79, 132.62, 129.97, 129.24, 125.96, 124.20, 122.58, 113.78, 111.35, 78.89,
57.48, 55.14, 47.83, 43.91, 37.05, 34.67, 34.54, 31.60, 31.24, 29.65, 27.57, 26.25, 25.29,
25.18, 22.67, 17.19, 14.16. HR-FT-MS calcd for C30H33O5N1Na1 510.2251 found
510.22454.

3.4.25 5-bromothiphene enone MMA311 and MMA330:
O
HO

HO

O
S

Br

o

LDA/ -78 C
THF

H
H

H

O
8 and 8

5-Br-2-thiophenaldehyde
O
78. 5%

H
H

H

MM311 and MMA330

To a stirred solution of hydroxyl ketone 8 and 8` (0.3g, 0.847mmole) in a dry
tetrahydrofuran (THF) (1.7ml), lithiumdiisopropyl amine (LDA) (1.5ml, 3.05mmole) was
added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC for 1 h, then
the solution of Para-anisaldehyde (0.206ml, 1.7mmole) in THF (11.33ml) was added to
the reaction mixture at -78oC. The reaction was allowed to stir and warm to the room
temperature for 24h. The quench of the reaction was completed by the addition of
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate
(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl
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acetate in hexane) to obtained 5-bromothiphene enone MMA311 and MMA330 (0.35g,
78.5%).
Compound MMA311 1H NMR (600 MHz, Chloroform-d) δ 7.86 (m, 1H), 7.19 –
7.10 (m, 2H), 7.08 (m, 1H), 6.77 – 6.69 (m, 2H), 6.66 (m, 1H), 6.03 (m, 1H), 4.47 (s, 1H),
3.80 (s, 3H), 2.98 – 2.84 (m, 2H), 2.39 – 2.29 (m, 2H), 2.07 (m, 1H), 1.94 (m, 1H), 1.70 –
1.51 (m, 3H), 1.44 (m, 1H), 1.38 – 1.19 (m, 4H), 1.08 (s, 3H), 0.98 – 0.88 (m, 3H), 0.89 (s,
1H).
13C

NMR (151 MHz, Chloroform-d) δ 200.39, 157.42, 155.26, 141.39, 137.85,

136.24, 132.97, 132.82, 131.45, 129.46, 126.02, 117.97, 117.15, 113.83, 111.36, 78.54,
57.42, 55.17, 47.81, 43.93, 37.13, 36.70, 34.25, 31.22, 27.61, 26.80, 25.34, 17.22. HR-FTMS calcd for C28H31O3Br1Na1S1 549.1069 found 549.10931.
Compound MMA330 1H NMR (600 MHz, Chloroform-d) δ 7.84 (m, 1H), 7.17 –
7.08 (m, 2H), 7.06 (m, 1H), 6.75 – 6.67 (m, 2H), 6.64 (m, 1H), 6.01 (m, 1H), 4.45 (s, 1H),
3.78 (s, 3H), 2.96 – 2.82 (m, 2H), 2.37 – 2.27 (m, 2H), 2.05 (m, 1H), 1.92 (m, 1H), 1.68 –
1.49 (m, 3H), 1.42 (m, 1H), 1.36 – 1.17 (m, 4H), 1.06 (s, 3H), 0.96 – 0.86 (m, 3H), 0.87 (s,
1H).
13C

NMR (151 MHz, Chloroform-d) δ 200.37, 157.40, 155.24, 141.37, 137.83,

136.22, 132.95, 132.80, 131.43, 129.44, 126.01, 117.95, 117.13, 113.81, 111.34, 78.52,
57.40, 55.15, 47.79, 43.91, 37.11, 36.68, 34.23, 31.19, 27.60, 26.79, 25.32, 17.21. . HRFT-MS calcd for C28H31O3Br1Na1S1 549.1069 found 549.1019.
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Chapter Four

Design, Synthesis and Biological Screening of CUCUS-inspired Estrone Analogues
with Sulfamoyl Moiety at C-3 Targeting Epidermal Growth Factor toward
Treatment of Hepatocellular Carcinoma

4.1

Introduction:
The study of molecular docking provided background information about the

behavior of the CUCUS-inspired estrone analogues in the binding pocket of the EGFR and
pointed out at the analogues that will be synthesized and then biologically screened.
Number of research groups have done chemical modification on the main structure of
cucurbitacins such as installing tosyl functional groups in the ring A, followed by addition
of halogens [1, 2] and alkylation reaction [3, 4]. Various synthetic approaches were
conducted to totally synthesized cucurbitacins but all of these trays were failed to provide
fully synthesized cucurbitacin [5, 6]. However, there are some successful studies on
modification of cucurbitacins including quantitative structure activity relationship (QSAR)
study of semi synthetic cucurbitacin by Bartalis and Halaweish [4], partial synthesis of
cucurbitacin B and D by Jung [7], synthesis of hexanorcucurbitacin compounds by Ryu [8]
and synthesis of dihydrocucurbitacin B by Lang [1]. However, some of these synthetic
paths are impracticable for cucurbitacins pharmacophores to be modified for biological
activities.
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There have been few studies and researches trying to install the cucurbitacins enone
side chain into the C-17 of the steroid main structure (Fig4.1). However, assembling the
enone side chain is challenging mission because of interfering functional groups on the
main skeleton which may affect each other during the chemical reactions. Ourisson et al.
1973 using Grinard reagent, tetrhydro pyranyl ether, tried to install cucurbitacin I side chain
into C-17 of tetracyclic steroid but he ended up with racemic mixture of S- and R-isomers
at C-20 [9]. An attempting to modify lanastrol, which is tetracyclic triterpins, Paryzek et
al. 1981 resulted in the synthesis of different analogue which is 4, 4, 14α-trimethyl-19(108β) abeo-steroids with side chain at C-2 and C-5 [10]. In another study Levy et al. tried to
modify 3β-acetoxy-lanost-9 chemically to cucurbitacin structure; however, his attempts
did not provide the expected results and instead they got organo-tin structure [11].
The main structure of cucurbitacin which known as [19(10

9β) abeo-10α-lanost-

5-en][12] is similar in the structure to that of steroids in the fact of the presence of four
rings system. However, they are structurally different from each other in the ring system
that C-19 methyl group of cucurbitacin is at C-9 and ring C and B fusion. So, estrone
scaffold was selected to install the cucurbitacin enone side chain at C-17 (Fig.4.1). In
chapter 3, we discussed the importance of substitution at C-3 of estrone structure for the
biological activities, particularly the presence methoxy at C-3 [13]. However, these estrone
derivatives with cucurbitacin enone side chain at C-17 and methoxy at C-3 are slightly nonpolar as proved in our group previously [14]. In addition, metabolism of the methoxy group
at C-3 by the CYP450 O-dealkylation might retrieve the estrogenic activity of the estrone
as feminizing horman. So, substituting the methoxy group at C-3 with more polar groups
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such as sulfamoyl will increase the polarity of the synthesized compounds and in the same
time it will prevent the expected metabolism of the C-3 methoxy group. All of these
structural modifications lead to dramatically change in the pharmacokinetic and biological
activities of the CUCUS-inspired estrone analogues.
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Figure 4.1 general structure of cucurbitacin and estrone.
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Installation of sulfamoyl moiety into the estrone skeleton has got the attention due
to its ability to change the biological activities. Leese et al proved that estratrine sulfmate
compounds improved the anti-cancer activities and increased the oral bioavailability [15].
In addition, other studies demonstrated the ability of estrone derivatives with sulfamoyl
group at C-3 to have effect on different cancer cell lines such as breast cancer cell line [16],
and effect on pharmacokinetic of the modified estrone structure [17]. All of these studies
and results proved that installing sulfamoyl functional group into C-3 of the estrone
scaffold along with the cucurbitacin enone side chain at C-17 will enhance the anti-cancer
activities as well as the pharmacokinetic properties of the CUCUS-inspired estrone
analogues.

O

HO
11

17

11

R1

HO

H

24

17

R1

H

H
3

O

HO

24

H

3

H

H

O
O S O
NH2

R1= C(CH3)2 OH, P-PhF, P-PhCl, P-PhBr
P-PhCF3, P-PhNO2, 5-Bromo-2-thiophene,
5-Bromo-2-furan.
Figure 4.2 proposed positions for estrone structure modification.
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In order to find the hit analogues to identify the lead compounds (LDs) targeting
EGFR, bioisosterism process are used to design systematically the CUCS-inspired estrone
analogues. Therefore, a virtual library of 900 compounds were created including esterone
derivatives with cucurbitacins enone side chain at C-17 and sulfamoyl or hydroxyl groups
at C-3, known EGFR inhibitors a nd different types of cucurbitacins, to be involved in the
molecular docking studies [18]. Estrone main structure were studied and investigated in
three different positions 1) assembling of cucurbitacin enone side chain at C-17, 2)
installation of sulfamoyl or hydroxyl moieties at C-3 and 3) installation of various aliphatic
and aromatic substituents at C-25 (Fig.4.2). OpenEye® scientific software were utilized for
the molecular docking studies including fast executive docking (FRED), OMEGA and
VIDA.

4.2

Results and Discussion:

4.2.1

Results of Molecular Docking with EGFR:
The molecular docking calculations of CUCUS-inspired estrone analogues that

consist of cucurbitacins enone side chain at C-17, sulfomyl or hydroxyl groups at C-3 and
different aliphatic and aromatic functional groups at C-25, such as MMA-240, MMA-242,
MMA-294, MMA-295, MMA-297, MMA-300, MMA-301, MMA-306, MMA-307,
MMA-308, MMA-309, MMA-310, MMA-312, MMA-313 AND MMA-314 (Fig. 2.8
and 2.9), showed an outstanding binding mode toward the EGFR binding site compare to
the known EGFR inhibitor, such as Erlotinib, by making H-bonds and hydrophobic
interactions with the amino acids residues of the EGFR binding pocket (Fig. AP-3).

167

Analogues that contain cucurbitacin enone side chain at C-17 along with sulfamoyl moiety
at C-3 such as MMA-240 and MMA242 showed a distinguishable binding affinity toward
the EGFR binding site by associating in H-bond with ALA:719:A inside the EGFR pocket
along with hydrophobic interactions with other amino acids inside the same binding
pocket; while analogue with the same enone side chain at C-17 but with hydroxyl group at
C-3 instead of sulfamoyl as in MMA301 demonstrated less binding mode with only
hydrophobic interactions (Fig.4.3). This outstanding result proved that the presence of
sulfmoyl moiety at C-3 along with the cucurbitacin enone side chain is essential for the
binding affinity toward the EGFR binding pocket.
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A

Figure
4.3
Visual
representation of A) MMA240 (Red) B) MMA-301
(purple) in the EGFR ATPbinding site.

B

On the other hand, compounds that contain cucurbitacin enone side chain at C-17
along with different aromatic substituents at C-25 and sulfamoyl group at C-3 such as
MMA294, MMA295, MMA297, MMA300, MMA307 and MMA312 showed better
binding mode toward the EGFR binding pocket by making H-bonds and hydrophobic
interactions compare to the analogues that contain the same aromatic enone side chain but
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with hydroxyl group at C-3 such as MMA269, MMA306, MMA309, MMA310,
MMA313 and MMA314 which only showed hydrophobic interactions with the amino
acids of the EGFR binding pocket (Fig.4.4).

In conclusion, CUCUS-inspired estrone analogues that contain cucurbitacin enone
side chain at C-17 along with aliphatic and aromatic substituents at C-25 and sulfamoyl
moiety at C-3 demonstrated significant binding mode toward the 3D crystal structure of
EGFR binding side by making H-bonds and hydrophobic interactions. In addition, the
presence of hydroxyl group at C-3 of the estrone scaffold along with cucurbitacin enone
side chain at C-17 showed lower binding affinity toward the same binding site of the EGFR.
All of these signs and results demonstrated the important of assembling of the sulfamoyl
group at C-3 for the binding affinity and may be for the biological activities. The results of
the molecular docking was the core to move to the synthesis of the most promising
analogues to be investigated biologically in next step.
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A

Figure
4.4
Visual
representation of A) MMA312 (purple) B) MMA-313
(yellow) in the EGFR ATPbinding site.

B

4.2.2

Synthesis of MMA Analogues:
In order to investigating the biologically activities of CUCUS-inspired estrone

analogues (CIEA), chemical reactions were used to assemble the cucurbitacins enone side
chain at C-17 along with sulfamoyl or hydroxyl groups at C-3 of the estrone skeleton
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(Fig.4.1). The challenges on conducting these chemical reactions were started by making
the decision what step should the sulfamoyl group at C-3 to be installed during the process
of assembling the cucurbitacin enone side chain at C-17. Due to the diversity of the
chemical reactions that will be used to install the cucurbitacin enone side chain into the
estrone scaffold, the concept of trial and error were used to optimaize the complete
synthetic schemes. In the beginning, installation of sulfamoyl functional group at C-3 of
the estrone structure were done utilizing sulfamoyl chloride in the presence of N, Ndimethylacetamide to provide 3-sulfamoyl estrone (Scheme 4.1) [19]. However, the
resulted 3-sulfamoyl estrone was found to be polar and cannot be used for the next chemical
reactions to install cucurbitacin enone side chain. Therefore, protection of hydroxyl group
at C-3 of the estrone main structure with tert-butyldimethylsilyl chloride were carried out
first in the presence of imidazole and dimethyl formamide to provide estrone tertbutyldimethylsilyl ether 1 [20]. Wittig reaction was utilized on estrone tertbutyldimethylsilyl ether 1 to prepare alkene 2 by reacting the phosphonium yield with C17 ketone [21].
O
H
H
HO

H

O

O
H2N S Cl
O

H

N, N-dimethylacetamide

92%
Estrone

O
O S O
NH2

H

H

3-sulfamoyl estrone

Scheme 4.1 Synthesis of 3-sulfamoyl estrone.
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Alcohol 3 was produced by hydroboration reaction on alkene 2 using 9Borabicyclo[3.3.1]nonane (9-BBN) in presence of tetrahydrofuran (THF) as solvent for
overnight followed by the drop wise addition of sodium hydroxide (NaOH) and hydrogen
peroxide (H2O2) [14]. This was followed by oxidation of alcohol 3 utilizing pyridinum
chlorochromate (PCC) to give ketone 4 in 91% yield [22, 23]. Treatment of ketone 4 with
trimethylsilyl cyanide (TMSCN) in the presence of zinc iodide (ZnI2) as Lewis acid to
activate the ketone to provide the desired disteriomer cyanohydrin 5 [24]. Ahmed et al. was
the first to form cyanohydrin using OTMS in this scaffold [14]. Addition of methyl lithium
to cyanohydrin 5 in the presence of ether as solvent to produce the desired disteriomer αhydroxyl ketone 6 (Scheme 4.2) [14]. The 3-D structure of the Compound MMA242 were
confirmed using x-ray crystallography as shown in Figure 4.5, which demonstrated the Rconfiguration.
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Scheme 4.2 Synthesis of α-hydroxyl ketone 6.

Figure 4.5 X-ray crystallography of α-hydroxyl ketone MMA242.
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α-Hyd roxyl ketone 6 was utilized as a starting material to install various functional
groups including cucurbitacin D enone side chain at C-17 with different aromatic moieties
at C-25 and sulfamoyl at C-3. First, α-hydroxyl ketone 6 was used as starting material for
Aldo condensation reaction with the prepared aldehyde 9 to prepare compound 10, which
is protected estrone with protected enone side chain [14]; followed by deportation of
protected hydroxyl groups at C-3 and C-25 using tetra-n-butylammonium fluoride (TBAF)
to produce estrone derivative MMA301 with hydroxyl group at C-3 and cucurbitacin D
enone side chain at C-17 [25]. Compound MMA240 was prepared to by adding sulfamoyl
chloride to compound MMA301 in presence of N, N-dimethyl acetamide as solvent;
sulfamoyl chloride selectively reacted with phenolic hydroxyl group as shown in scheme
4.3 [19]. Aldehyde 9 was prepared in our group previously as shown in scheme 4.4 [14].
O

O

O

HO

HO

HO
O TBS

H
H
O
TBS

6

H

o

1- LDA/ -78 C/ 1h
H

2- Aldehyde 9
56%

H
O
TBS

10

OH
H

TBAF/ THF
H

86%

H
HO

H

MMA301
91% SMCl/
DMACM
O
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O
H

H
H
O
O S O
NH2

H
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Scheme 4.3 Synthesis of compounds MMA301 and MMA240.
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Scheme 4.4 Synthesis of Aldehyde 9.
In addition, α-hydroxyl ketone 6 was used to prepare analogue MMA280 by
deportation of TBS-protecting group utilizing tetra-n-butylammonium fluoride (TBAF)
[25]; followed by preparing compound MMA242 by adding sulfamoyl chloride in presence
of N, N-dimethylacetamide as solvent (Scheme 4.5) [19].
O

H
H
O
TBS

6

HO

HO
TBAF/ THF

H

O

O

HO

86%

HO

H

H

SMCl/DMACM
H H
94%
O
MMA280
O S O
NH2

H

H

MMA242

Scheme 4.5 synthesis of compounds MMA280 and MMA242.

Various number of aromatic enone side chains, such as para-methoxybenzene
enone side chain along with hydroxyl group at C-3 as in MMA268 or sulfamoyl group at
C-3 as in MMA267, para-flurobenzene enone side chain along with hydroxyl group at C3 as in MMA269 or sulfamoyl group at C-3 as in MMA271, para-chlorobenzene enone
side chains along with hydroxyl group at C-3 as in MMA309 or sulfamoyl group at C-3 as
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Figure 4.6 Synthesis of estrone derivatives with various aromatic enone side chain along
with hydroxyl or sulfamoyl groups at C-3.
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in MMA294, para-bromobenzene enone side chain along with hydroxyl group at
C-3 as in MM310 or sulfamoyl group at C-3 as in MMA295, 5-bromofuran enone side
chain along with hydroxyl group at C-3 as in MMA297 or sulfamoyl group at C-3 as in
MMA314, para-trifluromethyl benzene along with hydroxyl group at C-3 as in MMA308
or sulfamoyl group at C-3 as in MMA300, para-nitrobenzene enone side chain along with
hydroxyl group at C-3 as in MMA306 or sulfamoyl group at C-3 as in MMA307 and 5bromothiphene enone side chain along with hydroxyl group at C-3 as in MM313 or
sulfamoyl or sulfamoyl group at C-3 as in MMA312, were assembled in the C-17 of αhydroxyl ketone 6 using Aldol condensation reaction to form the related compound of 11
followed by the deportaction reaction of TBS group with TBAF [25] followed by addition
of sulfamoyl chloride (Scheme 4.6) [19].

4.2.3

Biological Evaluation of the Synthesized Compounds:
The biological studies for the synthesized compounds started by in vitro study to

identify their capability to inhibit the EGFR. MTT cell viability assay were utilized to find
the cytotoxicity of the synthesized compounds against the hepatocellular carcinoma cell
line (HepG2) and that expressed as IC50 (inhibition concentration). Compound MMA242,
which contain α-hydroxyl ketone on C-17 along with sulfamoyl group at C-3, showed
potent inhibitory activity toward the HepG2 cell line with IC50 value of 3µM compare to
the known EGFR inhibitor, Erlotinib with 25 µM (Table 4.1). Compounds with aliphatic
enone side chain at C-17 along with sulfamoyl at C-3 such as MMA240 demonstrated
modest inhibitory activity with IC50 value of 8µM; while the same compound but with
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hydroxyl group at C-3 instead of sulfamoyl such as MMA301 lost their cytotoxicity
completely. These results verify the importance of possessing sulfamoyl group at C-3,
which we confirmed at the molecular docking study (Fig. 4.3). Analogues that contain
cucurbitacin enone side chain at C-17 with various aromatic and heterocyclic functional
groups at C-25 along with sulfamoyl moiety at C-3 such as MMA267, MMA271,
MMA294, MMA295, MMA297, MMA300, MMA307 and MMA312 demonstrated
various cytotoxicity levels with IC50 values 12 µM, 8 µM, 11.5 µM, NA, 1 µM, 3 µM, 10
µM, 8 µM; respectively (Table 4.1). On the other hand, compounds with same enone side
chains at C-17 but with hydroxyl group at C-3 Such as MMA268, MMA269, MMA306,
MMA308, MMA309, MMA310, MMA313 and MMA314 showed various cytotoxicity
with IC50 values 7 µM, 2 µM, 8 µM, 8 µM, NA, 6 µM, 9 µM and 1.5 µM; respectively
(Table 4.1). All of the previous results proved the biological importance of possessing the
sulfamoyl moiety at the C-3 of the estrone main structure along with various aliphatic,
aromatic and heterocyclic functionalities at the enone side chain compare to the first set
synthesized compounds that contain methoxy group at C-3 (Table 3.1).
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Table 4.1 IC50 values of the synthesized compounds.

Compound

IC50 (𝜇𝑀)

Compound

IC50 (𝜇𝑀)

Erlotinib

25 𝜇𝑀

MMA310

6 𝜇𝑀

MMA240

8 𝜇𝑀

MMA295

NA

MMA301

NA

MMA297

1 𝜇𝑀

MMA242

3 𝜇𝑀

MMA314

1.5 𝜇𝑀

MMA267

12 𝜇𝑀

MMA300

3 𝜇𝑀

MMA268

7 𝜇𝑀

MMA308

8 𝜇𝑀

MMA269

2 𝜇𝑀

MMA306

8 𝜇𝑀

MMA271

8 𝜇𝑀

MMA307

10 𝜇𝑀

MMA309

NA

MMA313

9 𝜇𝑀

MMA294

11.5 𝜇𝑀

MMA312

8 𝜇𝑀

180
30
25

IC50 𝜇𝑀

20
15
10
5
0

CIEA

Figure 4.7 Chart represent the ability of CIEA to inhibit the growth of HepG2 cell line.

4.3

Conclusion:
CUCUS-inspired estrone analogues were structurally designed utilizing molecular

docking technique by assembling the biologically important pharmacophores such as
cucurbitacin’s enone side chain at C-17, various aromatic and heterocyclic substituents at
C-25 and sulfamoyl or hydroxyl groups at C-3 to be explored biologically as anti-cancer
candidates toward the treatment of Hepatocellular carcinoma (HCC) through the inhibition
of EGFR. Various aliphatic, aromatic and heterocyclic enone side chains were installed
chemically on the estrone main skeleton such as isopropanol, para-methoxybenzene, paraflurobenzene,

para-chlorobenzene,

para-bromobenzene,

5-bromofuran,

para-
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trifluromethyl, para-nitrobenzene, 5-bromothiphene along with sulfamoyl or hydroxyl
groups at C-3 (Fig. 4.6). The biological evaluation demonstrated that analogues that
contain cucurbitacin enone side chain at C-17 of the estrone along with sulfamoyl group at
C-3 such as MMA240 showed a modest inhibitory activity; while the same compound but
with hydroxyl group at C-3 such as MMA301 lost their biological activity. On the other
hand, compounds with various aromatic and heterocyclic enone side chains at C-17 showed
wide range of cytotoxicity compare to the known EGFR inhibitor, erlotinib. However,
installing sulfamoyl group at C-3 of the CUCS-inspired estrone analogues (CIEA) proved
to increase the cytotoxicity in comparison to the same analogues but with methoxy group
at C-3. Compound MMA292 showed the most potent cytotoxicity in HepG2 with IC50
value 1𝜇𝑀.

4.5

Experimental section:

4.5.1

General:
All chemicals and solvents (ACS grades) were provided from Fisher Scientific or

Sigma Aldrich and used without any additional purification. All glassware were cleaned,
washed and dried in oven for overnight before conducting chemical reactions requires
anhydrous environment and nitrogen gas applied at the reaction time. Pre-coated silica gel
PE plates were used to analyze the reaction condition and UV-light were also used at 254
or 365 to visualize the chemical reactions spots. All synthetic intermediate and final
compounds were purified using column chromatography with 230ˣ400 mesh silica gel. 1H
and

13

C NMR spectra were using Bruker AVANCE-400 MHZ and 600 MHZ NMR
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spectrometer, in CDCl3 and D-acetone. NMR chemical shifts were presented in 𝛿(PPM)
using residual solvent peaks as standards (CDCl3, 7.26 (H), 77.16 (C)). High resolution
mass (HRMS) was gained using thermofinnigan MAT 95XL mass spectrometer at Buffalo
mass spectroscopy facility. X-ray crystallography were conducted in University of South
Dakota on compound 8 using Brouker APEXᴵᴵ diffractometer.

4.5.2

3-Sulfamoyl Estrone:
O
H
H
HO

H

O

O
H2N S Cl
O

H

N, N-dimethylacetamide

92%
Estrone

O
O S O
NH2

H

H

3-sulfamoyl estrone

Estrone (0.2g, 0.74mmole) were dissolved in N, N-dimethyacetamide (1.8 ml) then
cooled down to 0 0C; followed by addition of sulfamoyl chloride (0.26g, 2.22mmole). the
reaction mixture was allowed to be stirred and warm to the room temperature for 18h.
amixture of ethyl acetate (30ml) and water (30ml) was added to the reaction mixture and
the organic layer was separated, washed by water (3×25ml) followed by the addition of
brain (30ml). Sodium sulfate anhydrous (Na2SO4) to dry the organic layer, filtered and
concentrated in vacuo. Column chromatography (30% ethyl acetate in hexane) to provide
white solid of 3-Sulfamoyl Estrone (0.24g, 92%).
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1H

NMR (400 MHz, Acetone-d6) δ 7.35 (dd, J = 8.6, 1.1 Hz, 1H), 7.07 (dd, J = 8.5,

2.6 Hz, 1H), 7.06 – 7.02 (m, 2H), 3.03 – 2.84 (m, 2H), 2.57 – 2.37 (m, 2H), 2.30 (m, 2H),
2.14 – 1.98 (m, 4H), 1.86 (m, 1H), 1.76 – 1.34 (m, 5H), 0.90 (s, 3H).

13C

NMR (101 MHz, Acetone-d6) δ 219.62, 149.44, 139.22 (d, J = 6.2 Hz), 127.46,

123.03, 120.25, 51.07, 48.40, 45.01, 38.90, 36.11, 32.56, 30.06, 27.02, 26.56, 22.16, 14.15.

4.5.3

Estrone tert-butyldimethylsilyl ether 1:
O

O
H

H

TBSCl /Imidazol
H
HO

H
DMF

Estrone

95%

O
TBS

H

H

1

To a stirred solution of estrone (5 g, 18.5 mmole) in DMF (75 ml); followed by the
addition of imidazole (3.5 g, 50.85 mmole), tert-butyldimethylsilyl chloride (TBSCl) (4.2
g, 27.75 mmole). The reaction stirred at room temperature for 24h. The reaction solvent
were evaporated to provide brown oil. Column chromatography (40% ethyl acetate in
hexane) were used to purify the crude material which give white solid of Estrone tertbutyldimethylsilyl ether 1 (6.75 g, 95%).

1H

NMR (400 MHz, Chloroform-d) δ 6.91 (dd, J = 8.6, 1.0 Hz, 1H), 6.47 – 6.33

(m, 2H), 2.72 – 2.59 (m, 3H), 2.28 (dd, J = 18.7, 8.7 Hz, 1H), 2.16 (dt, J = 14.0, 3.7 Hz,
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1H), 2.08 – 1.65 (m, 5H), 1.48 – 1.14 (m, 7H), 0.79 (s, 9H), 0.75 – 0.65 (m, 4H), 0.00 (s,
6H).
13C

NMR (101 MHz, Chloroform-d) δ 219.97, 153.47, 137.57, 132.47, 126.17,

120.02, 117.35, 50.44, 47.98, 44.04, 38.34, 35.87, 31.65, 29.54, 26.62, 25.85 21.63, 18.20,
13.90, -4.30.

4.5.4

Alkene 2:
O
H
H
O
TBS

H
H

EtPPh3 / T-BUOK
THF

1

86%

O
TBS

H

H

2

First, the ylide was prepared by adding potassium tert-butoxide in different portions
(5.85 g, 52.13 mmole) to the solution of ethyl triphenylphosphonium bromide (20.73 g,
55.85 mmole) in THF (93 ml) at room temperature for 1h. Then solution of Estrone tertbutyldimethylsilyl ether 1 (6.5g, 18.617 mmole) in THF (37 ml) was added to the first
mixture and allowed to be stirred for 6h at 70 0C. The reaction mixture was allowed to cool
down to the room temperature, solution of saturated ammonium chloride (NH4Cl) was
added to the reaction mixture followed by extraction of the aqueous layer using ethyl
acetate (3×100 ml), brain, dried over sodium sulfate anhydrous (Na2SO4), filtrated and
concentrated in vacuo. The purification of the crude material was purified by silica gel
column chromatography (20% ethyl acetate in hexane) to obtained alkene 2 (5.8 g, 85%).
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1H

NMR (400 MHz, Chloroform-d) δ 7.13 – 7.04 (m, 1H), 6.62 – 6.49 (m, 2H),

5.12 (m, 1H), 2.87 – 2.69 (m, 3H), 2.45 – 2.12 (m, 3H), 1.95 – 1.82 (m, 1H), 1.77 – 1.60
(m, 5H), 1.58 – 1.42 (m, 1H), 1.42 – 1.21 (m, 3H), 1.09 – 0.99 (m, 1H), 0.96 (s, 9H), 0.86
(m, 4H), 0.16 (s, 6H).
13C

NMR (101 MHz, Chloroform-d) δ 153.38, 150.26, 137.87, 133.35, 126.17,

120.04, 117.25, 113.53, 55.40, 44.69, 44.00, 38.48, 37.41, 31.58, 29.86, 27.76, 27.05,
25.89, 24.33, 18.30, 17.12, 13.33, -4.22.

4.5.5

Alcohol 3:
OH

1- 9-BBN/THF, 0oC

H
H
O
TBS

2

H

H

2-10%NaOH/30%H2O2
O
91%

TBS

H

H

3

To a solid alkene 2 (5.5 g, 13.865 mmole), 9-BBN (0.5 M in THF, 110.9 ml, 55.46
mmole) was added at room temperature. The reaction mixture was allowed to be stirred for
20h, then cooled down to 0 0C; followed by the addition of 105ml of 10%NaOH and 180ml
of 30% H2O2 sequentially in drop-wise matter. The reaction mixture then stirred for 1h at
0 0C, then stirred for 1h at room temperature. Ethyl acetate (3×100 ml) was utilized to
extract the organic layer, then the collected organic layers washed with 100 ml of saturated
sodium thiosulfate, dries over sodium sulfate anhydrous (Na2SO4) and concentrated in
vacuo. Column chromatography was used to purify the crude material (20% ethyl acetate
in hexane) to provide alcohol 3 (5.25 g, 91%).
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1H

NMR (400 MHz, Chloroform-d) δ 6.94 (m, 1H), 6.47 – 6.32 (m, 2H), 3.56 (m,

1H), 2.75 – 2.52 (m, 2H), 2.25 – 21.98 (m, 1H), 1.79 – 1.44 (m, 4H), 1.40 – 1.12 (m, 4H),
1.14 – 1.01 (m, 6H), 0.98 (d, 3H), 0.82 (s, 9H), 0.61 (s, 3H), 0.02 (s, 6H).
13C

NMR (101 MHz, Chloroform-d) δ 153.25, 137.80, 133.41, 126.15, 119.97,

117.17, 70.45, 58.63, 55.07, 43.93, 42.84, 41.96, 40.05, 38.67, 29.78, 27.92, 27.24, 26.67,
24.31, 23.79, 18.23, 12.56, -4.27.

4.5.6

Ketone 4:
OH
H
H
O
TBS

3

O
H

PCC / NaOAC
H

DCM
87%

H
O
TBS

H

4

The produced alcohol 3 (5 g, 12.01 mmole) was dissolved in DCM (60.3 ml);
followed by the addition of 4 0A powdered molecular sieves (4.73g), sodium acetate
(NaOAc) (4.73 g, 57.6 mmole) and Pyridinium chlorochromate (PCC) (5.2 g, 24.02
mmole). The reaction mixture was allowed to be stirred at room temperature for 2h. Ether
was added to the reaction mixture, then filtered over silica gel pad using ether to elute the
material. The collected material then concentrated in vacuo. The resulted crude material
was purified by column chromatography (20% ethyl acetate in hexane) to give ketone 4
(4.3 g, 87%).
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1H

NMR (400 MHz, Chloroform-d) δ 6.91 (m, 1H), 6.46 – 6.32 (m, 2H), 2.70 –

2.53 (m, 2H), 2.39 (m, 1H), 2.17 – 1.98 (m, 2H), 1.94 (s, 4H), 1.76 – 1.02 (m, 10H), 0.79
(s, 9H), 0.45 (s, 3H), 0.00 (s, 6H).
13C

NMR (101 MHz, Chloroform-d) δ 209.20, 153.37, 137.74, 132.81, 126.06,

120.01, 117.23, 63.83, 55.72, 44.39, 43.74, 39.04, 38.73, 31.52, 29.67, 27.77, 26.65, 25.79,
24.20, 22.91, 18.21, 13.48, -4.31.

4.5.7

Cyanohydrin 5:
TMS
O
H
H
O
TBS

4

DCM
79%

N

H

TMSCN/ZnI2
H

O

H
O
TBS

H

5

To attired solution of ketone 4 (4 g, 9.7 mmole) in DCM (19.4 ml), zinc iodide
(ZnI2) (0.25 g, 0.78 mmole) was added, followed by the addition of trimethylsilyl cyanide
(TMSCN) (2.4 g, 24.25 mmole) in one portion. The reaction mixture then allowed to be
stirred at the room temperature for 3h. Then the solvent was evaporated to produce a slurry
mixture which was mixed with ethyl acetate/water (2:1, 100 ml). The aqueous layer was
extracted using ethyl acetate (3×100 ml), then the extracted organic layer dried over
sodium sulfate anhydrous (Na2SO4) and concentrated in vacou. Column chromatography
was used to purify the crude material (20% ethyl acetate in hexane) to give cyanohydrin 5
(3.95 g, 79%).
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1H

NMR (400 MHz, Chloroform-d) δ 6.95 (m, 1H), 6.50 – 6.37 (m, 2H), 2.76 –

2.58 (m, 2H), 2.17 – 1.94 (m, 3H), 1.87 (m, 1H), 1.78 – 1.50 (m, 4H), 1.46 (m, 3H), 1.42
– 0.96 (m, 5H), 0.85 (s, 9H), 0.78 – 0.73 (m, 1H), 0.14 (s, 9H), 0.10 (m, 3H), 0.05 (s, 6H).
13C

NMR (101 MHz, Chloroform-d) δ 151.67, 136.05, 131.49, 124.44, 120.43,

118.32, 115.56, 70.77, 58.90, 53.28, 42.24, 42.15, 38.40, 36.53, 33.11, 30.06, 29.21, 28.03,
26.13, 26.01, 24.88, 24.16, 23.72, 23.26, 22.27, 21.12, 19.49, 16.57, 12.61, 11.23, -5.94.

4.5.8

α-hydroxyl ketone 6:
TMS

O
O

O
TBS

5

N

MeLi / Et2O/0oC

H
H

HO

H

GAA
77%

H
H
O
TBS

H

6

To a stirred solution of cyanohydrin 5 (3.5 g, 6.88 mmole) in a dry ether (20ml),
methyl lithium (MeLi) (1.6 M in ether, 17.2ml, 27.52 mmole) was added in dropwise at
00C. The reaction mixture was allowed to stir for 2h at 00C, then the reaction quenched by
adding glacial acetic acid (2.9 ml) in one portion at 00C and allowed to stir for 30 min at
00C. Sodium bicarbonate solution was added to neutralize the acidic mixture.
Dichloromethane (DCM) was used to extract the aqueous layer (3ˣ50ml), dried under
sodium sulfate anhydrous (Na2SO4), then concentrated under vacuo. The resulted
diasteriomers were purified by silica gel column chromatography (100% hexane, 5% ethyl
acetate in hexane and 10% ethyl acetate in hexane) to give the α-hydroxyl ketone 6 (2.4 g,
77%).
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1H

NMR (400 MHz, Chloroform-d) δ 6.99 – 6.87 (m, 1H), 6.47 – 6.34 (m, 2H),

3.79 (s, 1H), 2.73 – 2.52 (m, 3H), 2.16 – 2.04 (m, 2H), 2.02 (s, 3H), 1.74 – 1.57 (m, 2H),
1.55 – 1.31 (m, 3H), 1.27 (s, 3H), 1.26 – 0.93 (m, 5H), 0.79 (s, 9H), 0.74 (s, 3H), 0.00 (s,
6H).
13C

NMR (101 MHz, Chloroform-d) δ 211.71, 153.32, 137.78, 133.10, 126.05,

119.99, 117.18, 80.12, 55.77, 55.14, 44.26, 43.88, 40.72, 38.08, 29.68, 27.72, 26.61, 25.81,
24.67, 23.77, 23.32, 22.15, 18.22, 13.59, -4.29.

4.5.9

Ester 7:
O

TBSCl/
Imidazol
O
OH
DMF
methyl2-hydroxy
isobutyrate

O
O

O
7

TBS

To a stirred solution of commercially available methyl2-hydroxy isobutyrate (5g,
42.3mmole) in dimethyl formmide (DMF) (12.5ml), tert-butylsilyl chloride (TBSCl)
(7.65g, 50.75mmole) were added followed by the addition of imidazole (7.45g,
110mmole). The reaction was stirred for 24h, then solution of sodium bicarbonate (25ml)
was added. The aqueous layer was extracted using ethyl acetate (3ˣ50ml), dried over
sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under vacuo. The crude
product was purified using silica gel column chromatography (10% ethyl acetate in hexane)
to give ester 7 (7.2g, 73.2%) as a yellow oil.
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1H

NMR (400 MHz, CDCl3): d=3.60(s, 3H), 1.34 (s, 6H), 0.80 (s, 9 H), 0.08 ppm

(s, 6H);
13C

NMR (100 MHz, CDCl3): d=175.8, 74.5, 51.4, 28.4, 25.5, 17.9, _3.2 ppm.

4.5.10 Alcohol 8:
O
DiBAL-H

O

O
7

HO
TBS

O

o

Hexane/ -78 C

TBS

8

To a stirred solution of ester 7 (7.2g, 30.98mmole) in hexane (98ml),
Diisobutylaluminium hydride (DiBAL-H) (56.8ml, 68.16mmole) was added at -78oC in a dropwise
matter. The reaction stirred for 30 min. at 00C, then for 20 min. at the room temperature. The

reaction then cooled back to -78oC, followed by the addition of solution of potassium tartrate
(45ml). The reaction was allowed to stir for overnight. The aqueous phase was extracted
using ethyl acetate (3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and
concentrated under vacuo. Silica gel column chromatography was used to purify the crude
material (20% ethyl acetate in hexane) to give alcohol 8 (5.75g, 90.8%) as colorless liquid.
1H

NMR (400 MHz, CDCl3): d=3.19 (s, 2H), 2.31 (s, 1 H), 1.11 (s, 6 H), 0.76 (s,

9 H), 0.08 ppm (s, 6H).
13C

NMR (100 MHz, CDCl3): d=76.3, 74.4, 28.5, 28.0, 20.3, 0.3 ppm.
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4.5.11 Aldehyde 9:
O
TPAP/NMO

HO

O

TBS

DCM/ 5oMS

H

O
9

8

TBS

To a stirred solution of alcohol 8 (2g, 9.7858mmole) in a dry dichloromethane
(DCM) (98ml), active molecular sieves (4oA, 2.3g) was added, then the reaction mixture
was allowed to stir for 5 min. followed by the addition on N-Methylmorpholine N-oxide
(NMO) (2.3g, 19.57mmole), then Tetrapropylammonium perruthenate (TPAP) (0.34g,
0.98mmole) was added at 00C. The reaction stirred at 00C for 2h, then at room temperature

for 24h. Pad of silica gel were used to filtrate the reaction mixture using diethyl ether as
eluting solvent. The filtrated material concentrated under vacuo to provide aldehyde 9
(1.45g, 73.3%) as colorless oil.
1H

NMR (400 MHz, CDCl3): d=9.44 (s, 1H), 1.17 (s, 6 H), 0.79 (s, 9H), 0.08 ppm

(s, 6H).
13C

NMR (100 MHz, CDCl3): d=206.4, 80.3, 28.0, 27.2, 20.4, 0.3 ppm.

4.5.12 Protected estrone with protected enone side chain 10:
O

O

HO

HO

O TBS
H
H
O
TBS

6

H

1- LDA/ -78oC/ 1h
H

2- Aldehyde 9
56%

H
O
TBS

10

H
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To a stirred solution of α-hydroxyl ketone 6 (0.4g, 0.879 mmole) in a dry
tetrahydrofuran (THF) (5.85 ml), lithiumdiisopropyl amine (LDA) (1.6 ml, 3.154 mmole)
was added in a dropwise at -78oC the reaction mixture was allowed to stir at -78oC for 1
h, then the solution of aldehyde 9 (0.354 g, 1.75 mmole) in THF (11.5 ml) was added to
the reaction mixture at -78oC. The reaction was allowed to stir and warm to the room
temperature for 24h. The quench of the reaction was completed by the addition of
ammonium chloride (NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate
(3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under
vacuo. Silica gel column chromatography was used to purify the crude material (10% ethyl
acetate in hexane) to provide protected estrone with protected enone side chain 10 (0.31 g,
56%).
1H

NMR (600 MHz, Chloroform-d) δ 6.96 – 6.92 (m, 1H), 6.89 (m, 1H), 6.55 (m,

1H), 6.43 (m, , 1H), 3.96 (s, 1H), 2.62 (m, 2H), 2.18 – 1.97 (m, 2H), 1.71 – 1.60 (m, 2H),
1.52 – 1.31 (m, 3H), 1.29 (s, 2H), 1.20 – 1.16 (m, 6H), 1.13 – 0.97 (m, 6H), 0.79 (s, 9H),
0.76 (m, 9H), 0.00 (s, 6H), -0.04 – -0.11 (m, 12H).
13C

NMR (151 MHz, Chloroform-d) δ 204.55, 159.22, 156.58, 155.34, 139.88,

135.17, 128.07, 126.60, 122.03, 120.34, 119.20, 81.15, 75.63, 57.97, 56.92, 55.48, 46.30,
46.00, 42.79, 40.14, 32.01, 31.96, 31.72, 30.69, 29.71, 29.10, 28.02 – 27.77 (m), 26.24,
25.75, 23.97, 20.36, 20.25, 15.63, 0.00, -2.31.
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4.5.13 Compound MMA301:
O

O

HO

HO
O TBS

H
H
O
TBS

OH
H

TBAF/ THF
H

10

86%

H
HO

H

MMA301

To a stirred solution of protected enone 10 (0.3 g, 0.47 mmole) in tetrahydrofuran
(THF) (2.5ml), tetrabutyl ammonium fluoride (TBAF) (1 M in THF, 2.914 ml, 2.914
mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was added to
quench the reaction. Ethyl acetate (3ˣ50ml), dried over sodium sulfate anhydrous (Na2SO4),
filtrated, and concentrated under vacuo. Silica gel column chromatography was used to
purify the crude material (10% ethyl acetate in hexane) to provide Compound MMA301
(0.165 g, 86%).
1H

NMR (400 MHz, Chloroform-d) δ 7.13 – 6.96 (m, 2H), 6.64 – 6.44 (m, 2H),

5.82 (m, 1H), 5.21 (s, 1H), 4.01 (s, 1H), 2.75 (m, 2H), 2.32 (s, 1H), 2.25 – 2.06 (m, 3H),
1.96 – 1.69 (m, 3H), 1.61 (m, 2H), 1.44 (s, 3H), 1.41 (m, 6H), 1.23 – 1.06 (m, 4H), 0.85 –
0.72 (m, 2H), 0.64 (s, 3H).
13C

NMR (101 MHz, Chloroform-d) δ 201.36, 155.37, 151.23, 146.75, 137.73, ,

129.04, 125.07, 113.73, 111.28, 80.17, 75.25, 56.89, 55.07, 48.02, 43.86, 37.22, 36.18,
31.01, 29.58, 29.39, 29.34, 27.57, 26.59, 24.88, 17.28. HR-FT-MS calcd for
C26H36O4Na1 412.56163 found 412.56159.
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4.5.14 Compound MMA240:
O

O

HO

HO
OH

H
H
HO

OH
H

SMCl
H

MMA301

DMACM
91%

H
O
O S O
NH2

H

MMA240

Compound MMA301 (0.1g, 0.24 mmole) was dissolved in N, N-dimethyacetamide
(0.6 ml) then cooled down to 0 0C; followed by addition of sulfamoyl chloride (0.08 g,
0.72 mmole). The reaction mixture was allowed to be stirred and warm to the room
temperature for 18h. Admixture of ethyl acetate (30ml) and water (30ml) was added to the
reaction mixture and the organic layer was separated, washed by water (3×25ml) followed
by the addition of brain (30ml). Sodium sulfate anhydrous (Na2SO4) to dry the organic
layer, filtered and concentrated in vacuo. Column chromatography (30% ethyl acetate in
hexane) to provide compound MMA240 (0.102 g, 91%).
1H

NMR (400 MHz, Chloroform-d) δ 7.19 – 6.98 (m, 2H), 6.66 – 6.46 (m, 2H),

5.85 (m, 1H), 4.06 (s, 1H), 2.77 (m, 2H), 2.35 (s, 1H), 2.27 – 2.08 (m, 3H), 1.99 – 1.72 (m,
3H), 1.63 (m, 2H), 1.45 (s, 3H), 1.43 (m, 6H), 1.25 – 1.08 (m, 4H), 0.87 – 0.74 (m, 2H),
0.66 (s, 3H).
13C

NMR (101 MHz, Chloroform-d) δ 215.15, 151.37, 148.18, 146.21, 137.32, ,

130.07, 125.88, 113.97, 111.49, 80.17, 75.25, 56.89, 55.07, 48.02, 43.86, 37.22, 36.18,
31.01, 29.58, 29.39, 29.34, 27.57, 26.59, 24.88, 17.28. HR-FT-MS calcd for
C26H37N1O6S1Na1491.64006 found 491.64001.
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4.5.15 Compound MMA280:
O

O

HO
H
H
O
TBS

HO
H

TBAF/ THF
H

86%

6

H
HO

To a stirred solution of α-hydroxyl ketone 6

H

MMA280

(0.3 g, 0.657 mmole) in

tetrahydrofuran (THF) (2.2ml), tetrabutyl ammonium fluoride (TBAF) (1 M in THF,
2.0367 ml, 2.0367 mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl)
solution was added to quench the reaction. Ethyl acetate (3ˣ50ml), dried over sodium
sulfate anhydrous (Na2SO4), filtrated, and concentrated under vacuo. Silica gel column
chromatography was used to purify the crude material (10% ethyl acetate in hexane) to
provide compound MMA280 (0.195 g, 86%).
1H

NMR (400 MHz, Acetone-d6) δ 7.98 (s, 1H), 7.09 – 7.02 (m, 1H), 6.60 – 6.47

(m, 2H), 4.06 (s, 1H), 3.22 (m, 2H), 2.82 – 2.62 (m, 3H), 2.23 (m, 1H), 2.20 (s, 3H), 2.11
(m, 1H), 2.06 (s, 1H), 2.02 (m, 1H), 1.90 (m, 1H), 1.86 – 1.74 (m, 1H), 1.73 – 1.44 (m,
2H), 1.40 (s, 3H), 1.37 – 1.09 (m, 3H), 0.88 (s, 3H).

13C

NMR (101 MHz, Acetone-d6) δ 213.19, 155.95, 138.35, 132.03, 126.99,

116.00, 113.63, 81.00, 56.27, 56.03, 44.74, 44.68, 41.24, 39.24, 28.52, 27.51, 25.19,
24.43, 24.11, 22.78, 14.09.
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4.5.16 Compound MMA242:
O

O

HO

HO

H

H

HO

SMCl/DMACM
H H
94%
O
MMA280
O S O
NH2

H

H

MMA242

Compound MMA280 (0.1g, 0.3 mmole) was dissolved in N, N-dimethyacetamide
(0.7 ml) then cooled down to 0 0C; followed by addition of sulfamoyl chloride (0.1 g, 0.88
mmole). The reaction mixture was allowed to be stirred and warm to the room temperature
for 18h. Admixture of ethyl acetate (30ml) and water (30ml) was added to the reaction
mixture and the organic layer was separated, washed by water (3×25ml) followed by the
addition of brain (30ml). Sodium sulfate anhydrous (Na2SO4) to dry the organic layer,
filtered and concentrated in vacuo. Column chromatography (30% ethyl acetate in hexane)
to provide compound MMA242 (0.116 g, 94%).
1H

NMR (400 MHz, Acetone-d6) δ 7.32 (m, 1H), 7.07 (m, 1H), 7.01 (m, 3H), 4.09

(s, 1H), 2.85 (m, 2H), 2.37 – 2.26 (m, 4H), 2.23 (s, 3H), 2.00 – 1.81 (m, 3H), 1.80 – 1.48
(m, 3H), 1.43 (s, 3H), 1.40 – 1.12 (m, 4H), 0.91 (s, 3H).
13C

NMR (101 MHz, Acetone-d6) δ 213.26, 149.32, 139.73, 139.18, 127.36,

123.02, 120.22, 56.22, 55.95, 44.81, 44.66, 41.09, 38.73, 30.63, 29.48, 28.17, 27.28, 25.21,
24.44, 24.17, 22.78, 14.08.
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4.5.17 general procedure for preparing protected estrone with various aromatic
enone side chain at C-17 (compound 11):
O

O

HO

HO
H
H
O
TBS

6

H

1- LDA/ -78oC/ 1h
H

2- Aldehydes

H
O
TBS

R

H

11

To a stirred solution of α-hydroxyl ketone 6 (0.4g, 0.876 mmole) in a dry
tetrahydrofuran (THF) (1.75 ml), lithiumdiisopropyl amine (LDA) (1.6 ml, 3.2 mmole)
was added in a dropwise at -78oC the reaction mixture was allowed to stir at -78 oC for 1
h, then the solution of aldehydes (1.75 mmole) in THF (0.15 M) was added to the reaction
mixture at -78 oC. The reaction was allowed to stir and warm to the room temperature for
24h. The quench of the reaction was completed by the addition of ammonium chloride
(NH4Cl) (25ml). The aqueous layer was extracted using ethyl acetate (3ˣ50ml), dried over
sodium sulfate anhydrous (Na2SO4), filtrated, and concentrated under vacuo. Silica gel
column chromatography was used to purify the crude material (10% ethyl acetate in
hexane) to provide protected estrone with various aromatic enone side chain at C-17
(compound 11).
TBS-protected Para-methoxyphenyl 1H NMR (400 MHz, Chloroform-d) δ 7.63
(m, 1H), 7.38 (m, 2H), 6.94 (m, 1H), 6.80 – 6.70 (m, 3H), 6.47 – 6.34 (m, 2H), 4.09 (s,
1H), 3.65 (s, 3H), 2.72 – 2.53 (m, 2H), 2.23 – 1.96 (m, 3H), 1.76 – 1.59 (m, 2H), 1.57 –
1.39 (m, 3H), 1.36 (s, 3H), 1.34 – 0.96 (m, 6H), 0.79 (m, 12H), 0.00 (m, 6H). 13C NMR
(101 MHz, Chloroform-d) δ 201.84, 162.03, 153.31, 145.52, 137.86, 133.18, 130.53,
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127.03, 126.04, 119.99, 117.15, 115.98, 114.48, 79.02, 55.79, 55.46, 55.21, 44.32, 43.91,
40.76, 38.11, 29.66, 27.68, 26.64, 25.78, 24.48, 23.70, 22.06, 18.22, 13.69, -4.32.
TBS-protected Para-Flurophenyl 1H NMR (400 MHz, Chloroform-d) δ 7.62 (m,
1H), 7.46 – 7.37 (m, 2H), 6.97 – 6.87 (m, 3H), 6.80 (m, 1H), 6.46 – 6.34 (m, 2H), 3.98 (s,
1H), 2.61 (m, 2H), 2.20 – 1.96 (m, 2H), 1.75 – 1.59 (m, 3H), 1.57 – 1.38 (m, 3H), 1.33 –
0.92 (m, 3H), 0.79 (m, 12H), 0.75 – 0.61 (m, 6H), 0.00 (s, 6H).

13C

NMR (101 MHz,

Chloroform-d) δ 201.75, 153.33, 144.34, 137.82, 133.11, 130.65 (d, J = 8.4 Hz), 126.02,
120.00, 118.19, 117.16, 116.32, 116.10, 79.19, 55.80, 55.12, 44.37, 43.92, 40.77, 38.10,
29.86 – 29.55 (m), 29.42, 27.68, 26.62, 25.76, 24.36, 23.69, 22.08, 18.21, 14.18, 13.69, 4.35.
TBS-protected Para-chlorophenyl 1H NMR (400 MHz, Chloroform-d) δ 7.59
(m, 1H), 7.35 (m, 2H), 7.26 – 7.16 (m, 2H), 6.93 (m, 1H), 6.84 (m, 1H), 6.49 – 6.33 (m,
2H), 3.96 (s, 1H), 2.73 – 2.52 (m, 2H), 2.19 – 1.95 (m, 3H), 1.66 (m, 2H), 1.44 (m, 3H),
1.37 (s, 3H), 1.30 – 0.98 (m, 6H), 0.79 (m, 12H), 0.00 (s, 6H).

13C

NMR (101 MHz,

Chloroform-d) δ 201.76, 153.33, 144.18, 137.83, 136.90, 133.11, 132.81, 129.84, 129.31,
126.04, 120.01, 118.93, 117.17, 79.26, 55.78, 55.08, 44.38, 43.90, 40.75, 38.10, 29.66,
27.68, 26.62, 25.79, 24.35, 23.70, 22.10, 18.23, 13.72, -4.31.
TBS-protected Para-bromophenyl 1H NMR (400 MHz, Chloroform-d) δ 7.57
(m, 1H), 7.39 – 7.31 (m, 2H), 7.31 – 7.24 (m, 2H), 6.93 (m, 1H), 6.85 (d, J = 15.6 Hz, 1H),
6.48 – 6.35 (m, 2H), 3.95 (s, 1H), 2.71 – 2.52 (m, 2H), 2.21 – 1.95 (m, 3H), 1.73 – 1.60
(m, 2H), 1.54 – 1.39 (m, 3H), 1.37 (s, 3H), 1.33 – 1.01 (m, 6H), 0.79 (m, 12H), 0.00 (s,
6H).

13C

NMR (101 MHz, Chloroform-d) δ 201.77, 153.33, 144.25, 137.83, 133.22,
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133.16, 132.27, 130.02, 126.04, 125.32, 120.00, 119.02, 117.17, 79.27, 55.77, 55.06,
44.38, 43.90, 40.75, 38.09, 29.65, 27.67, 26.62, 25.79, 24.34, 23.70, 22.09, 18.36 18.23,
13.72, -4.31.
TBS-protected Para-trifluromethylphenyl 1H NMR (400 MHz, Chloroform-d)
δ 7.65 (m, 1H), 7.50 (m, 4H), 6.94 (m, 2H), 6.48 – 6.35 (m, 2H), 3.89 (s, 1H), 2.61 (m,
2H), 2.21 – 1.94 (m, 3H), 1.75 – 1.60 (m, 2H), 1.45 (m, 3H), 1.39 (s, 3H), 1.32 – 0.99 (m,
6H), 0.79 (s, 12H), 0.00 (s, 6H). 13C NMR (101 MHz, Chloroform-d) δ 201.72, 153.34,
143.60, 137.75 (d, J = 14.0 Hz), 133.06, 132.44, 128.75, 125.99 (d, J = 6.2 Hz), 120.84,
120.00, 117.17, 79.40, 55.77, 55.04, 44.41, 43.89, 40.74, 38.09, 29.63, 27.66, 26.60, 25.75,
24.27, 23.67, 22.10, 18.20, 13.70, -4.36.
TBS-protected Para-nitrophenyl 1H NMR (400 MHz, Chloroform-d) δ 8.08 (m,
2H), 7.65 (d, 1H), 7.61 – 7.54 (m, 2H), 7.10 – 6.91 (m, 2H), 6.49 – 6.33 (m, 2H), 3.81 (s,
1H), 2.71 – 2.54 (m, 2H), 2.21 – 1.96 (m, 3H), 1.67 (m, 2H), 1.61 – 1.41 (m, 3H), 1.39 (s,
3H), 1.01 – 0.83 (m, 6H), 0.79 (s, 12H), 0.00 (s, 6H). 13C NMR (151 MHz, Chloroformd) δ 201.50, 153.35, 148.78, 142.31, 140.38, 137.74, 132.97, 129.15, 125.97, 124.17,
122.40, 119.97, 117.15, 79.51, 55.78, 55.05, 44.43, 43.89, 40.73, 38.09, 34.60, 31.96,
29.75, 29.32, 29.07, 27.65, 26.58, 25.27, 24.22, 23.65, 22.11, 20.66, 18.72, 18.15, 14.08,
13.66, 11.39, -4.44.
TBS-protected 2-Bromofuran 1H NMR (400 MHz, Chloroform-d) δ 7.27 (d, 1H),
6.94 (d, 1H), 6.70 (d, , 1H), 6.50 – 6.35 (m, 3H), 6.26 (d, 1H), 3.98 (s, 1H), 2.72 – 2.49 (m,
2H), 2.22 – 1.95 (m, 3H), 1.77 – 1.59 (m, 2H), 1.56 – 1.39 (m, 3H), 1.35 (s, 3H), 1.32 –
0.96 (m, 6H), 0.78 (d, 12H), 0.00 (s, 6H). 13C NMR (101 MHz, Chloroform-d) δ 201.61,
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153.29, 153.03, 137.83, 133.18, 130.01, 126.37, 126.05, 119.98, 119.08, 117.15, 116.41,
114.78, 79.17, 55.70, 54.90, 44.35, 43.87, 40.65, 38.11, 29.66, 27.67, 26.62, 25.77, 24.31,
23.70, 22.06, 18.21, 13.69, -4.32.
TBS-protected 2-Bromothiophene 1H NMR (400 MHz, Chloroform-d) δ 7.62 (d,
1H), 6.93 (d, 1H), 6.89 (m, 1H), 6.85 (m, , 1H), 6.52 (m, 1H), 6.46 – 6.34 (m, 2H), 3.92 (s,
1H), 2.70 – 2.51 (m, 2H), 1.70 – 1.58 (m, 3H), 1.56 – 1.37 (m, 2H), 1.33 (s, 3H), 1.08 (q, ,
3H), 0.78 (m, 12H), 0.73 – 0.62 (m, 6H), 0.00 (s, 6H). 13C NMR (101 MHz, Chloroformd) δ 201.40, 153.32, 141.35, 137.82, 136.97, 133.13, 132.94, 131.41, 126.04, 119.99,
117.58, 117.16, 117.06, 79.13, 55.74, 55.13, 44.35, 43.87, 40.71, 38.10, 29.66, 27.67,
26.62, 25.77, 24.35, 23.69, 22.09, 18.22, 13.68, -4.33.

4.5.18 Compound MMA268:
O

O

HO
O

H
H
O
TBS

11

HO

H

TBAF/ THF
87%

O

H
H
HO

H

MMA268

To a stirred solution of desired compound 11 (0.3 g, 0.5218 mmole) in
tetrahydrofuran (THF) (2.6 ml), tetrabutyl ammonium fluoride (TBAF) (1 M in THF, 1.62
ml, 1.62 mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was
added to quench the reaction. Ethyl acetate (3×50ml), dried over sodium sulfate anhydrous
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was
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used to purify the crude material (10% ethyl acetate in hexane) to provide Compound
MMA268 (0.21 g, 87.5%).
1H

NMR (400 MHz, Chloroform-d) δ 7.72 (m, 1H), 7.45 (m, 2H), 7.01 (m, 1H),

6.88 – 6.78 (m, 3H), 6.60 – 6.45 (m, 2H), 4.34 (s, 1H), 3.72 (s, 3H), 2.67 (m, 2H), 2.34 –
1.99 (m, 3H), 1.95 (m, 2H), 1.47 (m, 3H), 1.53 – 1.42 (m, 1H), 1.24 – 1.10 (m, 5H).
13C

NMR (101 MHz, Chloroform-d) δ 202.01, 162.10, 153.91, 145.96, 138.06,

132.21, 130.65, 126.98, 126.36, 115.84, 115.45, 114.50, 112.88, 79.32, 55.70, 55.45,
55.26, 44.31, 43.84, 40.69, 38.19, 32.00, 29.74, 29.68, 27.65, 26.71, 24.34, 23.67, 22.77.
HR-FT-MS calcd for C30H37O4 461.2686 found 461.26819.

4.5.19 Compound MMA267:
O

O

HO

HO
O
SMCl

H
H
HO

H

MMA268

DMACM
89.7% O
O S O
NH2

O

H
H

H

MMA267

Compound MMA268 (0.2g, 0.434 mmole) was dissolved in N, Ndimethyacetamide (1.05 ml) then cooled down to 0 0C; followed by addition of sulfamoyl
chloride (0.15 g, 1.302 mmole). The reaction mixture was allowed to be stirred and warm
to the room temperature for 18h. Admixture of ethyl acetate (30 ml) and water (30 ml) was
added to the reaction mixture and the organic layer was separated, washed by water (3×25
ml) followed by the addition of brain (30 ml). Sodium sulfate anhydrous (Na2SO4) to dry

202

the organic layer, filtered and concentrated in vacuo. Column chromatography (30% ethyl
acetate in hexane) to provide compound MMA267 (0.21 g, 89.7%).
1H

NMR (400 MHz, Chloroform-d) δ 7.75 (m, 1H), 7.58 – 7.44 (m, 2H), 7.26 (s,

1H), 7.05 – 6.92 (m, 2H), 6.91 – 6.83 (m, 3H), 4.93 (s, 2H), 4.21 (s, 1H), 3.91 – 3.75 (m,
3H), 2.34 – 2.13 (m, 2H), 2.11 (s, 3H), 1.97 (m, 2H), 1.68 – 1.50 (m, 3H), 1.48 (s, 1H),
1.21 – 1.17 (m, 5H), 0.89 (s, 3H), 0.86 – 0.74 (m, 3H).
13C

NMR (101 MHz, Chloroform-d) δ 202.03, 162.113, 148.88, 145.94, 138.03,

132.19, 130.62, 126.95, 126.35, 115.85, 115.43, 114.52, 112.86, 79.37, 55.69, 55.43,
55.24, 44.29, 43.82, 40.67, 38.17, 32.06, 29.73, 29.66, 27.62, 26.70, 24.32, 23.65, 22.75.
HR-FT-MS calcd for C30H37O6N1Na1S1 562.2234 found 562.22222.

4.5.20 Compound MMA269:
O

O

HO
F

H
H
O
TBS

11

HO

H

TBAF/ THF
92%

F

H
H
HO

H

MMA269

To a stirred solution of desired compound 11 (0.3 g, 0.533 mmole) in
tetrahydrofuran (THF) (2.6 ml), tetrabutyl ammonium fluoride (TBAF) (1 M in THF, 1.65
ml, 1.65 mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was
added to quench the reaction. Ethyl acetate (3×50ml), dried over sodium sulfate anhydrous
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was
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used to purify the crude material (10% ethyl acetate in hexane) to provide Compound
MMA269 (0.22 g, 92%).
1H

NMR (400 MHz, Chloroform-d) δ 7.86 (m, 1H), 7.71 – 7.61 (m, 2H), 7.22 –

7.10 (m, 3H), 7.05 (m, 1H), 6.70 (m, 1H), 6.62 (m, 1H), 6.33 – 6.14 (m, 1H), 4.39 (s, 1H),
2.92 – 2.75 (m, 2H), 2.42 – 2.16 (m, 4H), 1.98 – 1.82 (m, 2H), 1.63 (s, 3H), 1.52 – 1.20
(m, 5H), 1.01 (s, 3H), 0.92 (m, 3H).
13C

NMR (101 MHz, Chloroform-d) δ 201.97, 153.65, 144.79, 138.15, 132.41,

130.81, 130.72, 130.53, 130.50, 126.41, 118.04, 116.35, 116.13, 115.42, 112.83, 79.51,
55.69, 55.14, 44.35, 43.83, 40.66, 38.14, 29.72, 29.65, 27.61, 26.68, 24.23, 23.65, 22.09.
HR-FT-MS calcd for C29H33O3F1Na1 471.2306 found 471.23231.

4.5.21 Compound MMA271:
HO

O

H
H
HO

H

MMA269

HO
F
SMCl
DMACM
91.5%

O

H
H
O
O S O
NH2

F
H

MMA271

Compound MMA269 (0.2g, 0.446 mmole) was dissolved in N, Ndimethyacetamide (1.1 ml) then cooled down to 0 0C; followed by addition of sulfamoyl
chloride (0.2 g, 1.338 mmole). The reaction mixture was allowed to be stirred and warm to
the room temperature for 18h. Admixture of ethyl acetate (30 ml) and water (30 ml) was
added to the reaction mixture and the organic layer was separated, washed by water (3×25
ml) followed by the addition of brain (30 ml). Sodium sulfate anhydrous (Na2SO4) to dry
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the organic layer, filtered and concentrated in vacuo. Column chromatography (30% ethyl
acetate in hexane) to provide compound MMA271 (0.215 g, 91.5%).
1H

NMR (600 MHz, Chloroform-d) δ 7.73 (m, 1H), 7.58 – 7.46 (m, 2H), 7.25 –

7.18 (m, 1H), 7.02 (m, , 3H), 6.95 (m, 1H), 6.89 (m, 1H), 5.14 (s, 2H), 4.11 (s, 1H), 2.83 –
2.73 (m, 2H), 2.33 – 2.12 (m, 3H), 1.97 (s, 1H), 1.92 – 1.74 (m, 3H), 1.72 – 1.50 (m, 2H),
1.47 (s, 3H), 1.44 – 1.24 (m, 3H), 1.23 – 1.16 (m, 5H).
13C

NMR (151 MHz, Chloroform-d) δ 201.75, 147.90, 144.57, 139.64, 138.90,

130.71, 130.65, 126.69, 121.93, 118.95, 116.30, 116.16, 79.19, 55.69, 55.06, 44.22, 43.99,
40.54, 37.66, 29.72, 29.51, 27.27, 26.45, 24.30, 23.64, 22.71, 22.02. HR-FT-MS calcd for
C29H34O5F1Na1S1 550.2034 found 550.20497.

4.5.22 Compound MMA309:
HO

O
TBS

11

HO
Cl

H
H

O

H

Cl

H

TBAF/ THF
83%

O

H
HO

H

MMA309

To a stirred solution of desired compound 11 (0.3 g, 0.518 mmole) in
tetrahydrofuran (THF) (2.6 ml), tetrabutyl ammonium fluoride (TBAF) (1 M in THF, 1.6
ml, 1.6 mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was
added to quench the reaction. Ethyl acetate (3×50ml), dried over sodium sulfate anhydrous
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was
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used to purify the crude material (10% ethyl acetate in hexane) to provide Compound
MMA309 (0.2 g, 83%).
1H

NMR (400 MHz, Chloroform-d) δ 7.71 (m, 1H), 7.57 – 7.42 (m, 2H), 7.38 –

7.28 (m, 2H), 7.08 (m, 1H), 6.94 (m, 1H), 6.63 – 6.44 (m, 2H), 4.95 (s, 1H), 4.11 (s, 1H),
2.83 – 2.63 (m, 3H), 2.33 – 2.17 (m, 3H), 2.11 (s, 3H), 1.86 – 1.71 (m, 2H), 1.67 – 1.50
(m, 3H), 1.49 (s, 3H), 1.42 – 1.09 (m, 5H).
13C

NMR (101 MHz, Chloroform-d) δ 201.80, 153.41, 144.30, 138.24, 136.95,

132.74, 132.63, 129.83, 129.30, 126.42, 118.83, 115.27, 112.66, 79.31, 55.69, 55.07,
44.35, 43.82, 40.67, 38.10, 30.98, 29.61, 27.56, 26.65, 24.27, 23.64, 22.04. HR-FT-MS
calcd for C29H33O3Cl1Na1 487.2010 found 487.20045.

4.5.23 Compound MMA294:
HO

O

H
H
HO

H

MMA309

HO
Cl
SMCl
DMACM
89%

O

H
H
O
O S O
NH2

Cl
H

MMA294

Compound MMA309 (0.2g, 0.43 mmole) was dissolved in N, Ndimethyacetamide (1.1 ml) then cooled down to 0 0C; followed by addition of sulfamoyl
chloride (0.15 g, 1.3 mmole). The reaction mixture was allowed to be stirred and warm to
the room temperature for 18h. Admixture of ethyl acetate (30 ml) and water (30 ml) was
added to the reaction mixture and the organic layer was separated, washed by water (3×25
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ml) followed by the addition of brain (30 ml). Sodium sulfate anhydrous (Na2SO4) to dry
the organic layer, filtered and concentrated in vacuo. Column chromatography (30% ethyl
acetate in hexane) to provide compound MMA294 (0.209 g, 89%).
1H

NMR (400 MHz, Acetone-d6) δ 7.86 (m, 2H), 7.50 (m, 3H), 7.35 (m, 1H), 7.12

– 7.00 (m, 3H), 5.13 (m, 2H), 4.29 (m, 1H), 2.35 (m, 3H), 2.29 – 2.22 (m, 3H), 2.12 (s,
3H), 1.71 (m, 2H), 1.62 – 1.57 (m, 3H), 1.43 (m, 3H), 1.39 – 1.19 (m, 5H).
13C

NMR (101 MHz, Acetone-d6) δ 203.04, 149.36, 143.75, 139.68, 139.16,

136.79, 134.54, 131.22, 129.95, 127.32, 122.99, 121.30, 120.18, 80.17, 56.30, 55.61,
44.89, 44.80, 41.01, 38.77, 32.68, 28.14, 27.26, 24.83, 24.38, 23.39, 22.80. HR-FT-MS
calcd for C29H34O5N1Cl1Na1S1 566.1738 found 566.17551.

4.5.24 Compound MMA310:
HO

O
TBS

11

HO
Br

H
H

O

H

Br

H

TBAF/ THF
79%

O

H
HO

H

MMA310

To a stirred solution of desired compound 11 (0.3 g, 0.48 mmole) in tetrahydrofuran
(THF) (2.4 ml), tetrabutyl ammonium fluoride (TBAF) (1 M in THF, 1.5 ml, 1.5 mmole)
was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was added to quench
the reaction. Ethyl acetate (3×50ml), dried over sodium sulfate anhydrous (Na2SO4),
filtrated, and concentrated under vacuo. Silica gel column chromatography was used to

207

purify the crude material (10% ethyl acetate in hexane) to provide Compound MMA310
(0.194 g, 79%).
1H

NMR (400 MHz, Chloroform-d) δ 7.69 (m, , 1H), 7.51 – 7.36 (m, 4H), 7.07 (d,

J = 8.5 Hz, 1H), 6.96 (m, 1H), 6.63 – 6.44 (m, 2H), 5.17 (s, 1H), 4.12 (s, 1H), 2.85 – 2.64
(m, 3H), 2.34 – 2.17 (m, 3H), 2.11 (s, 3H), 1.86 – 1.70 (m, 2H), 1.67 – 1.50 (m, 3H), 1.49
(s, 3H), 1.41 – 1.10 (m, 5H).
13C

NMR (101 MHz, Chloroform-d) δ 201.84, 153.46, 144.43, 138.22, 133.15,

132.57, 132.27, 130.02, 126.42, 125.37, 118.92, 115.30, 112.69, 79.37, 55.69, 55.06,
44.35, 43.82, 40.67, 38.11, 31.61, 30.99, 29.63, 27.56, 26.65, 24.25, 23.64, 22.06. HR-FTMS calcd for C29H33O3Br1Na1 531.1505 found 531.15002.

4.5.25 Compound MMA295:
HO

O

H
H
HO

H

MMA310

HO
Br
SMCl
O
DMACM
90%
O S O
NH2

O

H
H

Br
H

MMA295

Compound MMA310 (0.1 g, 0.2 mmole) was dissolved in N, N-dimethyacetamide
(0.5 ml) then cooled down to 0 0C; followed by addition of sulfamoyl chloride (0.07 g, 0.6
mmole). The reaction mixture was allowed to be stirred and warm to the room temperature
for 18h. Admixture of ethyl acetate (30 ml) and water (30 ml) was added to the reaction
mixture and the organic layer was separated, washed by water (3×25 ml) followed by the
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addition of brain (30 ml). Sodium sulfate anhydrous (Na2SO4) to dry the organic layer,
filtered and concentrated in vacuo. Column chromatography (30% ethyl acetate in hexane)
to provide compound MMA295 (0.104 g, 90%).
1H

NMR (400 MHz, Acetone-d6) δ 7.69 (m, 2H), 7.54 (m, 3H), 7.47 (m, , 1H) 7.08

– 6.92 (m, 3H), 5.16 (s, 2H), 4.09 (s, , 1H), 2.41 (s, 3H), 2.30 – 2.25 (m, 3H), 2.25 – 2.12
(s, 3H), 1.84 – 1.70 (m, 2H), 1.58 (m, 3H), 1.47 (m, 3H), 1.27 – 1.16 (m, 5H).
13C

NMR (101 MHz, Acetone-d6) δ 203.09, 149.36, 143.84, 139.70, 139.17, 134.93,

132.95, 131.40, 127.32, 125.20, 122.98, 121.42, 120.18, 80.18, 56.37, 55.47, 44.89, 44.85,
41.01, 38.78, 32.66, 28.11, 27.26, 24.80, 24.36, 23.37, 22.79. HR-FT-MS calcd for
C29H34O5N1Br1Na1S1 610.1233 found 610.12377.

4.5.26 Compound MMA308:
HO

O
TBS

11

HO
CF3

H
H

O

H

CF3

H

TBAF/ THF
90%

O

H
HO

H

MMA308

To a stirred solution of desired compound 11 (0.3 g, 0.49 mmole) in tetrahydrofuran
(THF) (2.5 ml), tetrabutyl ammonium fluoride (TBAF) (1 M in THF, 1.519 ml, 1.519
mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was added to
quench the reaction. Ethyl acetate (3×50ml), dried over sodium sulfate anhydrous
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was
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used to purify the crude material (10% ethyl acetate in hexane) to provide Compound
MMA308 (0.23 g, 90%).
1H

NMR (400 MHz, Chloroform-d) δ 7.73 (m, 1H), 7.57 (m, 4H), 7.07 – 6.99 (m,

2H), 6.58 – 6.42 (m, 2H), 5.54 (s, 1H), 4.07 (s, 1H), 2.86 – 2.62 (m, 3H), 2.55 (m, 3H),
2.28 – 2.01 (m, 3H), 1.85 – 1.66 (m, 2H), 1.66 – 1.51 (m, 3H), 1.51 – 1.45 (m, 3H), 1.38 –
1.02 (m, 5H).
13C

NMR (101 MHz, Chloroform-d) δ 201.83, 153.55, 143.86, 138.18, 137.61,

132.48, 128.79, 126.40, 125.94, 120.73, 115.35, 112.75, 79.59, 55.68, 55.06, 44.39, 43.81,
40.65, 38.12, 31.96, 29.62, 27.57, 26.65, 24.17, 23.64, 22.73, 22.10. HR-FT-MS calcd for
C30H33O3F3Na1 521.2274 found 521.22942.

4.5.27 Compound MMA300:
HO

O

H
H
HO

H

MMA308

HO
CF3
SMCl
O
DMACM
O S O
92%
NH2

O

H
H

CF3
H

MMA300

Compound MMA308 (0.2 g, 0.4 mmole) was dissolved in N, N-dimethyacetamide
(1 ml) then cooled down to 0 0C; followed by addition of sulfamoyl chloride (0.14 g, 1.2
mmole). The reaction mixture was allowed to be stirred and warm to the room temperature
for 18h. Admixture of ethyl acetate (30 ml) and water (30 ml) was added to the reaction
mixture and the organic layer was separated, washed by water (3×25 ml) followed by the
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addition of brain (30 ml). Sodium sulfate anhydrous (Na2SO4) to dry the organic layer,
filtered and concentrated in vacuo. Column chromatography (30% ethyl acetate in hexane)
to provide compound MMA300 (0.214 g, 92%).
1H

NMR (600 MHz, Chloroform-d) δ 7.77 (m, 1H), 7.68 – 7.57 (m, 4H), 7.24 (m,

1H), 7.03 (s, 2H), 6.95 (m, 1H), 4.97 (s, 2H), 4.01 (s, 1H), 2.79 (m, 3H), 2.56 (m, 3H), 2.33
– 2.13 (m, 3H), 1.86 – 1.73 (m, 2H), 1.69 – 1.52 (m, 3H), 1.50 (s, 3H), 1.20 – 1.17 (m, 5H).
13C

NMR (151 MHz, Chloroform-d) δ 201.66, 147.90, 143.76, 139.66, 138.92,

137.62, 132.45, 132.23, 128.75, 126.71, 121.90, 120.71, 118.92, 79.36, 55.69, 55.02,
44.28, 43.99, 40.55, 37.66, 30.96, 29.25, 27.26, 26.45, 24.26, 23.64, 22.71. HR-FT-MS
calcd for C30H34O5N1F3Na1S1 600.2002 found 600.20229.

4.5.28 Compound MMA306:
HO

O
TBS

11

HO
NO2

H
H

O

H

NO2

H

TBAF/ THF
78%

O

H
HO

H

MMA306

To a stirred solution of desired compound 11 (0.3 g, 0.51 mmole) in tetrahydrofuran
(THF) (2.5 ml), tetrabutyl ammonium fluoride (TBAF) (1 M in THF, 1.6 ml, 1.6 mmole)
was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was added to quench
the reaction. Ethyl acetate (3×50ml), dried over sodium sulfate anhydrous (Na2SO4),
filtrated, and concentrated under vacuo. Silica gel column chromatography was used to
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purify the crude material (10% ethyl acetate in hexane) to provide Compound MMA306
(0.187 g, 78%).
1H

NMR (400 MHz, Chloroform-d) δ 8.30 – 8.13 (m, 2H), 7.77 (d, J = 15.7 Hz,

1H), 7.72 – 7.65 (m, 2H), 7.15 – 7.04 (m, 2H), 6.60 – 6.46 (m, 2H), 5.02 (s, 1H), 3.95 (s,
1H), 2.85 – 2.63 (m, 3H), 2.58 (m, 3H), 2.33 – 2.04 (m, 3H), 1.86 – 1.72 (m, 2H), 1.72 –
1.54 (m, 3H), 1.51 (d, J = 2.8 Hz, 3H), 1.42 – 1.04 (m, 5H).
13C

NMR (101 MHz, Chloroform-d) δ 201.59, 153.46, 148.78, 142.48, 140.35,

138.20, 132.51, 129.21, 126.40, 124.22, 122.34, 115.28, 112.68, 79.60, 55.68, 55.02,
44.42, 43.80, 40.65, 38.10, 31.94, 29.60, 27.55, 26.63, 24.21, 23.64, 22.11. HR-FT-MS
calcd for C29H33O5N1Na1 498.2251 found 498.22654.

4.5.29 Compound MMA307:
HO

O

H
H
HO

H

MMA306

HO
NO2
SMCl
O
DMACM
O S O
91%
NH2

O

H
H

NO2
H

MMA307

Compound MMA306 (0.15 g, 0.135 mmole) was dissolved in N, Ndimethyacetamide (0.8 ml) then cooled down to 0 0C; followed by addition of sulfamoyl
chloride (0.12 g, 0.945 mmole). The reaction mixture was allowed to be stirred and warm
to the room temperature for 18h. Admixture of ethyl acetate (30 ml) and water (30 ml) was
added to the reaction mixture and the organic layer was separated, washed by water (3×25
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ml) followed by the addition of brain (30 ml). Sodium sulfate anhydrous (Na2SO4) to dry
the organic layer, filtered and concentrated in vacuo. Column chromatography (30% ethyl
acetate in hexane) to provide compound MMA307 (0.16 g, 91%).
1H

NMR (400 MHz, Chloroform-d) δ 8.36 – 8.19 (m, 2H), 7.82 (d, J = 15.7 Hz,

1H), 7.79 – 7.71 (m, 2H), 7.20 – 7.09 (m, 2H), 6.68 – 6.56 (m, 2H), 5.12 (s, 2H), 4.13 (s,
1H), 3.99 (s, 1H), 2.89 – 2.65 (m, 3H), 2.62 (m, 3H), 2.35 – 2.10 (m, 3H), 1.92 – 1.79 (m,
2H), 1.75 – 1.58 (m, 3H), 1.62 (d, J = 2.8 Hz, 3H), 1.45 – 1.10 (m, 5H).
13C

NMR (101 MHz, Chloroform-d) δ 201.12, 149.46, 146.78, 142.31, 140.12,

138.22, 132.43, 129.09, 126.36, 124.17, 122.29, 115.19, 112.57, 79.52, 55.61, 54.96,
44.38, 43.67, 40.60, 38.01, 31.88, 29.60, 27.48, 26.58, 24.17, 23.59, 22.03. HR-FT-MS
calcd for C29H34O7N2Na1S1 577.1979 found 577.19790.

4.5.30 Compound MMA297:
O
HO

O
HO

O
Br

Br

H
H
O
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O

H
H

TBAF/ THF
84%

H

H

HO
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To a stirred solution of desired compound 11 (0.3 g, 0.184 mmole) in
tetrahydrofuran (THF) (1 ml), tetrabutyl ammonium fluoride (TBAF) (1 M in THF, 0.6
ml, 0.6 mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was
added to quench the reaction. Ethyl acetate (3×50ml), dried over sodium sulfate anhydrous
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was
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used to purify the crude material (10% ethyl acetate in hexane) to provide Compound
MMA297 (0.204 g, 84%).
1H

NMR (400 MHz, Chloroform-d) δ 7.38 (m, 1H), 7.07 (m, , 1H), 6.80 (m, 1H),

6.57 (m, 2H), 6.49 (d, J = 2.7 Hz, 1H), 6.38 (d, J = 3.4 Hz, 1H), 5.46 (s, 1H), 4.17 (s, 1H),
2.88 – 2.64 (m, 3H), 2.22 (m, 3H), 2.12 (m, 3H), 1.87 – 1.69 (m, 2H), 1.54 (m, 3H), 1.48
(s, 3H), 1.40 – 1.05 (m, 5H).
13C

NMR (101 MHz, Chloroform-d) δ 201.72, 153.52, 152.98, 138.20, 132.57,

130.18, 126.47, 126.42, 119.24, 116.29, 115.30, 114.81, 112.71, 79.31, 55.63, 54.92,
44.33, 43.80, 40.58, 38.13, 30.99, 29.64, 27.58, 26.66, 24.22, 23.65, 22.04. HR-FT-MS
calcd for C27H31O4Br1Na1 521.1298 found 521.12905.

4.5.31 Compound MMA314:
O
HO

O
HO

O
Br

Br

H
H
HO

O

H
H

MMA297

SMCl

DMACM
90%

H
O
O S O
NH2

H

MMA297

Compound MMA297 (0.2 g, 0.4 mmole) was dissolved in N, N-dimethyacetamide
(1 ml) then cooled down to 0 0C; followed by addition of sulfamoyl chloride (0.14 g, 1.2
mmole). The reaction mixture was allowed to be stirred and warm to the room temperature
for 18h. Admixture of ethyl acetate (30 ml) and water (30 ml) was added to the reaction
mixture and the organic layer was separated, washed by water (3×25 ml) followed by the
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addition of brain (30 ml). Sodium sulfate anhydrous (Na2SO4) to dry the organic layer,
filtered and concentrated in vacuo. Column chromatography (30% ethyl acetate in hexane)
to provide compound MMA314 (0.208 g, 90%).
1H

NMR (400 MHz, Chloroform-d) δ 7.56 – 7.45 (m, 3H), 7.39 – 7.27 (m, 1H),

7.11 (m, 2H), 6.90 (m, 1H), 5.28 (s, 2H), 4.24 (s, 1H), 2.98 (m, 3H), 2.61 (m, 3H), 2.41 –
2.22 (m, 3H), 2.02 – 1.84 (m, 2H), 1.66 (m, 3H), 1.56 (m, 3H), 1.23 – 1.09 (m, 5H).
13C

NMR (101 MHz, Chloroform-d) δ 201.52, 153.01, 147.92, 139.86, 138.85,

130,15, 126.68, 126.44, 122.10, 119.21, 118,98, 116.17, 114.77, 79.14, 55.70, 55.02,
44.21, 43.99, 34.45, 34.23, 32.78, 31.98, 29.76, 28.01, 26.80, 26.49, 22.74. . HR-FT-MS
calcd for C27H32O6N1Br1Na1S1 600.1026 found 600.10038.

4.5.32 Compound MMA313:
HO

O
S

HO
Br

H
H
O
TBS

11

O
S

Br

H
H

TBAF/ THF
93%

H
HO

H

MMA313

To a stirred solution of desired compound 11 (0.3 g, 0.476 mmole) in
tetrahydrofuran (THF) (2.4 ml), tetrabutyl ammonium fluoride (TBAF) (1 M in THF, 1.47
ml, 1.47 mmole) was added and stirred for 6h. Ammonium chloride (NH4Cl) solution was
added to quench the reaction. Ethyl acetate (3×50ml), dried over sodium sulfate anhydrous
(Na2SO4), filtrated, and concentrated under vacuo. Silica gel column chromatography was
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used to purify the crude material (10% ethyl acetate in hexane) to provide Compound
MMA313 (0.229 g, 93%).
1H

NMR (400 MHz, Chloroform-d) δ 7.86 (d, J = 15.3 Hz, 1H), 7.21 – 7.03 (m,

3H), 6.83 – 6.57 (m, 3H), 6.17 (s, 1H), 4.32 (s, 1H), 2.95 – 2.73 (m, 3H), 2.48 (m, 3H),
2.24 (m, 3H), 1.88 (dd, J = 12.2, 6.4 Hz, 2H), 1.82 – 1.62 (m, 3H), 1.60 (d, J = 3.3 Hz, 3H),
1.51 – 1.19 (m, 5H).
13C

NMR (101 MHz, Chloroform-d) δ 201.59, 153.63, 141.28, 138.12, 137.36,

133.19, 132.41, 131.47, 126.40, 117.40, 117.32, 115.42, 112.83, 79.44, 55.65, 55.19,
44.34, 43.80, 40.63, 38.15, 32.00, 29.66, 27.62, 26.68, 24.22, 23.67, 22.11. HR-FT-MS
calcd for C27H31O3Br1Na1S1 537.1069 found 537.10627.

4.5.33 Compound MMA312:
HO

O
S

HO
Br

H
H
HO

O
S

Br

H
H

MMA297

SMCl
O
DMACM
O S O
91%
NH2

H

H

MMA312

Compound MMA313 (0.2 g, 0.388 mmole) was dissolved in N, N-dimethyacetamide (1
ml) then cooled down to 0 0C; followed by addition of sulfamoyl chloride (0.134 g, 1.164 mmole).
The reaction mixture was allowed to be stirred and warm to the room temperature for 18h.
Admixture of ethyl acetate (30 ml) and water (30 ml) was added to the reaction mixture and the
organic layer was separated, washed by water (3×25 ml) followed by the addition of brain (30 ml).
Sodium sulfate anhydrous (Na2SO4) to dry the organic layer, filtered and concentrated in vacuo.
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Column chromatography (30% ethyl acetate in hexane) to provide compound MMA312 (0.21 g,
91%).
1H

NMR (600 MHz, Chloroform-d) δ 7.97-7.80 (m, 1H), 7.38-7.27 (m, 2H), 7.09

(m, 3H), 6.73 (m, 1H), 5.36 (s, 2H), 4.18 (s, 1H), 2.82 (m, 3H), 2.59 (m, 3H), 2.35 – 2.17
(m, 3H), 1.90 – 1.79 (m, 2H), 1.54 (m, 3H), 1.47 (m, 3H), 1.13 – 0.89 (m, 5H).
13C

NMR (101 MHz, Chloroform-d) δ 201.43, 147.88, 141.25, 139.63, 138.88,

137.28, 133.19, 131.47, 126.69, 121.97, 118.98, 117.34, 117.22, 79.17, 55.63, 55.08,
44.19, 43.95, 40.49, 37.65, 31.96, 29.74, 27.27, 26.45, 24.25, 23.64, 22.74. . HR-FT-MS
calcd for C27H32O5N1Br1Na1S2 616.0797 found 616.07782.
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Chapter Five

Design, Synthesis and Biological Evaluation of CUCS-Inspired Estrone Analogues
Targeting Multidrug Resistance Protein 1 (MRP1)

5.1

Introduction:
Cancer is a serious disease that rank on the second position among diseases that

lead to death, which found to be behind the death of one person in every five or six people
in the western countries. It is also responsible for 8.2 million of deaths around the world.
Every year more than 14.1 million cancer cases revealed mainly in the developing
countries. In addition, people who live with cancer count more than 32.5 million [1, 2].

Cancer is known as serious genatic disorder when the cells become abnormally fast
divided. So, if the abnormal divided cells untreated, it will affect the other tissues of the
body and lead to death. The main available treatments of cancer are chemotherapeutic
agents which can either stop or slow the abnormal fast division of the cells [3, 4]. The
major problem associated with the available chemotherapeutic agents is the drug resistance
which involved with 30%- 80% of cancer patients [5]. Therefore, there is an urgent need
to find a new agent to overcome the chemotherapeutic resistance.
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Drug resistance in cancer cells is not specific for one anticancer drug, but the whole
available chemotherapeutic agents within the same family can be influenced by the same
mechanism. Some cancer cells that developed drug resistance can be resistance to other
type of drugs that different in their mechanism of action and structure. This process defined
as multidrug resistance (MDR). This phenomenon might clarify the failure drug
combination to overcome the cancer cell resistance [3]. There are two main clinical times
of MDR; first one happen at the time of treatment and the second is already present at the
time of the diagnosis [6].

Various biological reactions represent the frist defense for the cells include:


Activation of cellular elimination process, cellular uptake process and metabolic reactions
to inactivate the drug process inside the cell, all of these processes will cause the decrease
of the chemotherapy concentration inside the cell (Fig.5.1) [7-9].
 Changes of the drug delivery to the targeted tissues because of different reasons
including poor pharmacokinetics profile of the drug such as absorption, distribution,
metabolism and excretion (ADME) [10, 11].
 Enhance the process of DNA repair [9, 11].
 Structural modification of the targeted tissues [9, 11].

All the previous process were extracellular factors that increase the cell anticancer
drug resistance. However, the cellular factors that affect the drug presence inside the cell
play the main role for the cell resistance to anticancer drugs through biochemical changes

222

in the tumor cells and this process include transport-based MDR known as ATP-binding
cassette (ABC).

Figure 5.1 Different mechanisms of cell development of drug resistance (copied from
[3]).
Different transporter proteins are located in the lipophilic membrane of the cell,
which play significant role in the pharmacodynamics and pharmacokinetics of various
drugs. Therefore, enormous studies on the transporters have been conducted to identify
their locations, functions, structures, selectivity and cellular distribution [3, 12]. Cellular
MDR decrease the intracellular concentration of the drugs by enhance the ATP-dependent
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efflux pumps, which is one of the family membrane of ATP-binding cassette (ABC) [13].
ATP-binding cassette is the largest transmembrane protein family that demonstrated wide
range of specificity. There are 49 known human ABC genes, which are categorized into 7
subfamilies starting with ABC and end with ABCG and the classification were relay on the
arranging of the domain and similarity of the sequence [9, 14].

Products resulted from the metabolic reactions, lipids and various types of
chemotherapeutic agents are pumped out of the cells through ATB-transporter utilizing
ATP-energy dependent movement processes [15-17]. The chemotherapeutic agents that
commonly affected by MDR process are hydrophobic containing drugs, natural products
such as docetaxel and paclitaxel, anthracyclines (daunorubicin, doxorubicin), antimicrotubule alkaloids (vincristine), antimetabolic agents (6-mercaptpurin, methotrexate,
gemcitabine, fluorouracil), natural compounds of epipodophyllotoxin (teniposide and
etoposide) and RNA elongation inhibitors (actinomycin-D) [3, 18, 19].
MRP1 (Multidrug Resistance Protein 1) is one of the ABC-transporter protein
family specifically belong to the C subfamily that consist of 12 proteins [19, 20]. MRP1
functionally categorized as an ATP-dependent protein [19]. They can be found in various
types of human cells and tissues with distinguishable level in placenta, lung, macrophages,
kidney, cardiac muscle, testis and skeletal muscle [21]. MRP1 is responsible for low
intracellular concentration of many hydrophobic anticancer drugs by ATP-dependent
efflux mechanism, which lead to improve the cell resistance toward these drugs [17, 22].
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For example, various number of hydrophobic and cationic chemotherapeutic agents such
as anthracycline (epirubicin, daunorubicin, doxorubicin), methotrexate, mitoxantrone and
flutamide have been resisted by MRP1 ATP-binding efflux [17]. In addition, some phase
II metabolic products such as glutathione, sulfate and glucuronide conjugates are preferable
substrates of MRP1 [23]. Therefore, discovery of new agents that has the ability to inhibit
the MRP1 and lead to increase the intracellular concentration of the chemotherapeutic
agents to perform their anticancer activity without being pumped out of the cell.
Natural products possess many pharmacophores that provide fertile base for the
chemists to discover new analogues targeting various molecular biology [10]. Natural
products were extensively studied as precious source for drug design and discovery [24].
Cucurbitacins is one of the natural products that is known of their broad biological
activities such as anticancer, hepatoprotective and antiviral activities such as chronic
hepatitis [25] (Fig5.2). in addition, cucurbitacins proved to be potent on various molecular
pathways [26]. Therefore, cucurbitacins have been chosen to be studied as anti-MRP1
agents to overcome the drug resistance. However, the limitation of cucurbitacins as natural
products was one of the obstacles that redirect our intention to conduct the chemical
synthesis of and/or cucurbitacin-inspired estrone analogues. Due to the varieties of
functional groups in the cucurbitacins, the total synthesis of cucrbitacins s almost
practically challenging.

A study conducted on 24 different types of cucurbitacins, Van Dang identified all
the pharmacophores that responsible for different biological activities [27]. In the result of
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their studies they demonstrated that α-β-unsaturated ketone of the enone side chain, C-3
functionality and C-16 functional groups are significant for the biological activities [27,
28]. Therefore, possessing these pharmacophores during the chemical synthesis are very
important.
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Figure 5.2 General structures of cucurbitacins and steroid.
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The similarity between cucurbitacins general structure and steroids moieties is very
close, mainly in the tetracyclic system (Fig5.2). However, the main differences between
the two structures are in the presence of aromatic ring of the steroids which is aliphatic ring
in the cucurbitacins, also the presence of gem-dimethyl group at C-4 [29] (Fig 5.2). Due to
the similarity between the main skeletons of estrone and cucurbitacins, the main
pharmacophores of cucurbitacins were chemically installed into the steroid skeleton to be
synthesized and biologically evaluated [30, 31].
Utilizing estrone as main skeleton to assemble the cucurbitacin’s enone side chain
has been done by Ahmed et al. [32]. However, further structural modifications on estrone
like cucurbitacin analogues were performed such as assembling various aliphatic and
aromatic enone side chains at C-17, modification on C-16 and substituting the hydroxyl
group at C-3 with methoxy and sulfamoyl groups to investigate their biological activities
as anti-MRP1 agents (Fig.5.3). The ability of estrone derivatives to dramatically possess a
new biological activity along with losing the estrogenic activity as a side effect was the
motive to use the estrone as starting scaffold to install various cucurbitacins
pharmacophores [33-35].
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Figure 5.3 Proposed modified estrone structures.

To prove the ability of CUCUS-inspired estrone analogues to bind to MRP1,
molecular docking study were conducted. First, a virtual library of 900 compounds were
prepared using the concept of bioisosterism to have a systematic way of designing the
structures and these include esterone derivatives with cucurbitacins enone side chain at C17, various aliphatic and aromatic groups at C-25, double bond at C-16 and C-17 and
hydroxyl, methoxy and sulfamoyl groups at C-3, known MRP1 inhibitors, cucurbitacins.
Second, OpenEye® scientific software were utilized for the semi-flexible molecular
docking studies including fast executive docking (FRED), OMEGA and VIDA.
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5.2

Materials and Methods:

5.2.1

General:
Calcein-AM was acquired from Corning life science. Doxorubicin, Adenosine

triphosphate (ATP), Adenosine monophosphate (AMP), estradiol, thiazolyl blue
tetrazolium bromide (MTT) and poly-D-lysin were purchased from sigma Aldrich. MK571 was purchased from Cayman chemical. H69AR cells were provided from ATCC.

5.2.2

Inhibition screening of MRP1 with florescent accumulation of calcein-Am in

H69AR cell line:
The inhibition screening of MRP1 were completed in H69AR cells in the presence
of known MRP1 inhibitor as positive control (MK-571) and fluorescent substrate (CalceinAM). The inhibition screening of the CIEA were conducted in 96-well Optical-Bottom
plates. The seeding of the cells started by the injection of 6 ˣ 104 cells per well in 100 µL
of cultural medium then to be incubated for 24 h. before the injection of the CIEA, cultural
medium was substituted with 80 µL of serum-free medium, followed by the addition of 10
µL of the tested compounds (10 µM). the negative control, 0.2% of DMSO in medium, and
the positive control, 50 µM of MK-571, were injected in the 96-well plates. Calcein-Am
were injected (10 µL, 0.25 µM) after 30 min and the cells were incubated for 1 h. then the
cells were washed two times with 100 µL PBS that contain 10 mM HEPES and 4.5%
glucose. The fluorescent measurements of the calcein-AM level were performed utilizing
MetaXpress software [39].
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5.2.3 Data analysis of the screened compounds:
The metaXpress software automatically measure the fluorescent intensity in every single
well to obtain the % inhibition of MRP1 [39]. The inhibition activity of the injected
compounds on MRP1 (Calcein-AM efflux) was calculated using:

X= average florescent intensity,

T= tested compounds.

5.3

Results and Discussion:

5.3.1

Results of Molecular Docking with Homology Structure of MRP1:
To conduct the molecular docking, the crystal structure of the targeted protein

should be used. Since there is no crystal structure for the MRP1 available in the protein
data bank (PDB) [36], the homology structure of MRP1 was prepared using Swiss-Model
Workspace (Fig.5.4). Homology modeling is commonly utilized in various studies
including molecular docking of virtual library. It consists of four essential steps; first,
template recognition of the protein structure; second, alignment between the structure of
the template and the sequence of targeted protein; third, building the model; fourth, general
evaluation of the resulted homology structure. The repetition of all of these steps is
recommended until a satisfaction reached [37, 38].
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The molecular docking studies of the CUCUS-inspired estrone analogues that
contain the cucurbitacins enone side chains at C-17 along with various aliphatic and
aromatic moieties at C-25, functionalities at C-16 and C-17 and hydroxyl, methoxy and
sulfamoyl groups at C-3 on the homology structure of MRP1 showed distinguishable
results of binding affinities to the MRP1. Several analogues showed better binding modes
compare to the known MRP1 inhibitors such as brobenecide, MK-571 and JS-2190 (Table
AP-3). Compounds that contain aromatic (hydrophobic) enone side chains at C-17, double
bond at C-16 and C-17 and methoxy group at C-3 such as MMA265, MMA270,
MMA287, MMA288, MMA289, MMA290, MMA292, MMA305 and MMA311
showed significant binding affinity toward the 3D structure of the MRP1 by making Hbonds and hydrophobic interactions compare to the analogues that contain aliphatic enone
side chains such as MMA102 and MMA132 (Fig.5.5). These results are lined up with the
nature of the MRP1, which is hydrophobic membrane protein and bind to substrates which
are mostly hydrophobic ligands [35].

In addition, stereochemistry played a significant role in the determination of
binding affinity. For example, compounds that possess cucurbitacin D stereochemistry
with aromatic enone side chain at C-17, double bond at C-16 and C-17 and methoxy group
at C-3 such as MMA265, MMA270, MMA287, MMA288, MMA289, MMA290,
MMA292, MMA305 and MMA311 showed better binding affinity along with H-bonds
and hydrophobic interactions compare to the compounds that possess the opposite
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stereochemistry with the same functional groups such as MMA316, MMA317, MMA318,
MMA319, MMA320,MMA321,MMA330 and MMA334 (Fig.5.6).

Figure 5.4 Homology structure of MRP1.

On the other hand, the presence of sulfamoyl moiety at C-3 of the estrone skeleton
along with aromatic enone side chains at C-17 such in MMA271, MMA294, MMA295,
MMA297, MMA300 and MMA312 showed significant binding affinity with H-bonds and
hydrophobic interactions inside the binding site of the MRP1 compare to the analogues
that have the same functional groups but with hydroxyl group at C-3 instead of sulfamoyl
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such as MMA269, MMA306, MMA308, MMA309, MMA310, MMA313 and MMA314
(Fig.5.7).
Finally, compound MMA242 which contain α-hydroxyl ketone at C-17 and
sulfamoyl moiety at C-3 demonstrated an outstanding binding mode with H-bonds and
hydrophobic interactions with the amino acids inside the binding pocket of the MRP1
crystal structure compare to known inhibitors of MRP1 such as MK-571 (Fig.5.8).
In conclusion, CUCUS-inspired estrone analogues that contain aromatic enone side
chain at C-17 demonstrated an outstanding binding affinity toward the binding site of the
3D structure of MRP1 compare to the same analogues but with aliphatic enone side chain
at C-17. In addition, stereochemistry played a significant role for the binding affinity; for
example, analogues that contain the stereochemistry of cucurbitacin D enone side chain
demonstrated better binding mode compare to the same analogues but with opposite
stereochemistry. Finally, the presence of sulfamoyl moiety at C-3 of the estrone derivatives
along with the aromatic enone side chains proved to improve the binding mode toward the
crystal structure of MRP1 compare to the same compounds but with hydroxyl group at C3. All of the molecular docking calculations and results were the bases to decide the
analogues that should be chemically synthesized and tested in different biological assays
as MRP1 inhibitors to overcome the resistance of the anticancer drugs.
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A

B

Figure 5. 5 Visual representation of A) MMA292 (black) B) MMA132 (brown)
in the MRP1 binding site.
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A

B

Figure 5.6 Visual representation of A) MMA292 (purple) B) MMA320 (green) in
the MRP1 binding site.

5.3.2

Study of synthesized CUCUS-Inspired Estrone Analogues Targeting MRP1:
To explore the inhibitory activity of CUCUS-inspired estrone analogues as MRP1

inhibitor, three sets of CUCUS-inspired estrone compounds which were synthesized using
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various chemical reactions reported in the third and fourth chapters. First set of CUCUSinspired estrone derivatives contain the cucurbitacins enone side along with aliphatic and
aromatic functional groups at C-17, double bond at C-16 and C-17, and methoxy group at
C-3 (Fig.5.9). Second set of analogues consist of cucurbitacin enone side chain along with
aliphatic and aromatic moieties at C-17 and sulfamoyl group at C-3 (Fig.5.10). Third set
of synthesized compounds contain the cucurbitacin enone side chain along with aliphatic
and aromatic moieties at C-17 and hydroxyl group at C-3 (Fig.5.11).
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A

B

Figure 5.7 Visual representation of A) MMA300 (purple) B) MMA308 (green) in
the MRP1 binding site.
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A

B

Figure 5.8 Visual representation of A) MMA242 (red) B) MK-571 (yellow) in the
MRP1 binding site.
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Figure 5.9 First set of synthesized MMA analogues.
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5.1.1

Biological Evaluation of CIAE towards MRP1:

High-content imaging based assay were utilized on the CIEA to detect their inhibitory
activities on MRP1. The screening were conducted on H69AR cells in the presence of
Calcein-Am as MRP1 substrate. MK-571, which is known inhibitor of MRP1, was used
as standard to compare the % inhibition of CIEA. Compounds MMAmix, MMA242,
MMA132, MMA335, MMA337 and MMA320 showed potential inhibitory activity on
MRP1 (Table 5.2). All of these results were compared to the known MRP1 inhibitor, MK571 as shown in figure 5.12. Compound MMAmix and MMA132, which possess the
enone side chain, proved to be a potential candidate as MRP1 inhibitor with 70%, 46.2%
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inhibitory activity; respectively. Compound MMA242, which contain sulfamoyl group at
C-3 along with hydroxyl methyl ketone at C-17, demonstrated a very significant inhibitory
activity for MRP1 with 63% inhibition, which demonstrated the important of possessing
the sulfamoyl moiety. On the other hand, compounds MMA320 and MMA337, which
contain hydrophobic functional groups at C-17, showed moderate inhibitory activities for
MRP1.
Table 5.2. Inhibitory effect of CIEA to MRP1 activities (% calcein accumulation inhibition)
in comparison of standard MRP1 inhibitor MK-571.
Compound ID Provided
MK-571

Average % Control
Inhibition
100

MMAMIX

70.2

MMA242

62.6

MMA132

46.2

MMA335

46

MMA337

30.2

MMA320

21.8

MMA326

18

MMA328

17.8

MMA318

17.4

MMA315

16.3

MMA324

15.6

MMA321

15.3
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CIEA
Figure 5.12. Chart represent the inhibitory activities of CIEA for MRP1.

5.2

Conclusion:

CUCUS-inspired estrone analogues were structurally designed utilizing molecular docking
technique by assembling the

biologically important pharmacophores such as

cucurbitacin’s enone side chain at C-17, various aromatic and heterocyclic substituents at
C-25 and sulfamoyl or hydroxyl groups at C-3 to be explored biologically as anti-cancer
candidates toward the treatment of Hepatocellular carcinoma (HCC) through the inhibition
of EGFR. Various aliphatic, aromatic and heterocyclic enone side chains were installed
chemically on the estrone main skeleton such as isopropanol, para-methoxybenzene, paraflurobenzene,

para-chlorobenzene,

para-bromobenzene,

5-bromofuran,

para-

trifluromethyl, para-nitrobenzene, 5-bromothiphene along with sulfamoyl, hydroxyl and
methoxy groups at C-3. The biological evaluation using high-content based assay
demonstrated that compounds MMAmix and MMA132, which possess the enone side
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chain, proved to be a potential candidate as MRP1 inhibitor with 70%, 46.2% inhibitory
activity; respectively.

5.3
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Chapter Six
General Conclusion and Future Trends

Our objectives and goals of this study were accomplished through design, synthesis
and biological evaluation of novel hit candidates as anticancer agents. Various
cucurbitacins structures were studied and reviewed as promising anticancer natural
products utilizing significant number of literature reviews and articles in order to determine
essential pharmacophores that responsible for their anticancer activities. Studies in our
group by Ahmed et al have determined the significant pharmacophores including α-βunsaturated enone side chain, functionalities at C-3, functional groups at C-11 and C16.
However, cucurbitacins have very weak selectivity and specificity due to the presence of
multiple functional groups which targets different biological targets. Therefore, there is
need to design novel compounds based on the cucurbitacin main structure to overcome the
side effects of the available cucurbitacins.

The first step to find the lead compounds was the design step utilizing the concepts
of hybrid structural design between the main scaffold of the estrone to assemble the
cucurbitacins pharmacophores and investigate their anticancer activities. The concept of
bioisosterism was used to install different aliphatic and aromatic moieties at C-3, C-16 and
C-25 of the designed analogues along with the cucurbitacins pharmacophores. Three
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different objectives were outlined in this research to optimize the biological activities of
CIEA as anticancer agents.

First objective, CUCS-inspired estrone analouges were designed by assembling the
α-β-unsaturated enone side chain of the cucurbitacins at C-17 of the estrone main structure
along with various aliphatic and aromatic moieties at C-25, methoxy at C-3 and double
bond at C-16 and C-17. The molecular docking results reveled the significant of possessing
the α-β-unsaturated enone side chain of cucurbitacin D with the exact stereochemistry at
C-18 as in MMA132, which demonstrated an outstanding binding affinity toward the
crystal structure of EGFR compare to known inhibitor such as Erlotinib. Compound
MMA132 found to have H-bond with MET:769:A which is the same H-bond with
erlotinib that responsible for its anticancer activity.; while the same compound but with
opposite stereochemistry at C-18 as in MMA102 did not show H-bond inside the binding
pocket of the crystal structure of EGFR. Compounds with various aromatic groups at C25 of the enone side chain showed different binding modes with the 3D structure of EGFR
compare to erlotinib. The top consensus scored analogues were chemically synthesized
utilizing different chemical reactions and their potential biological activity towards HCC
were investigated. Biological assays including MTT cell viability assay, western blot and
flowcytometry were used to study the mechanism of the anticancer activities of the
synthesized compounds. Compound MMA132 and MMA102 showed a significant
cytotoxicity with IC50 values 2µM and 3µM, respectively. Compounds that contain
aromatic and heterocyclic enone side chains such as MMA265, MMA270, MMA287,

250

MMA288, MMA290, MMA292, MMA305, MMA311, MMA316, MMA318,
MMA319, MMA320, MMA321, MMA330, MMA333 and MMA334 showed various
cytotoxicity toward HepG2 with IC50 values 16 µM, 7 µM, 25 µM, 32 µM, 6 µM, 2 µM,
29 µM, 0.7 µM, NA, NA, NA, 3 µM, 20 µM, 11 µM, 2 µM and 8 µM; respectively.
Western blot experiment was used to detect the antiproliferative mechanism of the potent
compounds, the results of the Western blot showed the ability of MMA132 to inhibit the
phosphorylated EGFR after 48 h of incubation at 3 µM. Finally, flowcytometry assay
showed induction activity at G1/S phases for compound MMA132.

To overcome the higher hydrophobic characters of the first set of CIEA compounds
and expected O-demethylation of C-3 methoxy group which may trigger the estrogenic
activity of the CUCUS-inspired estrone analogues side effects, sulfamoyl pharmacophore
was assembled at C-3 to improve the pharmacokinetic profile of CIEA. Molecular docking
study for the estrone analogs that contain cucurbitacin D enone side chain at C-17 along
with different aliphatic and aromatic moieties at C-25 and sulfamoyl and hydroxyl groups
at C-3 were conducted to predict the binding to molecular target (EGFR). The results of
the molecular docking showed that compound with the sulfamoyl group at C-3 of the
estrone scaffold along with various aliphatic and aromatic enone side chain showed
significant binding affinity with H-bonds and hydrophobic interactions in comparison to
the same compounds but with hydroxyl group instead of sulfamoyl at C-3. The results
revealed the importance of assembling the sulfamoyl group along with the different enone
side chains at the estrone scaffold for the binding affinity with the EGFR which may
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enhance the biological activity. Different chemical reactions were utilized to install these
functionalities at the estrone main structure. All synthesized analogues were biologically
screened to verify their anticancer activity. Cytotoxicity of all synthesized compounds on
hepatocellular carcinoma cell line such as HepG2 were conducted using MTT cell viability
assay. The IC50 values of the synthesized analogues including MMA240, MMA301,
MMA242, MMA267, MMA268, MMA269, MMA271, MMA309, MMA294,
MMA310, MMA295, MMA297, MMA314, MMA300, MMA308, MMA306,
MMA307, MMA313 and MMA312 were 8 µM, NA, 3 µM, 12 µM, 7 µM, 2 µM, 8 µM,
NA, 11.5 µM, 6 µM, NA, 1 µM, 1.5 µM, 3 µM, 8 µM, 8 µM, 10 µM, 9 µM and 8 µM;
respectively.

Finally, our objective to study the potential of synthesized CIEA to overcome the
resistance of cancer to current chemotherapy, we examine the inhibitory activity of
synthesized analogs on MRP1 which is one of the known protein that responsible for
multidrug resistance. Molecular docking study between the homology structure of MRP1
and CIEA revealed that the presence of hydrophobic moieties in the enone side chain at C17 such as MMA265, MMA270, MMA287, MMA288, MMA290, MMA292, MMA305
and MMA311 showed enhanced binding affinity in comparison to the aliphatic enone side
chain such as MMA102 and MMA132. In addition, the presence of sulfamoyl group at C3 along with hydrophobic (aromatic) enone side chain is essential for the binding affinity.
Biological activity of the synthesized compounds as MRP1 inhibitors were verified using
high-content imaging based assay. Compounds MMAmix, MMA242, MMA132,
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MMA335, MMA337 and MMA320 showed potential inhibitory activity on MRP1 (Table
5.2) with % inhibition 70%, 63%, 46.2%, 46%, 30% and 22%; respectively, in comparison
to MK-571, which known MRP1 inhibitor.
Our study demonstrated the design, synthesis of novel CIEA analogs of potent antiproliferation/anticancer activities toward hepatocellular carcinoma and potential
application to overcome cancer resistance to current chemotherapeutic agents.

253

Appendix
Protocol of the Molecular Modeling
I-

Steps of designing the virtual library:
The first step of designing the virtual library was the drawing of the structure of the

compounds utilizing Chem Draw software. Then all compounds in the virtual library were
energy minimized using chem3-D software, specifically MMFF94 application to obtain the
relative crystal structure of each compound. Every single compound was saved in pdb
format. After that, all created pdb files were combined into single pdb file. All of these
processes were conducted utilizing the command prompt as following start menu>
command prompt, then the address where the pdb file of the ligands were copied to be used
to combined into single pdb file as following:
cd address where the pdb file are located (enter)
Then using command, copy *.pdb name.pdb (enter), which tells the computer to
combined all the pdb files to be in one pdb file. The created pdb file can be visualized
utilizing notepad as shown in figure AP-1.

II-

Creating Different Conformers of each Ligands:
OMEGA application, particularly MMFF94 force filed was used to create different

conformers of each ligand so to be in the fast rigid exhaustive docking (FRED). The
resulted file of this process will be in this format name.gz.pdb. this process were done
following these steps:
a- Copy the combined file of ligand pdb.
b- Past it where the OMEGA application is.
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c- The application license should be available at the same place.
d- The following command was used to generate the conformers “omega2.2.1 –in name.pdb
–out newname.gz.pdb –includeinput –warts (Enter). The created file is the one that
should be used in the FRED calculation.

Figure AP-1 created pdb file using command prompt.
III-

Preparation of the targeted receptor:
FRED make receptor were utilized to prepare the targeted receptor. By starting the

program, clicking on file to import the pdb file of the receptor that downloaded from the
protein data bank to show the chains of the receptor, water molecules, binding ligands and
co-factors. Choosing the ligand that co-crystalized with the targeted protein help to
generate the grid box for the docking calculations, since it binds to the binding pocket. The
size of the created box cannot exceed 50,000- 60,000 Ao and that can be controlled by the
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mods controls. Next step is to generate the shape of the grid box by choosing the shape
mode. The created shape assign the shape of the active site of the receptor which will be
used during the molecular docking. The active site consist of two contours outer and inner
contours. Finally, the prepared receptor should be saved as .oeb.gz format (Fig.AP-2).

Figure AP-2 Sample of the prepared grid box.
IV-

Fast Rigid Executive Docking (FRED) Calculations:
In order to conduct the FRED calculations, three files should be available at where

the FRED application is located. First, the file of the fred license; second, the file that
contain the different conformers of each ligands, which generated by OMEGA
name.gz.pdb; third, the prepared rigid receptor “receptor.oeb.gz”. then certain command
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used to start the FRED calculations “fred.exe –rec receptor.oeb.gz –dbase name.gz.pdb –
prefix newname shapegauss –chemgauss3 –oechemscore –screenscore –plp –hitlist_size
5000 (enter)”. The result of FRED calculations will be in consensus score, which calculate
the binding affinity between the ligands and the targeted receptors. The lower the
consensus score the better the binding affinity (Fig.AP-3).
Table AP-3 sample of consensus score of the FRED docking.

VIDA Name

VIDA
ID

PLP

Chemgauss3 OEChemscore Screenscore

Consensus
Score

MMA292_6

2

-48.8383

-62.3556

-41.8789

-126.747

11

MMA305_71

3

-53.1802

-58.3102

-43.6724

-113.016

14

MMA266_109 4

-55.3548

-52.8859

-45.5678

-122.833

18

MMA311_103 5

-46.8621

-58.0439

-39.7369

-113.75

29

MMA128_44

6

-42.578

-55.8818

-43.6541

-116.397

31

MMA291_69

7

-44.6388

-54.3626

-39.1158

-118.789

36

MMA262_67

8

-44.5989

-60.0755

-41.0308

-102.036

43

MMA290_34

9

-44.039

-57.059

-39.6733

-108.785

43

MMA282_93

10

-43.5212

-52.4658

-43.2122

-110.732

45

MMA303_45

11

-43.5525

-51.6006

-45.7898

-105.967

48

MMA270_125 12

-43.5141

-63.5376

-39.6715

-104.555

49

MMA281_159 13

-45.0053

-48.3764

-43.1412

-116.666

50

MMA271_33

14

-41.0513

-54.1366

-40.7371

-107.453

54

MMA265_143 15

-42.9178

-53.0514

-41.1596

-101.578

64

MMA289_39

16

-42.6201

-52.9413

-41.639

-95.7639

74

MMA267_23

17

-39.3882

-53.0557

-37.9022

-107.407

77

MMA296_154 18

-42.6266

-54.3291

-34.3674

-111.931

77

MMA243_20

-37.7833

-53.6937

-39.8163

-104.531

78

19
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MMA312_105 20

-45.2513

-48.6491

-37.2378

-105.689

80

MMA285_15

21

-38.3901

-45.4425

-41.2682

-118.057

97

MMA288_52

22

-39.5374

-54.1164

-35.5891

-97.6439

100

MMA284_3

23

-40.9979

-53.7463

-34.8896

-96.2328

104

MMA102_159 24

-35.2947

-45.2269

-39.7102

-109.6

132

MMA100_33

25

-35.7384

-51.3318

-42.029

-83.6088

136

MMA129_35

26

-40.7517

-45.4562

-39.0489

-92.2197

138

MMA101_33

27

-35.7384

-51.3318

-42.029

-83.6088

140

MMA287_27

28

-33.7545

-52.434

-36.1576

-96.1252

142

MMA261_191 29

-43.7523

-41.8876

-34.9793

-93.2034

161

MMA297_168 30

-37.1344

-50.7964

-33.1599

-94.6202

161

MMA279_5

-36.2629

-52.6934

-33.4031

-87.0033

165

V-

31

VIDA visualization of the Docking Results:
VIDA application can be utilized to visualize and show 3D structure of the docked

ligands inside the targeted receptor (Fig.AP-4). In addition, by choosing the “Data
analysis”, all the docking numbers can be shown as in figure AP-3. Snapshot of the best
binding ligands with the receptor can be taken to visualize the behavior of the synthesized
ligands with the targeted receptor.
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Figure AP-4 Sample of VIDA Visual Representation.

